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ABSTRACT 
 
The BARD1 BRCT Domain in Tumor Suppression and Genome Stability 
David L. Billing, Jr. 
 
 
BRCA1 preserves genome integrity through both homology-directed repair (HDR) and stalled fork 
protection (SFP).  In vivo, BRCA1 exists as a heterodimer with the BARD1 tumor suppressor, and both 
proteins harbor a C-terminal BRCT domain with a phospho-recognition surface.  Most pathogenic lesions 
of BRCA1 and BARD1 disrupt their respective BRCT domains, and BRCA1 BRCT phospho-recognition is 
required for its tumor suppression activity.  Here we evaluate mice with mutations (Bard1S563F and 
Bard1K607A) that ablate Bard1 BRCT phospho-recognition.  Although not affecting HDR, these mutations 
impair BRCA1/BARD1 recruitment to stalled replication forks, resulting in stalled fork degradation, 
chromosomal instability, and sensitivity to PARP inhibitors.  However, Bard1S563F/S563F and Bard1K607A/K607A 
mice are not tumor-prone, indicating that ablation of SFP activity alone is insufficient for spontaneous tumor 
susceptibility.  Nevertheless, since SFP, unlike HDR, is also impaired in Brca1/Bard1 heterozygous-mutant 
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A. BRCA in breast cancer 
Approximately 250,000 new cases of breast cancer are diagnosed every year, making it the most 
common cancer among women in the United States.  Furthermore, breast cancer is the second leading 
cause of cancer mortality in women in the U.S., resulting in an estimated 40,000 deaths per year and 
more than 450,000 deaths worldwide (La Vecchia et al., 2010; Siegel, Miller, & Jemal, 2017). Therefore, 
breast cancer is a major public health concern that continues to affect the lives of a large proportion of the 
global population.  
Research carried out over the past few decades has revealed that breast cancers can be 
classified into several discrete molecular and immunological subtypes that carry important therapeutic 
and prognostic implications.  The three most commonly used pathological markers in breast cancer 
diagnosis are the estrogen receptor (ER), progesterone receptor (PR), and HER2/NEU growth factor 
receptor (Allred, 2010; Prat et al., 2015).  Of note, expression of ER and PR predict response to hormonal 
therapies such as tamoxifen and aromatase inhibitors, which have been shown to prolong survival and 
prevent recurrence in ER+PR+ breast cancers (Early Breast Cancer Trialists' Collaborative, 2005).  On the 
other hand, HER2/Neu, while initially used as an indicator of poor outcome, is now a target of therapy 
using trastuzumab, a humanized monoclonal antibody which improves overall survival and prevents 
disease recurrence in HER2+ breast cancers (Engel & Kaklamani, 2007; Pegram et al., 1998; Piccart-
Gebhart et al., 2005).  In recent years, gene expression profiling of breast cancers has revealed the 
genetic signatures that underlie the pathological markers discussed above.  Briefly, five distinct breast 
cancer molecular subtypes that correlate with ER/PR/HER2 expression status were initially identified: 
luminal A, luminal B, HER2-positive, normal-like, and basal-like (Perou et al., 2000), (Sorlie et al., 2001).  
This molecular subtyping, combined with immunohistochemistry expression data, facilitates the selection 
of optimal treatment regimens for individual patients (Dai et al., 2015; Sotiriou & Pusztai, 2009).  
The development of modern targeted therapies like tamoxifen and trastuzumab, combined with 
the ability to predict who will respond to them, has benefited a large number of patients. Nonetheless, a 
substantial subset of breast cancers is intrinsically resistant to these drugs.  Most notably, this includes 
the “triple-negative” breast cancers, which lack expression of ER, PR, and HER2.  Most triple-negative 
breast cancers fall into the basal-like molecular subtype, and, as a result of their resistance to targeted 
	 3	
therapies, are treated with classical chemotherapy regimens (Foulkes, Smith, & Reis-Filho, 2010).  As 
such, triple-negative breast cancers are associated with worse clinical outcomes when compared with the 
other breast cancer subtypes (Hennigs et al., 2016; Liedtke et al., 2008).   Therefore, continued research 
into the molecular basis of triple-negative breast cancer is a high priority, as it may yield new drug targets 
that improve patient outcomes.   
One of the main risk factors for developing breast cancer is family history, with up to a two-fold 
increase in risk for women who have a first-degree relative with breast cancer (Trentham-Dietz et al., 
2014).  Approximately 5-10% of all breast cancer cases are thought to be hereditary based on familial 
association (Foulkes, 2008).  The most common breast cancer susceptibility genes are BRCA1 and 
BRCA2, which collectively account for up to 25% of familial breast cancers (Easton, 1999).  Inheritance of 
a single mutant BRCA1 allele increases a woman’s risk of breast cancer 10-30 fold, resulting in a 50-80% 
lifetime risk of developing breast cancer (Antoniou et al., 2003; Roy, Chun, & Powell, 2011).  
Furthermore, BRCA1-mutant breast cancers are associated with triple-negative and basal-like molecular 
phenotypes (Foulkes et al., 2003; van der Kolk et al., 2010).  As a result, these tumors are largely 
resistant to modern targeted therapies.  
A closer look at the molecular details of BRCA1-mutant tumors reveals that the wild type allele is 
very commonly inactivated, leaving both BRCA1 genes nonfunctional (Maxwell et al., 2017).  Therefore, 
BRCA1 acts as a classic tumor suppressor.  BRCA1-mutant tumors are also characterized by a high 
degree of genome instability and mutation of certain other tumor suppressors such as p53.  A key feature 
of BRCA1-mutant tumors is their sensitivity to chemotherapeutic agents that damage DNA directly or 
inhibit the repair of damaged DNA, such as poly(ADP-ribose) polymerase inhibitors (PARPi) (Byrski et al., 
2010; Fong et al., 2009).   However, despite initial sensitivity to these agents, BRCA1-mutant tumors 
rapidly evolve resistance (Lord & Ashworth, 2013).  Therefore, understanding the mechanisms of 
resistance and how to circumvent them is an active area of BRCA1 research.    
Although BRCA1 is rarely mutated in sporadic breast cancer, there is increasing evidence that the 
BRCA1 pathway is functionally disrupted in many sporadic cases of basal-like and triple-negative breast 
cancer (Lord & Ashworth, 2016; N. C. Turner et al., 2007). Furthermore, mutations in the BRCA1 pathway 
continue to be found in other cancer types such as prostate, pancreatic, and, in particular, ovarian cancer 
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(Couch, Nathanson, & Offit, 2014; Lord & Ashworth, 2016).  Although common mechanisms of tumor 
formation in BRCA1 pathway-disrupted cancers are suspected, the exact molecular processes by which 
BRCA1 pathway disruption leads to tumorigenesis remain unclear.  Clearly, a better understanding of the 
underlying molecular workings of the BRCA1 pathway should reveal novel drug targets and potential 
mechanisms for therapy of basal-like breast cancers.  These scientific advances would have far reaching 
consequences for patients with either familial or sporadic breast cancer.   
 
B. BRCA1 in maintenance of genome stability 
 Since its discovery in 1990, BRCA1 has been implicated in a wide range of cellular functions (Hall 
et al., 1990).  These functions include, but are not limited to: transcriptional regulation, chromatin 
remodeling, protein ubiquitination, cell cycle checkpoint activation, stalled replication fork protection, 
centrosome duplication, maintenance of genome stability, and homology-directed repair (Jiang & 
Greenberg, 2015; Moynahan & Jasin, 2010; Nagaraju & Scully, 2007; Roy et al., 2011; Venkitaraman, 
2014).  The pleiotropic nature of BRCA1 has therefore made it challenging to determine which BRCA1 
functions are or are not required for its role as a tumor suppressor.  Two functions that have received 
much attention in recent years are the repair of double-strand DNA breaks (DSB) by homology-directed 
repair (HDR) and protection of stalled DNA replication forks from nucleolytic degradation (Moynahan, 
Chiu, Koller, & Jasin, 1999; Schlacher, Wu, & Jasin, 2012).  HDR and stalled fork protection (SFP) are 
believed to be vital to the tumor suppressor function of BRCA1 due to the role of both pathways in 
maintaining genome stability (Cortez, 2015; Moynahan & Jasin, 2010).  Furthermore, gross chromosomal 
instability and sensitivity to DNA-damaging agents are hallmarks of BRCA1-mutant cells and tumors.  
Additionally, BRCA2 has been shown to play a role in both HDR and SFP, suggesting the possibility of 
shared mechanisms of tumor suppression in both BRCA1 and BRCA2 mutation carriers (Lomonosov, 
Anand, Sangrithi, Davies, & Venkitaraman, 2003; Moynahan, Pierce, & Jasin, 2001; Schlacher et al., 
2011; Ying, Hamdy, & Helleday, 2012).   
 DSB repair by the HDR pathway involves the coordinated action of numerous DNA damage 
response proteins, including BRCA1 and BRCA2.  DSBs can arise through endogenous processes, such 
as replication fork collapse, or may be induced by a variety of exogenous agents, such as ionizing 
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radiation (Greenberg, 2008).  Since DSBs are a particularly toxic form of DNA damage that can lead to 
genome instability and cell death, cells rely on multiple repair pathways to resolve them, including HDR, 
non-homologous end joining (NHEJ), and microhomology-mediated end joining (MMEJ).  To repair DSBs 
in a relatively error-free manner, HDR relies on the presence of an undamaged sister chromatid to use as 
a template for DNA synthesis, and thus it occurs primarily during the S and G2 phases of the cell cycle 
(Moynahan & Jasin, 2010).  This contrasts with NHEJ and MMEJ, which may function throughout the cell 
cycle and are potentially error prone (Symington & Gautier, 2011).  
HDR initially entails the recruitment of various factors to DSB ends, such as the 
MRE11/RAD50/NBS1 (MRN) complex (including the MRE11 nuclease), CtIP, and the EXO1 nuclease 
(Figure 1) (Mimitou & Symington, 2008; Sartori et al., 2007; Zhu, Chung, Shim, Lee, & Ira, 2008).  These 
factors will nucleolytically resect the DNA end in a 5’-to-3’ manner to generate a 3’ single-strand DNA 
(ssDNA) overhang.  Moreover, by inhibiting NHEJ, DNA end resection commits the cell to the HDR 
pathway of DSB repair (Symington & Gautier, 2011).  The protein RPA is then assembled onto the 
ssDNA overhang to form a RPA/ssDNA nucleoprotein filament, which, in turn, can induce S and G2 cell 
cycle checkpoints through recruitment and activation of the ATR kinase (Cimprich & Cortez, 2008; Zhou & 
Elledge, 2000).  Next, a complex of PALB2 and BRCA2 promotes the replacement of RPA with the 
RAD51 recombinase (Lisby, Barlow, Burgess, & Rothstein, 2004; Sugawara, Wang, & Haber, 2003; Xia 
et al., 2006).  The resulting RAD51/ssDNA filament can invade a homologous duplex DNA, typically on 
the sister chromatid, to form a D-loop within which DNA synthesis can proceed past the break site, 
allowing error-free repair of the DSB (West, 2003).   
Loss of HDR function is believed to lead to genome instability by channeling DSB repair to more 
error-prone pathways, such as NHEJ or MMEJ, resulting in the accumulation of chromosomal aberrations 
(Symington & Gautier, 2011).  Interestingly, deletion of the NHEJ factor 53BP1 is able to rescue HDR 
function in Brca1-mutant cells, likely by restoring the balance between NHEJ and HDR (Bunting et al., 
2010). Further evidence for the importance of HDR in maintaining genome stability and tumor 
suppression can be found in the identification of cancer-associated loss-of-function mutations in many 
components of the HDR pathway in addition to BRCA1 and BRCA2, including RAD51C, BARD1, PALB2, 




While its precise role in HDR is not completely clear, there is extensive evidence implicating 
BRCA1 in this pathway pathway.  First, BRCA1 is highly phosphorylated in cells exposed to DNA-
damaging agents that induce DSBs, such as ionizing radiation.  Furthermore, immunofluorescent staining 
experiments show that BRCA1 forms nuclear foci at sites of DNA damage, together with other HDR 
components, such as RAD51, BARD1, and BRCA2 (Cortez, Wang, Qin, & Elledge, 1999; Jin et al., 1997; 
Scully, Chen, Ochs, et al., 1997).  Indeed, BRCA1 has also been shown to interact directly with additional 
HDR factors like CtIP and PALB2 (Scully, Chen, Plug, et al., 1997; Sharan et al., 1997; Yu & Baer, 2000; 
Yu, Wu, Bowcock, Aronheim, & Baer, 1998; F. Zhang et al., 2009).   More direct evidence for a role for 
BRCA1 in HDR emerged through the use of reporter constructs that can measure in vivo repair of an 
induced double-strand break (Rouet, Smih, & Jasin, 1994).  These experiments demonstrated definitively 
that BRCA1-deficient cells show a defect in HDR (Moynahan et al., 1999).  Furthermore, reconstitution of 
BRCA1-mutant cells with wild type BRCA1 readily restored HDR and genome stability (Moynahan, Cui, & 
Jasin, 2001).   
From a mechanistic standpoint, BRCA1 is believed to have distinct roles in different steps of 
HDR.  The antagonistic relationship between BRCA1 and 53BP1, an NHEJ factor that suppresses DNA 
resection, suggests that BRCA1 can act at the early stages of HDR by influencing whether a DSB is 
processed through either the NHEJ or HDR pathway.  On the other hand, the association of BRCA1 with 
PALB2/BRCA2/Rad51 complexes implies a subsequent role for BRCA1 during assembly of the Rad51 
ssDNA filament.  BRCA1 has also been shown to stimulate RAD51 recombinase activity, facilitating 
strand invasion and synapsis (Zhao et al., 2017).  Thus, HDR is a key pathway for maintaining genome 
stability in the face of DNA damage, and BRCA1 is a vital component of this pathway.  However, whether 
the HDR function of BRCA1 is actually required for tumor suppression has not been formally proven.   
 More recently, BRCA1 has also been implicated in the stalled fork protection (SFP) pathway 
(Ciccia & Elledge, 2010; Ciccia & Symington, 2016; Cortez, 2015; Errico & Costanzo, 2012; Zeman & 
Cimprich, 2014).  Indeed, many components of the HDR pathway, including RAD51, BRCA2, and RPA, 
are also involved in SFP (Kolinjivadi, Sannino, de Antoni, Techer, et al., 2017).   Replication fork stalling 
occurs when the cell is exposed to replication stress, leading to pausing of the DNA polymerase and 
potentially the uncoupling of the polymerase from the MCM helicase.  If a stalled fork is not adequately 
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protected from cellular nucleases, then it may be degraded and ultimately collapse before the replication 
block can be overcome and replication restarted.  The collapse of a replication fork may in turn lead to 
incomplete replication, DSB formation, and chromosomal instability.  Replication stress can be generated 
by exogenous agents, including DNA inter-strand crosslinking reagents, topoisomerase inhibitors that 
create protein-DNA adducts, and drugs that deplete nucleotide pools.  Replication stress can also occur 
from endogenous sources, such as oncogene activation, collision of the replication fork with the 
transcriptional machinery, or DNA adducts created by byproducts of cellular metabolism (Ciccia & 
Elledge, 2010; Cortez, 2015; Errico & Costanzo, 2012; Zeman & Cimprich, 2014).  Since replication fork 
stalling is a relatively common during cell division, protecting stalled forks from degradation and collapse 
is critical for proper maintenance of genome stability.   
Upon induction of replication stress, the uncoupling of the DNA polymerase from the replicative 
helicase generates long stretches of ssDNA, upon which RPA monomers assemble to form RPA/ssDNA 
nucleoprotein filaments (Figure 2) (Byun, Pacek, Yee, Walter, & Cimprich, 2005). The RPA/ssDNA 
filament then serves to activate the ATR kinase, which in turn induces the intra-S-phase checkpoint and 
coordinates the cellular response to the stalled replication fork (Zou & Elledge, 2003).   At this point, 
stalled forks may be remodeled into “regressed” or “reversed” forks, in which the two nascent strands 
have annealed and the two parental strands re-annealed to form a “chicken-foot” structure (Atkinson & 
McGlynn, 2009).  This fork regression may be catalyzed by a number of DNA helicases and translocases 
such as WRN, BLM, SMARCAL1, HTLF, and ZRANB3. (Achar, Balogh, & Haracska, 2011; Ciccia et al., 
2009; Ciccia et al., 2012; Machwe, Xiao, Groden, & Orren, 2006).   While fork regression may benefit the 
cell by limiting the amount of ssDNA or allowing the replisome to bypass a lesion on the parental strand 
by template switching, the regressed fork is also a substrate for degradation by nucleases such as 
MRE11 (Cortez, 2015; Kolinjivadi, Sannino, De Antoni, Zadorozhny, et al., 2017; Schlacher et al., 2011; 
Taglialatela et al., 2017).  Interestingly, assembly of RAD51 acts to protect reversed forks from nucleolytic 
degradation, thereby inhibiting replication fork collapse and genome instability (Schlacher et al., 2011).  
Thus, it is likely that helicase/translocase-mediated fork reversal exists in a delicate balance: too little fork 
reversal and stalled replication forks may fail to restart; too much fork reversal and MRE11-mediated 




demonstrates that SFP defects and chromosomal instability can be rescued by inhibiting factors that 
promote fork remodeling, such as HTLF, SMARCAL1, and ZRANB3 (Kolinjivadi, Sannino, De Antoni, 
Zadorozhny, et al., 2017; Taglialatela et al., 2017; Vujanovic et al., 2017).  
Early evidence for the role of BRCA1/2 at stalled replication forks came from 
immunocytochemistry experiments by Scully et al. (Scully, Chen, Ochs, et al., 1997).  In their study, it was 
observed that BRCA1 forms nuclear foci in cycling, unperturbed cells.  However, when these cells were 
exposed to a replication stress-inducing agent (hydroxyurea), these BRCA1 foci dissipated and BRCA1 
staining re-localized to PCNA-staining nuclear structures thought to represent replication factories.  More 
recently, this observation was confirmed using a biochemical method called isolation of proteins on 
nascent DNA (iPOND), showing that BRCA1 and its obligate binding partner, BARD1, are both highly 
enriched at stalled replication forks (Dungrawala et al., 2015).    A role for BRCA2 in SFP was also 
proposed after it was observed that BRCA2-mutant cells accumulate DNA damage after treatment with 
hydroxyurea (Lomonosov et al., 2003). Almost a decade later, in a series of seminal papers, Schlacher et 
al. reported that both BRCA1 and BRCA2 promote SFP by preventing MRE11-dependent nucleolytic 
degradation of the stalled fork (Schlacher et al., 2011; Schlacher et al., 2012).  Additionally, Schlacher et 
al. showed that BRCA2 is required for RAD51 loading onto stalled replication forks (Schlacher et al., 
2011).  While the role of BRCA1 in SFP has been firmly established, it is still unclear how BRCA1 
contributes mechanistically to fork protection.   
Although BRCA1 plays a vital role in both HDR and SFP, the molecular mechanisms by which it 
promotes these pathways remain unclear.  Nonetheless, research into these processes has already 
yielded clinical benefit, particularly with the development of PARP inhibitors as therapeutic agents for 
BRCA-mutant tumors (Bryant et al., 2005; Farmer et al., 2005; Fong et al., 2009). Indeed, the extreme 
sensitivity of BRCA1-deficient cells to PARP inhibitors may stem from the combined effects of PARP 
inhibitors (PARPi) on HDR and SFP.  Initially, PARPi treatment was thought to exploit the HDR deficiency 
of BRCA1-mutant cells by inhibiting single-strand break repair (SSB), resulting in a synthetic lethal 
interaction. Thus, since BRCA1-deficient cells are already deficient in DSB repair by HDR, inhibition of 
SSB repair would lead to a toxic accumulation of DNA damage.  Supporting this hypothesis is the clinical 
observation that BRCA1 tumors often evolve resistance to PARPi treatment by restoring HDR (Lord & 
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Ashworth, 2013).  However, PARPi treatment can also stall replication forks by generating DNA-protein 
adducts, and further analyses revealed that the sensitivity of BRCA1-mutant cells to PARPi correlates 
well with the ability of the PARP inhibitor to stabilize toxic PARP1-DNA or PARP2-DNA complexes 
(Helleday, 2011; Pommier, O'Connor, & de Bono, 2016). Moreover, recent reports suggest that 
restoration of the SFP pathway in BRCA1-deficient cells is a potential mechanism of PARPi resistance 
(Ray Chaudhuri et al., 2016; Taglialatela et al., 2017).   As such, continued research into the HDR and 
SFP pathways remains a high priority, as it may provide additional insights into the mechanisms of PARPi 
resistance and how to combat it.  Additionally, the central question regarding whether SFP, HDR, or both 
are required for the tumor suppressor functions of BRCA1 is still unresolved.   Insight into this issue 
should help clarify the longstanding question of how loss of BRCA1 leads to tumorigenesis.   
 
C. The BRCA1 protein 
BRCA1 encodes a large nuclear protein of 1863 amino acids in humans and 1812 amino acids in 
mice (Bennett et al., 1995; Miki et al., 1994).  BRCA1 shows a distinct expression pattern that varies with 
the cell cycle stage.  Specifically, BRCA1 expression levels are low in G0 or G1, increase at the G1/S 
transition, and remain high throughout S, G2, and M (Chen et al., 1996).  BRCA1 can be visualized by 
immunofluorescent staining as nuclear foci during the S and G2 phases of the cell cycle.  However, when 
cells are exposed to genotoxic agents, these BRCA1 foci disperse and BRCA1 staining reappears at sites 
of DNA damage (Scully, Chen, Ochs, et al., 1997).  
  The BRCA1 protein contains an N-terminal RING domain, a coiled-coil domain, and two C-
terminal BRCT repeats that together comprise the BRCT domain (Figure 3).  The RING domain, a 
cysteine-rich sequence that coordinates two atoms of zinc, is present in over 300 distinct human proteins 
(Freemont, Hanson, & Trowsdale, 1991; W. Li et al., 2008).  The RING domain has been shown to be a 
critical component of most E3 ubiquitin ligases (Deshaies & Joazeiro, 2009).  Indeed, the RING domain of 
BRCA1 readily catalyzes ubiquitination, and this activity remains the only known intrinsic enzymatic 
function of BRCA1 (Hashizume et al., 2001).  While ubiquitin conjugation is classically associated with 
protein degradation, BRCA1 has been shown to catalyze non-degradative polyubiquitination (i.e., non-




signaling, and chromatin remodeling (Densham & Morris, 2017; Dickson et al., 2016; Wu-Baer, Lagrazon, 
Yuan, & Baer, 2003).  Despite this, the E3 ubiquitin ligase activity of BRCA1 is dispensable for HDR and 
tumor suppression (Reid et al., 2008; Shakya et al., 2011).   
The coiled-coil domain is a relatively common protein interaction motif and, in the case of BRCA1, 
has been shown to facilitate its interaction with PALB2 (F. Zhang et al., 2009).  Through this interaction 
with PALB2, BRCA1 forms a complex with BRCA2, which also binds directly to a distinct region of the 
PALB2 polypeptide.  The association of BRCA1 with PALB2 through its coiled-coil domain is required for 
the recruitment of BRCA2/Rad51 to DSBs and assembly of Rad51/ssDNA filaments (Sy, Huen, & Chen, 
2009; F. Zhang et al., 2009).   
BRCT domains are phosphoprotein-recognition motifs found in over 20 human proteins, most of 
which function in the DNA damage response (Gerloff, Woods, Farago, & Monteiro, 2012). The BRCT 
domain of BRCA1 interacts, in a mutually exclusive manner, with several different phosphoproteins to 
form distinct BRCA1 complexes.  Of note, four of these phospho-ligands (Abraxas/CCDC98, 
BACH1/BRIP1/FANCJ, CtIP, and UHRF1) have been implicated in homology-directed repair of DNA 
double-strand breaks (Cantor et al., 2001; Kim, Huang, & Chen, 2007; Z. Liu, Wu, & Yu, 2007; Wang et 
al., 2007; Yu & Chen, 2004; Yu, Chini, He, Mer, & Chen, 2003; Yu et al., 1998; H. Zhang et al., 2016).  
Indeed, as discussed in depth below, the phosphoprotein recognition ability of the BRCA1 BRCT domain 
is itself required for HDR and tumor suppression (Shakya et al., 2011). 
Most, if not all, BRCA1 polypeptides exist in vivo as a stable heterodimer with the BARD1 protein 
(Jin et al., 1997; L. C. Wu et al., 1996; Yu & Baer, 2000).  At 777 amino acids, BARD1 is a smaller protein 
than BRCA1, but shares structural homology with BRCA1 in that it also harbors an N-terminal RING 
domain and two C-terminal BRCT repeats (Figure 3).  Additionally, BARD1 has four ankyrin repeats near 
its C-terminal end that interact with the CstF-50 poly-adenylation factor and may therefore play a role in 
RNA processing (Edwards et al., 2008; Fox et al., 2008; Kleiman & Manley, 1999; L. C. Wu et al., 
1996).    
BRCA1 and BARD1 interact through sequences that encompass their respective RING domains 
(Brzovic, Rajagopal, Hoyt, King, & Klevit, 2001; L. C. Wu et al., 1996).  Since the stability and nuclear 
retention of BRCA1 is dependent on its association with BARD1 and vice versa, the two proteins form an 
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obligate stoichiometric heterodimer in vivo (Baer & Ludwig, 2002; Fabbro, Rodriguez, Baer, & Henderson, 
2002; Yu & Baer, 2000).  In keeping with the obligate nature of their interaction, BRCA1 and BARD1 
colocalize in nuclear foci during S and G2 phase (Jin et al., 1997).  This is in contrast to other known 
BRCA1-binding proteins (e.g., PALB2, CtIP, Abraxas, BACH1, and UHRF1), which associate with BRCA1 
in a sub-stoichiometric manner.   
Not only is the interaction of BRCA1 and BARD1 important for the stability and localization of both 
polypeptides, formation of the BRCA1/BARD1 heterodimer is also vital for the functions of BRCA1.  
Specifically, the interaction with BARD1 is required for the E3 ubiquitin ligase activity of BRCA1, as well 
as its role in mitotic spindle assembly, homology-directed repair, and, as will be discussed further below, 
tumor suppression (Hashizume et al., 2001; Laufer et al., 2007; Shakya et al., 2008; Westermark et al., 
2003; Wu-Baer et al., 2003).  Like BRCA1-null cells, BARD1-null cells are defective for HDR and display 
gross chromosomal instability (Laufer et al., 2007; E. E. McCarthy, Celebi, Baer, & Ludwig, 2003; 
Westermark et al., 2003).  Furthermore, the phenotypes of Brca1 knockout, Bard1 knockout, and 
Brca1/Bard1 double-knockout mice are strikingly similar, with embryonic lethality occurring between 
embryonic days E7.5 and E8.5 as a result of an impairment in cell proliferation (Hakem et al., 1996; 
Ludwig, Chapman, Papaioannou, & Efstratiadis, 1997; E. E. McCarthy et al., 2003).  Taken together, the 
evidence strongly suggests that most, if not all, functions attributed to BRCA1 are mediated by the 
BRCA1/BARD1 heterodimer.   
 
D. The BRCA1/BARD1 heterodimer and tumor suppression 
 The study of BRCA1/BARD1-mediated tumor suppression in mice presents a unique challenge in 
that, in contrast to human patients, mice that are heterozygous for Brca1 do not develop tumors (X. Liu et 
al., 2007).  Furthermore, as discussed previously, deletion of Brca1 or Bard1 in mice results in early 
embryonic lethality.  Therefore, it is necessary to use either hypomorphic Brca1 (or Bard1) alleles or Cre-
Lox recombination of conditional Brca1 (or Bard1) alleles to study Brca1/Bard1-mediated tumor formation 
in mice.   
 Indeed, a number of groups have used mice harboring hypomorphic Brca1 alleles to carry out 
tumorigenesis studies.  For example, Ludwig et al. created a mutant allele (Brca1tr) that encodes a C-
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terminally truncated 900-amino acid polypeptide that lacks the coiled-coil and BRCT domains (Ludwig, 
Fisher, Ganesan, & Efstratiadis, 2001).  Mice that are homozygous for this allele are born at sub-
Mendelian ratios that depend on their genetic background.  Of note, after long latencies, these mice 
developed tumors at markedly increased rates compared with their wild type and heterozygous-mutant 
littermates.  Although most of these tumors were lymphomas and sarcomas, a small fraction (~13%) were 
mammary tumors.  Another strategy taken to study Brca1 hypomorphic alleles has been to introduce p53 
mutations, which prolong the survival of Brca1-null embryos and rescue the viability of some Brca1 
hypomorphic alleles (Cressman et al., 1999; Hakem et al., 1996; Xu et al., 2001).  While these Brca1/p53 
double-mutant mice develop tumors with faster kinetics (increased incidence and/or decreased latency) 
than Brca1 single-mutant mice, once again a major drawback is the predominance of non-mammary 
tumors such as lymphomas and sarcomas.  Therefore, while hypomorphic Brca1 alleles represent a 
viable strategy to study Brca1-mediated tumor suppression in mice, their usefulness is limited by the long 
latency to tumor formation and the preponderance of non-mammary tumors. 
 Another strategy to circumvent the embryonic lethality of Brca1 and Bard1 deletion to study their 
tumor suppressor functions is the use of Cre-Lox recombination systems.  Many systems have been 
developed using mammary-specific promoters to drive Cre recombinase expression and conditional 
inactivation of Brca1.  To achieve mammary-specific Cre expression, some groups have made use of 
promoters from the long-terminal repeat of the mouse mammary tumor virus (MMTV), the whey acidic 
protein (WAP) gene, the β-lactoglobulin gene, and the cytokeratin-14 (K-14) gene (Brodie et al., 2001; X. 
Liu et al., 2007; A. McCarthy et al., 2007; Selbert et al., 1998; Shakya et al., 2011; Shakya et al., 2008; 
Wagner et al., 1997; Xu et al., 1999).  In particular, the WAP and MMTV promoters, which have emerged 
as the popular approaches, both require the induction of pregnancy in the mice to activate expression of 
Cre recombinase at high levels in mammary epithelial cells.  Using these systems, mice harboring 
conditional Brca1 alleles have been shown to develop mammary tumors at relatively long latencies, 
thereby circumventing the problem of the predominance of non-mammary tumors in whole body 
hypomorphic Brca1 tumor cohorts (Shakya et al., 2008).  As is the case with the Brca1 hypomorphic 
mutants, addition of a p53 mutation leads to a decrease in the latency of mammary tumor formation, 
further supporting the hypothesis that p53 plays a role in BRCA1-mediated tumorigenesis (Brodie et al., 
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2001; Xu et al., 1999).  Of great importance, mammary tumors derived from these conditional Brca1 
models closely resemble the breast tumors that arise in human BRCA1 mutation carriers.  In particular, 
these mouse Brca1 tumors display the triple-negative phenotype, the basal-like histopathology, and high 
levels of chromosomal instability (X. Liu et al., 2007; A. McCarthy et al., 2007; Shakya et al., 2011; 
Shakya et al., 2008; Xu et al., 1999).  Therefore, Cre-lox mediated recombination systems in mice are an 
excellent model for the study of human BRCA1 pathway breast cancers. 
Given that Bard1-null mice and cells display a similar phenotype to Brca1-null mice and cells, it 
was proposed that BARD1 itself plays a role in BRCA1-mediated tumor suppression (Laufer et al., 2007; 
E. E. McCarthy et al., 2003; Westermark et al., 2003).  To address this hypothesis and circumvent the 
lethality of Bard1-null mice, Shakya et al. generated Brca1 and Bard1 mouse tumor cohorts by placing 
Cre recombinase under the control of the WAP promoter in mice harboring either conditional Brca1 or 
Bard1 alleles.  Upon induction of pregnancy and expression of Cre recombinase, loxP sites within the 
alleles were excised, resulting in mammary-specific inactivation of Brca1 or Bard1.  These mice were then 
monitored for tumor formation.  In keeping with previous studies, mammary-specific conditional Brca1-null 
mice developed mammary tumors at long latencies (T50= 512 days) that closely resembled human 
BRCA1 tumors in that they were triple negative and had a basal like-phenotype.  Strikingly, the Bard1 
cohort mice developed tumors at a rate that was statistically indistinguishable from that of the Brca1 mice 
(T50= 465 days).  Furthermore, these tumors displayed the same characteristics as the Brca1 tumors, 
possessing a high degree of genome instability, lacking expression of the ER, PR, and HER2/NEU, and 
displaying a basal-like histopathology.  Additionally, double-conditional Brca1/Bard1 mutant mice 
developed mammary tumors that arose with the same kinetics and displayed the same phenotype as the 
tumors of Brca1-only or Bard1-only conditional mice (T50 = 473 days), implying that BRCA1 and BARD1 
are epistatic with respect to tumor suppression.   
First, these data established that BARD1 is itself a tumor suppressor. In accord with these 
findings, pathogenic BARD1 mutations were subsequently identified in several human non-BRCA1/2 
breast cancer families (Couch et al., 2015; De Brakeleer et al., 2016; De Brakeleer et al., 2010; Ratajska 
et al., 2012; Sabatier et al., 2010).  Therefore, BARD1 is a clinically relevant tumor suppressor.  Second, 
the similarity of the phenotypes of the tumors derived from conditional Brca1, Bard1, and Brca1/Bard1 
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double-mutant mice demonstrate that the tumor suppressor functions previously ascribed to BRCA1 
alone are actually mediated by the BRCA1/BARD1 heterodimer.  However, the individual contributions 
that BRCA1 and BARD1 make to tumor suppression are largely unclear. 
 
E. Structural requirements for BRCA1/BARD1-mediated tumor suppression   
While experiments using mouse models that result in the conditional inactivation of either Brca1 
or Bard1 were instrumental in proving that BRCA1 and BARD1 are tumor suppressors in mammary 
epithelial cells, the experiments did not elucidate which domains and/or functions of these proteins are 
actually required for tumor suppression.  However, these questions can be addressed by pairing targeted 
mutations that disrupt different functional domains of Brca1 or Bard1 with a conditional-null Brca1 or 
Bard1 allele.  Thus, upon inactivation of the conditional allele, the mammary epithelial cells will solely 
express the targeted mutant Brca1 or Bard1 allele.  If the tumorigenicity of these mice can then be paired 
with insights into the functional consequences of each particular mutation (e.g., the mutation disrupts 
HDR or SFP function), it should be possible to achieve one of the main goals of BRCA1 research: 
determining which of its functions are required for tumor suppression.  Importantly, the landscape of 
human cancer-associated BRCA1 mutations provides clues as to what aspects of the protein may be 
required for tumor suppression.  These observations may then be formally tested in mouse models.  
While most of the human BRCA1 mutations are frameshift or nonsense mutations that disrupt most or all 
of the protein, in some families tumor susceptibility can be attributed to missense mutations.  These 
missense mutations cluster largely in the RING and BRCT domains of BRCA1, implying that these 
domains are vital to the tumor suppressor functions of the BRCA1/BARD1 heterodimer (Couch et al., 
2014).   
As outlined above, the RING domain of BRCA1 provides two important functions to the 
BRCA1/BARD1 heterodimer: first, it is required for the interaction between BRCA1 and BARD1 and 
second, it is required for the E3 ubiquitin ligase activity of the BRCA1/BARD1 heterodimer (Brzovic et al., 
2001; Hashizume et al., 2001; L. C. Wu et al., 1996; Wu-Baer et al., 2003).  Indeed, the association with 
BARD1 is also required for the stability of BRCA1, as the BRCA1/BARD1 interaction masks a nuclear 
export signal within BRCA1 that, if exposed, ultimately results in its proteolytic degradation (Fabbro et al., 
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2002).  Since the E3 ubiquitin ligase activity is the only known intrinsic enzymatic function of the 
BRCA1/BARD1 heterodimer, it was initially hypothesized that this activity was required for tumor 
suppression.  Indeed, the pathogenic BRCA1 mutation C61G was shown to disrupt the E3 ubiquitin ligase 
activity and resulted in tumor formation in a conditional mouse model (Drost et al., 2011).  However, since 
this BRCA1 mutation disrupts both its E3 ubiquitin ligase activity as well as its association with BARD1, it 
was unclear which function was actually mediating tumor suppression (Hashizume et al., 2001; L. C. Wu 
et al., 1996).   
To address this question, a separation-of-function mutation (Brca1I26A) that disrupts the E3 
ubiquitin ligase activity of Brca1 without disturbing its association with Bard1 was created (Reid et al., 
2008).  Cells harboring this mutation were found to be competent for HDR.  Upon expression of the 
BRCA1I26A allele in a conditional mouse model, it was found that these mice were not prone to mammary 
tumors, thus demonstrating that the E3 ubiquitin ligase is dispensable for the tumor suppression functions 
of the BRCA1/BARD1 heterodimer (Shakya et al., 2011).  Instead, the vital function that the RING domain 
contributes to BRCA1-mediated tumor suppression is likely to be its ability to mediate formation of the 
BRCA1/BARD1 heterodimer.  This result further underscores the importance of BARD1 in BRCA1-
mediated tumor suppression and serves as a proof of principle that targeted mutations combined with 
mouse models can be used to elucidate which of the BRCA1/BARD1 heterodimer’s many functions are 
required for tumor suppression.  However, since the stability of both BRCA1 and BARD1 is dependent 
upon the ability of the proteins to interact with each other, and these tumorigenic BRCA1 mutations in the 
RING domain disrupt this interaction, they are largely uninformative as to the larger question of which 
functions of BRCA1/BARD1 are required for tumor suppression.  
The pathogenic missense mutations of BRCA1 cluster largely, but not exclusively, within its RING 
and BRCT domains (Couch et al., 2014).  Indeed, if the truncating and frameshift mutations are taken into 
account along with the missense mutations, most (>90%) of the pathogenic BRCA1 mutations either 
eliminate or mutate the BRCT domain.  Moreover, mice that harbor a truncated Brca1 lacking its coiled-
coil and BRCT domains are tumor prone, suggesting that the BRCA1 BRCT domain may indeed be 
critical for BRCA1/BARD1 mediated tumor suppression (Ludwig et al., 2001).  Importantly, since the 
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BRCA1 BRCT domain is not required for the BRCA1/BARD1 interaction, BRCA1 BRCT mutants may be 
used to study specific contributions of BRCA1 to the BRCA1/BARD1 heterodimer.  
 
F. The BRCT domains of BRCA1 and BARD1 
 As was briefly discussed above, the evolutionarily-conserved BRCT (BRCA1 C-Terminus) 
domain was initially identified in BRCA1 but has since been found in over 20 human proteins (Bork et al., 
1997; Gerloff et al., 2012; Q. Wu, Jubb, & Blundell, 2015).  Many of the proteins which possess a BRCT 
domain, such as 53BP1, PARP1, MDC1, and TOPBP1, function in the DNA damage response.  BRCT 
domains may exist as a single unit, or, as in the case of both BRCA1 and BARD1, two tandem units that 
form a single structural domain. BRCT domains, like that of BRCA1, are thought to function primarily as 
phospho-recognition surfaces, but have also been reported to bind DNA and poly(ADP-ribose) (PAR) (M. 
Li & Yu, 2013; Manke, Lowery, Nguyen, & Yaffe, 2003; Pleschke, Kleczkowska, Strohm, & Althaus, 2000; 
Yamane & Tsuruo, 1999; Yu et al., 2003).  Given the importance of kinases like ATM, ATR, CHK1, and 
CHK2 in regulating the DNA damage response, the recognition of specific phosphorylation events by the 
BRCT domains may promote formation of protein complexes which ultimately coordinate DNA repair. 
 Structural studies have revealed the form and function of the BRCA1 BRCT domain.  The BRCA1 
BRCT domain exists as two repeats arranged in a head to tail fashion and joined by a 23-amino acid 
linker region, and the resulting structure is stabilized by interactions between the hydrophobic regions of 
both BRCT repeats (Figure 4) (Williams, Green, & Glover, 2001).  The BRCA1 BRCT domain 
preferentially recognizes phospho-serine peptides with the pSXXF sequence motif (in which “p” indicates 
phosphorylation and “X” indicates an undetermined amino acid) (Manke et al., 2003; Rodriguez, Yu, 
Chen, & Songyang, 2003; Yu et al., 2003). Two binding pockets, a hydrophilic pocket in the N-terminal 
BRCT repeat and a hydrophobic pocket in the C-terminal repeat, form the structural basis for recognition 
of pSXXF-containing peptides.  Specifically, the phospho-serine residue of pSXXF fits into the hydrophilic 
pocket of the N-terminal BRCT repeat while the phenylalanine is coordinated by the hydrophobic pocket. 
Three highly conserved residues, S1655, T1700, and K1702, as well as the amino group in the backbone 
of G1656, make up the hydrophilic pocket in the N-terminal BRCT repeat and coordinate binding to the 




BRCT domain can be disrupted by mutation of either S1655, T1700, or K1702 (Clapperton et al., 2004; 
Shiozaki, Gu, Yan, & Shi, 2004; Williams, Lee, Hau, & Glover, 2004).  Interestingly, some pathogenic 
BRCA1 missense mutations alter key structural features of the BRCT domain involved in coordinating the 
phosphopeptide.  In particular, the M1775R mutation disrupts the hydrophobic pocket that coordinates the 
phenylalanine in the pSXXF motif while the S1655F mutation disrupts one of the phospho-serine 
interacting residues (Figure 4).  
 To address the hypothesis that the phospho-recognition ability of the BRCA1 BRCT domain is 
required for tumor suppression, the equivalent mutation to BRCA1S1655F was introduced into mouse Brca1 
(Brca1S1598F) (Shakya et al., 2011).  In contrast to Brca1-null mice, homozygous Brca1S1598F/S1598F mice 
are viable, but born at sub-Mendelian ratios.  Furthermore, these mice display developmental defects 
characteristic of Brca1 hypomorphic mutations, such as growth retardation, kinked tails, and white spots 
on the abdomen and hind limbs.  Strikingly, mice harboring the Brca1S1598F mutation along with a 
mammary-specific Brca1 conditional allele (Brca1S1598F/co) developed mammary tumors at a rate that was 
statistically indistinguishable from that of mammary-specific conditional Brca1-null mice (Brca1co/co).  
Moreover, the mammary tumors derived from Brca1S1598F/co mice displayed the same triple-negative 
basal-like phenotype as the mammary tumors of conditional Brca1- or Bard1-null mice.  Therefore, the 
phospho-recognition ability of the BRCA1 BRCT domain is required for the tumor suppressor functions of 
the BRCA1/BARD1 heterodimer.  
 In light of these results, insights into which functions of the BRCA1/BARD1 heterodimer are 
required for tumor suppression may be acquired by considering the phospho-dependent protein 
interactions mediated by the BRCA1 BRCT domain.  As discussed above, the BRCA1 BRCT domain can 
interact with the phosphorylated forms of at least four different proteins implicated in HDR: 
Abraxas/CCDC98, BACH1/BRIP1/FANCJ, CtIP, and UHRF1 (Cantor et al., 2001; Kim et al., 2007; Z. Liu 
et al., 2007; Wang et al., 2007; Yu & Chen, 2004; Yu et al., 2003; Yu et al., 1998; H. Zhang et al., 2016).  
In contrast to the interaction between BRCA1 with BARD1, these interactions are all sub-stoichiometric.  
Moreover, since the BRCA1 BRCT domain may only bind one phospho-protein at a time, these 
interactions are mutually exclusive and thus result in the formation of distinct BRCA1 complexes within 
the cell.  Importantly, Brca1S1598F/S1598F cells are deficient for HDR (Shakya et al., 2011).  However, it is 
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currently unknown whether the phospho-recognition ability of the BRCA1 BRCT domain is required for 
stalled fork protection. Therefore, it cannot yet be definitively concluded whether the HDR function alone 
accounts for the tumor suppressor function of the BRCA1/BARD1 heterodimer. 
   Like BRCA1, BARD1 possesses two C-terminal BRCT repeats that together comprise a BRCT 
structural domain. Structural studies have revealed that the two BARD1 BRCT repeats are oriented in a 
head to tail fashion and their association is stabilized by the interaction of hydrophobic surfaces at their 
interfaces (Figure 5A).  Like BRCA1, the BARD1 BRCT domain contains two pockets, a hydrophilic 
pocket in the N-terminal repeat and a more hydrophobic pocket in the C-terminal repeat.  The hydrophilic 
pocket in the N-terminal repeat structurally resembles the BRCA1 BRCT phospho-binding pocket in that it 
retains the four conserved residues predicted to make hydrogen bonds with a phosphoserine peptide 
(S1655, G1656, T1700, and K1702 in human BRCA1; S575, G576, T617, and K619 in human BARD1) 
(Figure 5B).  Therefore, disruption of S575, G576, T617, or K619 is predicted to ablate the phospho-
recognition ability of the BARD1 BRCT domain.  However, the hydrophobic pocket in the C-terminal 
BARD1 BRCT repeat is very different from the BRCA1 C-terminal hydrophobic pocket, as the BARD1 
BRCT domain contains multiple histidine and serine residues not present in BRCA1.  This structural 
difference in the hydrophobic pocket likely explains the differing protein binding affinities of the two BRCT 
domains (Birrane, Varma, Soni, & Ladias, 2007; Edwards et al., 2008).  As such, the BARD1 BRCT 
domain has not been reported to bind any of the known BRCA1 BRCT phospho-ligands (e.g., Abraxas, 
BACH1, CtIP, UHRF1). 
Initially, the BARD1 BRCT domain was believed to bind phosphoserine peptides with the motif 
pS[D/E][D/E]E, similar to the interaction of BRCA1 with pSXXF motifs (Rodriguez et al., 2003).  However 
subsequent studies revealed very low binding affinity for phosphopeptides containing pS[D/E][D/E]E, 
indicating that the interaction of the BARD1 BRCT domain with this motif is either highly transient or non-
existent in vivo (Birrane et al., 2007; Edwards et al., 2008).  Indeed, no confirmed phosphoprotein ligands 
of the BARD1 BRCT domain have yet been identified.       
 The lack of known phosphoprotein ligands for the BARD1 BRCT domain has been an obstacle in 
uncovering its functions.  Recently, however, Li and Yu demonstrated that the BARD1 BRCT domain can 




of NAD+ (nicotinamide adenine dinucleotide) by certain enzymes of the poly(ADP-ribose) polymerase 
(PARP) family.  While PAR has been implicated in many different cellular pathways, PAR polymers are 
rapidly assembled at both DSBs and stalled replication forks (Ali et al., 2012; Bryant et al., 2009; Leung, 
2014; Schreiber, Dantzer, Ame, & de Murcia, 2006; Yang, Cortes, Patnaik, Jasin, & Wang, 2004). The 
ability of the BARD1 BRCT domain to bind PAR in a phospho-dependent manner, a function not 
attributed to BRCA1, suggests a unique role for BARD1 in the HDR and/or SFP functions of the 
BRCA1/BARD1 heterodimer.  Furthermore, mutation of the conserved K619 residue in the BARD1 BRCT 
domain ablated its interaction with PAR, suggesting that the same residues originally thought to 
coordinate phosphopeptide binding (S575, G576, T617, or K619) are likely to be required to bind the 
diphosphate linkages of PAR (M. Li & Yu, 2013).   
 Importantly, Li and Yu showed that the phospho-dependent binding of the BARD1 BRCT domain 
to PAR is required for early recruitment of the BRCA1/BARD1 heterodimer to DSBs (M. Li & Yu, 2013).  
In short, in the context of laser- or endonuclease-induced DSBs, they observed two temporally-distinct 
recruitment events of the BRCA1/BARD1 heterodimer.  The first event was a transient, early recruitment 
of the heterodimer that occurs within 20 seconds of DSB formation in a gH2AX-independent manner and 
dissipates within 5-10 minutes after break formation.  The second is a late recruitment that occurs within 
5-10 minutes after break formation in a gH2AX-dependent manner and remains stable for hours after DSB 
induction.  Notably, the early recruitment event was ablated by mutation of the BARD1 BRCT domain, as 
well as by treatment with PARP inhibitors (PARPi).  In contrast, the late recruitment event was dependent 
on the phospho-recognition ability of the BRCA1 BRCT domain (M. Li & Yu, 2013).  Together, these data 
suggest that the BRCA1 and BARD1 BRCT domains work together to facilitate distinct aspects of DSB 
repair.  However, whether the BARD1 BRCT domain is crucial for the BRCA1/BARD1 heterodimer’s roles 
in the HDR and SFP pathways is unknown.    
Interestingly, as was the case with the human BRCA1 mutation landscape, many of the BARD1 mutations 
found in human breast cancer patients either ablate or disrupt the BARD1 BRCT domain (Couch et al., 
2015; De Brakeleer et al., 2016; De Brakeleer et al., 2010; Ratajska et al., 2012; Sabatier et al., 2010).  
This suggests that the BARD1 BRCT domain may be required for BRCA1/BARD1-mediated tumor 
suppression.  Additionally, given that the BARD1 BRCT domain is not required for the interaction with 
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BRCA1, these cancer-associated mutations suggest that the BARD1 BRCT domain may be contributing 
functions, distinct from those of BRCA1, that are required for BRCA1/BARD1-mediated tumor 
suppression.  Further exploration of the roles of the BARD1 BRCT domain may help to clarify these 
fundamental questions.   
 
G. Goals and rationale 
 Since BRCA1 was discovered over twenty years ago, significant progress has been made 
identifying the diverse functions of the BRCA1/BARD1 heterodimer.  However, it is still unclear which of 
its plethora of cellular functions are relevant for tumor suppression. While the functions of BRCA1 in HDR 
and SFP are commonly thought to be important for tumor suppression, this hypothesis has never been 
formally proven.  Thus, it is not known whether loss of SFP, HDR, or both lead to tumor formation.  The 
use of targeted mutations that disrupt key functional domains combined with mouse models of breast 
cancer represents a significant opportunity to answer this longstanding question.  Indeed, further insights 
into the mechanisms of the SFP and HDR pathways, as well as their role in tumor suppression, may 
identify novel drug targets for the treatment of triple-negative breast cancer.  
 Another fundamental unanswered question regards the individual roles of the BRCA1 and 
BARD1 in cellular function and tumor suppression.  Numerous lines of evidence discussed above support 
the conclusion that BRCA1 and BARD1 act in the same cellular pathways and are reliant upon each other 
for their stability and function (Baer & Ludwig, 2002; Fabbro et al., 2002; Hashizume et al., 2001; Laufer 
et al., 2007; Shakya et al., 2008; Westermark et al., 2003; Wu-Baer et al., 2003; Yu & Baer, 2000). 
Therefore, the use of BRCA1-null or BARD1-null experimental systems inevitably affects the other 
binding partner, thus obscuring their individual functions.  It is likely that BRCA1 and BARD1 each 
contribute unique functions to the BRCA1/BARD1 heterodimer.  Indeed, the tumorigenicity of targeted 
mutations in the BRCT domain of BRCA1 that do not affect its association with BARD1 argues that 
BRCA1 contributes distinct functions to the BRCA1/BARD1 heterodimer (Ludwig et al., 2001; Shakya et 
al., 2011).  However, it is unknown whether BARD1 contributes any distinct, vital functions to the 
heterodimer.  While it is possible that BARD1 may play a largely housekeeping role in stabilizing BRCA1, 
the presence of pathogenic mutations in the BARD1 BRCT domain that are not predicted to disrupt the 
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association with BRCA1 argue that BARD1 makes unique contributions to the tumor suppressor functions 
of the BRCA1/BARD1 heterodimer (Couch et al., 2015; De Brakeleer et al., 2016; De Brakeleer et al., 
2010; Ratajska et al., 2012; Sabatier et al., 2010).  Once again, the use of functional analysis of targeted 
mutations combined with mouse models should help to tease out the distinct roles of BARD1.    
In summary, the decision to study the Bard1 BRCT domains is based on three main findings: 1) the 
phospho-recognition ability of the BRCA1 BRCT domains is required for tumor suppression, 2) the 
BARD1 BRCT domains are capable of phospho-recognition and/or poly-(ADP-ribose) (PAR) binding, and 
3) BARD1 mutations that disrupt the BRCT domains have been implicated as the tumor-predisposing 
lesion in several non-BRCA1/2 breast cancer families (Couch et al., 2015; De Brakeleer et al., 2016; De 
Brakeleer et al., 2010; Ratajska et al., 2012; Sabatier et al., 2010; Shakya et al., 2011).  Together, these 
findings suggest that the BARD1 BRCT domains are critical for the tumor suppression and genome 
stability functions of the BRCA1/BARD1 heterodimer.  
To test this hypothesis, we chose to model two distinct BARD1 BRCT point mutations in mice: 
Bard1-S563F and Bard1-K607A, equivalent to the S575 and K619 phospho-coordinating residues in 
human BARD1.  Indeed, mutation of either the S563 or K607 residue is predicted by structural studies to 
disrupt Bard1 binding to either phosphoproteins or PAR. Thus, by modeling these mutations in mice, we 
sought to ascertain whether the phosphoprotein-binding or PAR-binding functions of the BARD1 BRCT 
























MATERIALS AND METHODS 
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A. Mouse strain generation 
The mice used in this study were housed in an AAALAC-accredited facility at Columbia University 
Medical Center. All experiments involving mice were performed according to the Columbia University 
Institutional Animal Care and Use Committee-approved protocols.  
To generate the transgenic mouse strains, a S563F knock-in targeting vector containing mouse 
Bard1 genomic DNA was constructed by inserting a neomycin-resistance gene cassette flanked by loxP 
sites (loxP-neo-LoxP) into intron 7 and the S563F missense mutation into exon 8 (Figure 6B).  Likewise, a 
K607A targeting construct was generated by inserting the loxP-neo-LoxP cassette into intron 8 and the 
K607A missense mutation into exon 9 (Figure 7B).  These vectors were then electroporated into ES cells 
on a 129Sv background and selected with media supplemented with neomycin.  The presence of the 
desired mutations in neomycin-resistant clones was confirmed by sequence analysis and the proper 
integration confirmed by Southern blot analysis (Figures 7C, E and 8C, E).  Two independent clones of 
either Bard1S563F-neo/+ or Bard1K607A-neo/+ ES cells were injected into C57BL/6J blastocysts for the 
production of chimeric germline-transformed mice.  Once again, the presence of the S563F or K607A 
mutation was confirmed by sequence analysis, PCR, and Southern blot using genomic DNA harvested 
from mouse tails (see sections D, E, and F below).  The neomycin cassette was then removed by 
crossing heterozygous Bard1S563F-neo/+ or Bard1K607A-neo/+ with RosaCre mice, a mouse strain that 
ubiquitously expresses Cre recombinase (Figures 6D and 7D).  The excision of the neomycin cassette 
was confirmed by Southern blot analysis.  The heterozygous Bard1S563F/+ or Bard1K607A/+ mice were then 
backcrossed with pure C57Bl/6J mice (Jackson Laboratory) three times to yield animals that were 
approximately 94% C57BL/6J (N3 backcrossed).  All mouse tumor cohorts, mouse embryonic fibroblast 
(MEF) lines, and embryonic stem (ES) cell lines were generated using mice on this background.    
 
B. Tumor monitoring and histopathology 
Mice were monitored for tumor development on a weekly basis.   Upon detection of a palpable 
mass or moribund appearance, the mice were sacrificed and their tissues harvested for histological 
analysis.  For testicular histology, mice were sacrificed at 6 weeks of age.  The mice were euthanized with 
CO2 followed by cervical dislocation in accord with the American Veterinary Medical Association 
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Guidelines for the Euthanasia of Animals: 2013 Edition.  After euthanasia, a piece of the tail was 
harvested for confirmation of the genotype by PCR or Southern blot (see Sections D, E, and F below).  All 
major organs were collected and fixed overnight in 10% buffered formalin, followed by dehydration with 
70% ethanol the next day. Tissues were then embedded in paraffin, sectioned at a thickness of 4 µm, and 
stained with hematoxylin and eosin for histopathological evaluation.     
 
C. Mouse whole-body IR treatment 
 Five-week-old mice were treated with 7.5 Gy of radiation on a rotating platform using a Mark I 
Cesium-137 mouse irradiator (J.L. Shepard and associates).  Survival was monitored daily for 6 weeks 
post treatment.  
 
D. Genomic DNA isolation 
 Genomic DNA was isolated for polymerase chain reaction (PCR) or Southern blot analysis from 
mouse tails, embryo heads, MEFs, and ES cells.  To isolate the genomic DNA, cells or the mouse tail 
were dissolved by incubation with 500 µL of tail buffer (50 mM Tris-HCl, pH 8.0, 0.1 M NaCl, 2 mM EDTA, 
1% SDS) supplemented with 200 µg/mL of proteinase K at 56˚C overnight.  The next day, the dissolved 
cells or tails were vortexed for 5 minutes, supplemented with 200 µL 5M NaCl, and vortexed for another 5 
minutes.  The dissolved materials were then centrifuged at 13000 RPM for 10 minutes and the resulting 
supernatant transferred to a new 1.5 mL Eppendorf tube.  The DNA was then precipitated using 500 µL of 
isopropanol and centrifuged at 13000 RPM for 5 minutes to pellet the DNA.  The supernatant was 
subsequently removed, the pellet washed with 70% ethanol, and centrifuged at 13000 RPM for 2 minutes. 
The supernatant was again removed and the DNA pellet dried for 15 minutes in a speed vacuum 







E. Polymerase chain reaction (PCR) 
 All PCRs were performed in a final volume of 25 µL with Taq DNA polymerase (Invitrogen), 10X 
PCR reaction buffer (200 mM Tris, pH 8.4, 500 mM KCl), 50 mM MgCl2 10mM dNTP, 100% 
dimethylsulfoxide (DMSO), 10 µM oligonucleotide DNA primers (see Table 1), and 1 µL of genomic DNA 
in 1X TE isolated as described above.  The PCRs were then run on an Eppendorf Mastercycler Nexus 
GX2 gradient PCR machine.  After completion of the PCR, 10 µL of the reaction was run on a 2% 
agarose gel in 1X TAE (40 mM Tris, 20 mM Acetate, 1 mM EDTA, pH 8.0) supplemented with 0.5 µg/mL 
ethidium bromide (EtBr).  Finally, the gel was imaged on a Biodoc-IT UV transilluinator (UVP).   
 To genotype the BardK607A and Bard1+ alleles, the Qx1-21 and Qx1-H primers (see Table 1) were 
used at a concentration of 10 µM with the following PCR conditions: 94˚C 3 min (1 cycle); 94˚C 30 sec, 
62˚C 30 sec, 72˚C 45 sec (35 cycles); 72˚C 5 min (1 cycle); 4˚C hold.  The reaction yields a 596 bp band 
for the BardK607A allele and a 500 bp band for the Bard1+ allele. 
 To genotype the BardS563F and Bard1+ alleles, the Qx1-13 and Qx1-D primers were used at a 
concentration of 10 µM with the same PCR conditions as the Bard1K607A allele (see above).  The reaction 
yields a 521 bp band for the Bard1S563F allele and a 426 bp band for the Bard1+ alleles.  
 To genotype the Brca1S1598F-LNL and Brca1+ alleles, two separate PCR reactions were necessary.  
The first reaction, used to PCR the Brca1S1598F-LNL allele, utilized the S1598F-2 and LNL-A primers at a 
concentration of 10 µM.  This reaction yielded a band at 459 bp for the Brca1S1598F-LNL allele, and no band 
for the Brca1+ allele.  The second reaction, used to PCR the Brca1+ allele, utilized the S1598F-2 and 
S1598F-C primers at a concentration of 10 µM.  This reaction yielded a band at 396 bp for the Bard1+ 
allele, and no band for the Brca1S1598F-LNL allele.  Both reactions were carried out under the following 
conditions:  94˚C 3 min (1 cycle); 94˚C 30 sec, 65˚C 30 sec, 72˚C 45 sec (35 cycles); 72˚C 5 min (1 
cycle); 4˚C hold. 
 For PCRs involving ES cell DNA, the same reaction mixtures and primers were used to amplify 
the respective Bard1 and Brca1 alleles.  However, two different PCR conditions were run in the 
thermocycler in an effort to prevent DNA contamination from the primary MEF feeder cells with which the 
ES cells were co-cultured.  For each reaction, a “long” and a “short” condition were run using the same 
primers.  In the case of the Bard1 alleles, the “long” reaction was as follows: 94˚C 3 min (1 cycle); 94˚C 
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30 sec, 62˚C 30 sec, 72˚C 45 sec (38 cycles); 72˚C 5 min (1 cycle); 4˚C hold, while the “short” reaction 
conditions were: 94˚C 3 min (1 cycle); 94˚C 30 sec, 62˚C 30 sec, 72˚C 45 sec (25 cycles); 72˚C 5 min (1 
cycle); 4˚C hold.  In the case of the Brca1 alleles, the “long” reaction was as follows: 94˚C 3 min (1 cycle); 
94˚C 30 sec, 65˚C 30 sec, 72˚C 45 sec (38 cycles); 72˚C 5 min (1 cycle); 4˚C hold; while the “short” 
reaction conditions were: 94˚C 3 min (1 cycle); 94˚C 30 sec, 65˚C 30 sec, 72˚C 45 sec (25 cycles); 72˚C 5 
min (1 cycle); 4˚C hold.    
 
Table 1: PCR Primers 
Allele Primer name Primer sequence Product size 
Bard1K607A 
Qx1-21 5’-CACGTGGTTGCTGGAAATTG-3’ K607A: 596bp 
Wild type: 500 bp Qx1-H 5’-ATGTAAAGGAGCCAGCAGC-3’ 
Bard1S563F 
Qx1-13 5’-GCAGGTGCTCTACCCTCAAC-3’ S563F: 521 bp 
Wild type: 426 bp Qx1-D 5’-AACCTGGCCATCAACATG-3’ 
Brca1S1598F-LNL 
S1598F-2 5’-AACATTAAGCCCACTGAACCC-3’ S1598F-LNL: 459 bp 
Wild type: no band LNL-A 5’-TCAGCGGTGCTGTCCATCTGC-3’ 
S1598F-2 5’-AACATTAAGCCCACTGAACCC-3’ S1598F-LNL: no band 
Wild type: 396 bp S1598F-C 5’-GATTTTCCAGAGGAACTGCTGC-3’ 
 
F. Southern blot analysis 
Southern analysis was performed by digesting genomic DNA isolated from mouse tail or ES cells 
(prepared as described in Section D) with the appropriate restriction enzyme.  The digest was performed 
by incubating 10 µL of genomic DNA in 1X TE with 10 units of the appropriate restriction enzyme in a total 
volume of 30 µL at 37˚C overnight.  The following day, the complete digestion reaction was 
electrophoresed on a 0.8% high melt molecular biology grade agarose gel (Denville) in 1X TAE (40 mM 
Tris, 20 mM acetate, 1 mM EDTA, pH 8.0) supplemented with 0.5 µg/mL ethidium bromide (EtBr).  After 
electrophoresis, the gel was incubated in depurination solution (0.25 M HCl) on a shaking incubator for 20 
min at room temperature and then rinsed with ddH20 three times.  The gel was then incubated in 
denaturing solution (0.5 M NaOH and 1.5 M NaCl) on a shaking incubator for 20 minutes at room 
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temperature. After denaturation, the gel was blotted onto a Biodyne B 0.45 µm nylon membrane (Pall) by 
upward capillary transfer overnight.   
The following day, the membrane was allowed to dry on a piece of Whatman paper for 20 
minutes before immobilizing by baking the membrane at 100˚C in a vacuum oven for 30 minutes.  The 
membrane was then wet in 2X SSC (300 mM NaCl, 35 mM sodium citrate pH 7.0) and pre-hybridized in 
10 mL of rapid hybridization buffer (5X SSC, 10% polyethylene glycol MW 8000, 5% poly(sodium 4-
styrenesulfonate), 0.2% cetylpyridinium chloride monohydrate) supplemented with 1 mg sheared salmon 
sperm DNA (Thermo Fischer) at 65˚C for 30 minutes in a rotating hybridization chamber.  During 
prehybridization, a α32P-dCTP-labeled (Perkin Elmer) probe was prepared using Prime-It II Random 
Primer Labeling Kit (Agilent Technologies) by first denaturing the appropriate probe fragment along with 
random primer mix by heating at 95˚C for 5 minutes.  After denaturation, the α32P-dCTP-labeled probe 
was synthesized by combining the unlabeled denatured probe with α32P-dCTP and incubating with 
Klenow fragment enzyme (Agilent Technologies) at 37˚C for 10 minutes.  Stop mix buffer (0.5 M EDTA, 
pH 8.0; Agilent Technologies) and 500 µg sheared salmon sperm DNA were then added to the probe 
mixture and incubated at 95˚C for 5 minutes before cooling on ice for 1 minute in order to halt the 
reaction.  Next, the radiolabeled probe mixture was added to the membrane in pre-hybridization buffer 
and incubated at 65˚C in a rotating hybridization chamber for 2 hours.  Following incubation with the 
radiolabeled probe, the membrane was removed from hybridization buffer and washed for 10 minutes at 
65˚C in pre-warmed 2X SSC, 0.5% SDS at 65˚C on a shaking platform. Following the first wash, the 
membrane was washed two more times, first in pre-warmed 1X SSC, 0.1% SDS followed by pre-warmed 
0.1X SSC, 0.1% SDS for 10 min each at 65˚C on a shaking platform.  After washing, the membrane was 
dried on Whatman paper for 15 minutes, attached to a previously exposed western blot film by wrapping 
with plastic wrap, and placed between two amplifying screens along with Carestream Kodak BioMax MS 
film (Sigma).  The film was then exposed overnight at -80˚C and developed the following morning. 
Two separate strategies were designed to detect the properly targeted Bard1S563F allele.  In the 
first strategy, genomic DNA from mice or ES cells was digested with EcoRV and hybridized with a probe 
upstream of exon 7 (“5’ probe”) (Figure 6). Bard1S563F-neo or Bard1S563F was detected as a 7.4 kb band 
whereas Bard1+ was detected as a 9.3 kb band.  In the second strategy, which can ascertain the 
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presence or absence of the neomycin cassette included for selection during gene targeting and then 
removed subsequently via cre recombination (Bard1S563F-neo vs Bard1S563F), genomic DNA was digested 
with KpnI.  The digested DNA was then hybridized with a probe downstream of exon 9 (“3’ probe”) (Figure 
6), yielding bands of 9.4 kb for Bard1+, 5.9 kb for Bard1S563F-neo, and 4.0 kb for Bard1S563F. 
The two strategies outlined above were also applied to detect properly targeted Bard1K607A.   In 
the first strategy, genomic DNA from mice or ES cells was digested with EcoRV and hybridized with a 
probe upstream of exon 7 (“5’ probe”) (Figure 7). Bard1K607A-neo or BardK607A was detected as an 8.5 kb 
band whereas Bard1+ was detected as a 9.3 kb band. In the second strategy, which again could 
distinguish between the Bard1K607A-neo and Bard1K607A alleles, genomic DNA was digested with KpnI.  The 
digested DNA was then hybridized with a probe downstream of exon 9 (“3’ probe”) (Figure 7), yielding 
bands of 9.4 kb for Bard1+, 5.0 kb for Bard1K607A-neo, and 3.0 kb for Bard1K607A. 
 
G. Generation and immortalization of mouse embryonic fibroblasts (MEFs)  
Embryos were harvested under sterile conditions from a pregnant mouse on day E13.5 post-
fertilization by removing the uterine horns and placing them into a 10-cm dish with sterile 1X PBS.  The 
individual embryos were then separated from the uterine horn and yolk sac using scissors and forceps 
and placed into a 6-well plate containing sterile 1X PBS.  The scissors and forceps were rinsed with 70% 
ethanol and sterile 1X PBS between handling of each embryo to prevent cross contamination.  Once the 
embryos were placed into separate wells of the 6-well plate, the head of the embryo was removed and 
placed into a 1.5 mL Eppendorf tube for isolation of genomic DNA and genotyping (see Sections D and 
E).  Next, the liver of the embryo was removed and the remaining embryonic tissue was placed into a 15 
mL tube containing 500 µL of ice-cold 1X trypsin-EDTA (0.25% trypsin/2.21 mM EDTA in Hank’s 
Balanced Salt Solution without sodium bicarbonate, calcium, and magnesium; Cellgro) inside a sterile 
tissue culture hood and incubated on ice overnight in a 4˚C room.   
The following morning, excess trypsin was drained from each 15 mL tube before adding 2 µL 
DNase I (2000 U/mL, New England Biolabs) to the embryo.  The 15 mL tube was then placed into a 37˚C 
water bath for five minutes; gently vortexing before, midway through, and after the five minute incubation 
period.   Following the incubation, 2.5 mL of primary MEF media (Dulbecco’s Modified Eagle Medium 
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(DMEM; Cellgro) supplemented with 10% fetal bovine serum (FBS; Cellgro), 100 µg/mL 
penicillin/streptomycin, 2 mM L-glutamine, 1X nonessential amino acids (Cellgro) 1.25 µg/mL Plasmocin 
(InvivoGen), and 0.1 mM 2-mercaptoethanol), was used to inactivate the trypsin.  Using a sterile 10 mL 
serological pipette, the media/embryo mixture was pipetted up and down at least 10 times to break the 
embryo into a single cell suspension.  The 15 mL tube was then left undisturbed for 5 minutes to allow 
any undigested tissue to settle to the bottom.  The cells in single suspension at the top of the 15 mL tube 
were transferred to a new sterile 15 mL tube, while another 2.5 mL of primary MEF media was added to 
the original tube.  Once again, a 10 mL serological pipette was used to break up the undigested tissue 
into single cell suspension by pipetting up and down at least 10 times and then left undisturbed for five 
minutes, after which point the single cell suspension at the top of the tube was transferred to the second 
15 mL tube.  Finally, 5 mL of fresh primary MEF media was added to the 5 mL single cell suspension, 
mixed and plated on a 10 cm plate coated with 0.2% gelatin.  The cells were washed with 1X PBS and 
given fresh media the following day. 
  To immortalize the primary MEF lines, passage two (P2) MEFs at approximately 50% 
confluence were transfected with SV40 large-T antigen.  For transfection, 10 µg of the pMSSVLT plasmid 
was mixed with 25 µL of Lipofectamine 2000 (Invitrogen) in 1 mL of opti-MEM reduced serum media (Life 
Technologies) and incubated for 20 minutes.  After incubation, the lipofectamine/DNA mix was added 
dropwise to primary MEFs in a 10-cm dish and returned the incubator.  The next morning, the cells were 
washed with 1X PBS and given fresh primary MEF media.  The MEFs were subsequently cultured for 10-
12 passages until only immortalized cells remained (approximately 4 weeks in total).  The genotype of the 
immortalized MEFs was confirmed by PCR prior to freezing.  
    
H. Primary and immortalized MEF cultures 
 All MEFs were grown in a sterile 37˚C incubator with a humidified 5% CO2 atmosphere.  Primary 
MEFs were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Cellgro) supplemented with 10% fetal 
bovine serum (FBS; Cellgro), 100 µg/mL penicillin/streptomycin, 2 mM L-glutamine, 1X nonessential 
amino acids (Cellgro) 1.25 µg/mL Plasmocin (InvivoGen), and 0.1 mM 2-mercaptoethanol.  Immortalized 
MEFs were cultured in DMEM supplemented with 10% FBS, 100 µg/mL penicillin/streptomycin, and 2 mM 
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L-glutamine.   
All MEFs were passaged by washing with 1X PBS and incubating with 1X trypsin-EDTA (0.25% 
trypsin/2.21 mM EDTA in Hank’s Balanced Salt Solution without sodium bicarbonate, calcium, and 
magnesium; Cellgro) at 37˚C for 3 minutes.  Trypsin was then neutralized with the appropriate MEF 
medium, transferred to a 15-mL tube, and centrifuged at 1200 RPM for 3 minutes.  Primary MEFs were 
plated on dishes coated with 0.2% gelatin. 
To freeze cells, MEFs were resuspended in 2X freezing medium (80% FBS and 20% 
dimethylsulfoxide) and an equal volume of MEF media.  Cells were then kept at -80˚C overnight in a cell 
freezing container (Thermo Scientific) and transferred to liquid nitrogen the next morning.   
 
I. ES cell generation 
 Blastocysts were recovered from pregnant mice at embryonic day E3.5 and transferred into 96-
well plates containing a layer of primary MEF feeder cells (see Section J) in ES medium (Dulbecco’s 
Modified Eagle Medium (DMEM; Cellgro) supplemented with 15% Hyclone ES cell screened fetal bovine 
serum (FBS, Fisher Scientific), 100 µg/mL penicillin/streptomycin, 2 mM L-glutamine, 1X nonessential 
amino acids (Cellgro), 1.25 µg/mL Plasmocin (InvivoGen), 0.1 mM 2-mercaptoethanol, and 1000 units/mL 
leukemia inhibitory factor (LIF, Millipore)).  The Blastocysts were then left untouched for 6 days in a sterile 
37˚C incubator with a humidified 5% CO2 atmosphere.  After the 6-day incubation, the cells were washed 
with 1X PBS and incubated with 30 µL of half-strength trypsin (0.125% trypsin/2.21 mM EDTA in Hank’s 
Balanced Salt Solution without sodium bicarbonate, calcium, and magnesium; Cellgro) for 6 minutes at 
37˚C.  The trypsin was then neutralized with 180 µL of ES medium, and the cells transferred to another 
96-well plate with primary MEF feeder cells.  After overnight incubation at 37˚C, the cells were washed 
with 1X PBS and given fresh ES medium.  ES cell colonies were visible approximately two days after 
transfer to the second 96 well plate.  When confluent, the ES cells were then transferred to a 24-well plate 





J. ES cell culture 
Embryonic stem cells (ES cells) were cultured in Dulbecco’s Modified Eagle Medium (DMEM; 
Cellgro) supplemented with 15% Hyclone ES cell screened fetal bovine serum (FBS, Fisher Scientific), 
100 µg/mL penicillin/streptomycin, 2 mM L-glutamine, 1X nonessential amino acids (Cellgro), 1.25 µg/mL 
Plasmocin (InvivoGen), 0.1 mM 2-mercaptoethanol, and 1000 units/mL leukemia inhibitory factor (LIF, 
Millipore), and housed in a sterile 37˚C incubator with a humidified 5% CO2 atmosphere.  To prevent 
differentiation, ES cells were cultured on a layer of mitotically inactive primary mouse embryonic 
fibroblasts (MEFs).  Primary MEFs were seeded onto 0.2% gelatin coated plates and inactivated when 
approximately 90% confluent by 2-hour incubation with 5 µg/mL mitomycin C (MMC, Sigma) in primary 
MEF media (Dulbecco’s Modified Eagle Medium (DMEM; Cellgro) supplemented with 10% fetal bovine 
serum (FBS; Cellgro), 100 µg/mL penicillin/streptomycin, 2 mM L-glutamine, 1X nonessential amino acids 
(Cellgro), 1.25 µg/mL Plasmocin (InvivoGen), and 0.1 mM 2-mercaptoethanol).  Following MMC 
inactivation, the primary MEFs were washed twice with 1X PBS and cultured in ES cell media. 
ES cells were passaged by washing with 1X PBS and incubated with 1X trypsin-EDTA (0.25% 
trypsin/2.21 mM EDTA in Hank’s Balanced Salt Solution without sodium bicarbonate, calcium, and 
magnesium; Cellgro) at 37˚C for 5 minutes.  Trypsin was then neutralized with ES cell media, transferred 
to a 15-mL tube, and centrifuged at 1200 RPM for 3 minutes.  Finally, the ES cells were seeded onto 
dishes containing a single layer of mitotically inactivated primary MEFs. 
To freeze cells, ES cells were resuspended in 2X ES freezing medium (80% HyClone ES cell 
screened FBS and 20% dimethylsulfoxide) and an equal volume of ES media.  Cells were then kept at -
80˚C overnight in a cell freezing container (Thermo Scientific) and transferred to liquid nitrogen the next 
morning.   
 
K. Gene targeting analysis 
Gene targeting of Bard1+/+, Bard1KA/KA, and Bard1SF/SF ES cells at the Pim1 locus was 
accomplished by first linearizing the p59xDR-GFP6 targeting vector, a plasmid that contains the DR-GFP 
construct along with a promoterless hygromycin resistance gene flanked by the Pim1 sequence, with 
XhoI endonuclease (Pierce & Jasin, 2001).  An 80% confluent 10-cm dish of ES cells growing on 
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mitotically inactivated primary MEFs was trypsinized for 8 minutes, neutralized with ES cell media, and 
centrifuged at 1200 RPM for 2 minutes.  The media was aspirated and the cells resuspended in 500 µL of 
1X PBS.  The cells were then transferred to a 0.4 cm electroporation cuvette (USA Scientific) along with 
25 µg of the linearized p59xDR-GFP targeting vector, electroporated at 0.8V/10 µF, and incubated at 
room temperature for 5 minutes.  Following electroporation, the cells were resuspended in ES cell media, 
and then seeded onto three 10-cm dishes containing mitotically inactivated primary DR4 feeder MEFs 
(See Section J).  The DR4 MEFs are cells that have been genetically engineered to contain resistance 
genes to neomycin, hygromycin, puromycin, and 6-thioguanin.  The next day, the ES cell media was 
replaced with selection media (ES media supplemented with 0.2 mg/mL hygromycin B (Sigma).  The ES 
cells were then given fresh selection media daily for the next 7-10 days, until the hygromycin-resistant ES 
clones were large enough to be seen with the naked eye.  Individual hygromycin-resistant ES clones 
were then transferred from the 10-cm dish to a 96-well plate containing DR4 feeder MEFs, and each 
clone expanded into 48-, 12-, and finally 6-well plates.  At the 96-well plate stage, genomic DNA was 
harvested from each hygromycin resistant clone for verification of the genotype by PCR and verification of 
correct targeting by Southern blot analysis (See Section F).  For Southern analysis, the genomic DNA 
from the ES cell clones was digested with HincII, and hybridized with the “P22” probe, resulting in a 3.6 
kb fragment for the wild type Pim1 allele and a 2.4 kb fragment for the targeted Pim1 allele (Moynahan, 
Pierce, et al., 2001).   
 
L. DR-GFP assay 
To perform the DR-GFP assay, which measures the repair of I-SceI-induced chromosomal 
breaks, ES cells harboring the DR-GFP reporter at the Pim1 locus (See Section K) growing exponentially 
on primary MEF feeder cells were harvested by trypsinization, centrifuged at 1000 RPM for 5 minutes, 
and resuspended in ES transfection medium (ES medium without penicillin/streptomycin, plasmocin, or 
LIF) at a concentration of 0.8 x 106 cells per mL.  While harvesting the cells, the transfection mix was 
prepared by combining either 0.5 µg of empty vector (pCAGGs), I-SceI expression vector, or GFP 
expression vector with 1.2 µL of Lipofectamine 2000 (Invitrogen) in 66 µL of opti-MEM reduced serum 
media (Life Technologies) and incubating for 20 minutes.  After incubation, the ES cells from each clone 
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were seeded onto 7 wells of a gelatin-coated, feederless 24-well plate (0.2 mL total volume, 0.16 x 106 
cells per well, 3 wells for empty vector transfection, 3 wells for I-SceI transfection, and 1 well for GFP 
transfection).  Immediately after seeding the ES cells, the DNA/lipofectamine mix was added to the 
appropriate well and incubated for 6 hours.  The transfection mix was then diluted out by adding 1 mL of 
ES media (now with penicillin/streptomycin, plasmocin, and LIF) to each well.  The following morning the 
cells were given fresh ES media and allowed to grow undisturbed for an additional 48 hours.  After the 
48-hour growth step, the cells were washed with 1X PBS, trypsinized, centrifuged at 5000 RPM, and 
resuspended in 0.3 mL of 1% FBS/PBS, after which they were kept on ice and protected from light until 
analysis.   
Flow cytometry was performed on a FACScalibur machine using CellQuest software (BD 
Biosciences), and analysis of the data was carried out using FlowJo version X software.  The efficiency of 
repair of the I-SceI-induced chromosomal break was measured by the percentage of GFP-positive cells.  
Gating for ES cells was performed by sorting cells based on side-scatter height vs forward-scatter height 
and selecting the appropriate sized population of cells.  GFP-positive ES cells were then selected by 
sorting cells by green fluorescence intensity (FL1-H) vs orange fluorescence intensity (FL2-H) and gating 
for cells that showed a significant increase in green fluorescence intensity compared to orange 
fluorescent intensity (and therefore were not autofluorescent).  At least 25,000 cells were counted per 
experimental condition.  The percent of GFP positive cells was normalized to transfection efficiency by 
measuring the percentage of GFP positive cells in the well that was transfected with the GFP expression 
vector and then dividing the percentage of GFP positive cells in the I-SceI transfected wells with this 
value.   
 
M. Western blot and cell fractionation 
 Exponentially growing immortalized MEFs seeded 48 hours earlier were harvested by scraping in 
3 mL of ice cold 1X PBS and kept on ice.  To harvest any remaining cells, the plate was then washed with 
an additional 2 mL of ice-cold 1X PBS and the wash transferred to the 3 mL of cell/PBS suspension.  The 
cells were then centrifuged at 1200 RPM for 3 minutes at 4˚C.  After centrifugation, the cells were lysed in 
low-salt Nonidet-40 (NP40) lysis buffer (10 mM Hepes pH 7.6, 0.25 M NaCl, 0.1% NP40, 5 mM EDTA, 
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10% glycerol) supplemented with complete protease inhibitor cocktail (Roche), 1 mM dithiothreital (DTT), 
and 25 mM NaF, and incubated for 10 minutes on ice. The cell/lysis buffer mixture was then centrifuged 
at 13000 RPM for 10 minutes at 4˚C and the supernatant (now referred to as the “cell lysate”) transferred 
to a separate tube for protein concentration measurement. 
 To perform cell fractionation, exponentially growing immortalized MEFs seeded 48 hours earlier 
were harvested, washed with 1X PBS, and centrifuged as described above.  After centrifugation, the cells 
were lysed in 5 times the cell pellet volume of buffer A (10 mM Hepes pH 7.9, 10 mM KCl) supplemented 
with protease inhibitor cocktail (Roche) and incubated for 10 minutes on ice.  Following the incubation, 
1/16th lysate volume of 10% NP40 was added to the cell lysate and vortexed for 10 seconds.  The lysates 
were then centrifuged at 5000 RPM for 2 minutes at 4˚C to separate into nuclear (pellet) and cytoplasmic 
(supernatant) fractions.   
The resulting supernatant (cytoplasmic fraction) was removed and 0.11 times the total 
cytoplasmic fraction volume of buffer B (0.3 M Hepes pH 7.9, 1.4 M KCl, 1 mM DTT) was added.  The 
cytoplasmic fraction was then centrifuged at 13000 RPM for 10 minutes at 4˚C and the resulting 
supernatant collected for protein concentration measurement.   
To process the nuclear fraction, the cell pellet obtained from the 5000 RPM centrifugation step 
was resuspended in 2 times the cell pellet volume of buffer C (20 mM Hepes pH 7.9, 25% v/v glycerol, 
0.42 M NaCl, 0.2 mM EDTA, protease inhibitor cocktail, and 1 mM DTT).  The nuclear fraction was then 
vortexed for 10 minutes at 4˚C and centrifuged at 13000 RPM for 10 minutes.  The resulting supernatant 
(nuclear extract) was collected for protein concentration measurement.   
Using the Bradford protein assay reagent (Bio-Rad), a Bradford assay was performed to 
determine the concentration of proteins in the cell lysates, cytoplasmic fractions, and nuclear extracts.  5X 
protein loading dye (0.313 M Tris-Cl pH6.8, 10% SDS, 50% glycerol, 25% 2-mercaptoethanol, and 0.05% 
bromophenol blue) was then added to the cell lysates before boiling the loading dye/lysate mixture for 3 
minutes to denature the proteins.  The lysates were then loaded onto 6.5% polyacrylamide gels and 
electrophoresed in tris-glycine SDS gel running buffer (250 mM trizma base, 1.9 M glycine, 1% SDS) at 
130 V for approximately 1 hour and 45 minutes.  Following electrophoresis, lysates were transferred onto 
an Amersham Protran 0.45 µm nitrocellulose membrane (GE Healthcare Life Sciences) in western 
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transfer buffer (25 mM tris-Cl pH 7.6, 190 mM glycine, 20% methanol, 0.04% SDS) at 22 V overnight at 
room temperature.  The following day, the membrane was blocked in 10% milk in TBS-T (20 mM Tris-Cl 
pH 7.6, 0.137 M NaCl, 0.1% Tween 20) for 30 minutes at room temperature.  The membrane was then 
washed once in 1X TBS-T for 5 minutes on a shaking platform, followed by staining with the appropriate 
primary antibody (see Table 2 for antibody concentrations) diluted in 2% milk/TBS-T for 2 hours at room 
temperature.  Following primary antibody staining, the membrane was rinsed once with 1X TBS-T and 
then washed three times for 10 minutes each in 1X TBS-T on a shaking platform.  The membrane was 
then incubated with either HRP-conjugated goat anti-mouse (Sigma) or HRP-conjugated donkey anti-
rabbit (GE Healthcare Life Sciences) secondary antibodies diluted 1:10,000 in 2% milk/TBS-T.  Once 
again, the membrane was rinsed once and then washed three times for 10 minutes each with 1X TBS-T 
on a shaking platform.  After the wash steps, the membrane was incubated with either SuperSignal West 
Pico Chemiluminescent substrate (ThermoFischer Scientific) or SuperSignal West Dura 
Chemiluminescent substrate (ThermoFischer Scientific) for 3 minutes.  The membranes were then dried 
by blotting with Whatman paper and then exposed on CL-XPosure film (ThermoFischer Scientific).  
 
N. Immunoprecipitation with Bard1 
 For immunoprecipitation experiments, exponentially growing cells seeded 48-hours prior to 
collection were harvested in low salt lysis buffer supplemented with complete protease inhibitor cocktail, 1 
mM dithiothreital (DTT), and 25 mM NaF, and the protein concentration of the resulting lysate determined 
by Bradford assay as described in Section M.  Immunoprecipitation was then performed by incubating 
600 µg of protein with the mouse Bard1-specific 1734 rabbit polyclonal antibody (1:50) (E. E. McCarthy et 
al., 2003) at 4˚C on a rotator for 2 hours.  The 600 µg of protein was diluted as needed with low salt lysis 
buffer so that all samples were in the same total volume.  After the 2-hour incubation, 50 µL of protein A 
sepharose CL-4B beads (50% v/v in low salt lysis buffer, GE Healthcare Life Sciences) was added to the 
protein lysate/antibody mixture and incubated on a rotator at 4˚C for an additional 30 minutes.  The 
lysate/bead mixture was then centrifuged at 500 g for 3 minutes at 4˚C and the resulting supernatant was 
discarded.  The beads were then washed with 800 µL of low salt lysis buffer, incubated on a rotator at 4˚C 
for 3 minutes, and centrifuged at 500 g for 3 minutes at 4˚C.  The resulting supernatant was again 
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discarded and the wash procedure repeated two more times.  Following the final wash, approximately 25 
µL of low salt lysis buffer was left on the beads and the rest discarded.  Twenty-five µL of 2x protein 
loading dye was added to the beads and then boiled for 3 minutes to elute the protein.  Immediately after 
boiling, the samples were electrophoresed on 6.5% polyacrylamide gels in tris-glycine SDS gel running 
buffer at 140V for approximately 1 hour and 45 minutes.  The gel was then transferred overnight at 22 V 
at room temperature and the western blotting procedure was followed the next day as described in 
Section M.   
 
O. Rad51 staining and foci quantification 
Immortalized MEFs were seeded onto poly-L-lysine (Sigma) coated coverslips in 6-well plates.  
Forty-eight hours after seeding, the cells were treated with 10 Gy of ionizing radiation using an Atomic 
Energy of Canada Gammacell 40 Cesium Unit.  After irradiation, the cells were returned to the 37˚C 
incubator for one hour.  The cells were then fixed by washing three times with 1X PBS and incubating 
with 3.7% paraformaldehyde(PFA)/PBS solution for 20 minutes at room temperature.  The PFA was 
aspirated and the cells were washed four times with 1X PBS before permeabilization with 1% triton X-
100/PBS for 5 minutes at room temperature.  The cells were then washed an additional three times with 
1X PBS and blocked in 5% bovine serum albumin (BSA)/PBS for 1 hour at 37˚C.  After blocking, the cells 
were incubated with the Rad51 primary antibody (rabbit polyclonal, Calbiochem AB-1, 1:200 dilution) 
diluted in 5% BSA/PBS in a humidified chamber for 1 hour 45 minutes at 37˚C.  The cells were then 
washed three times with 1X PBS and incubated with secondary antibody (goat anti-rabbit Alexa 488, 
ThermoFischer Scientific, 1:1000 dilution) diluted in 5% BSA/PBS in a humidified chamber for 45 minutes 
at 37˚C.  Following application of the secondary antibody, the cells were rinsed four times with 1X PBS 
and dehydrated using successive rinses of 70%, 90%, and 100% ethanol.  The cells were then mounted 
onto a glass slide with Vectashield hard set mounting medium with 4’, 6-diamidino-2-phenylindole (DAPI; 
Vector Laboratories).  The mounting media was allowed to dry for 20 minutes before sealing the 
coverslips to the glass slides with clear nail polish. 
 The cells were imaged on an Axio Imager Z2 fluorescent microscope with Coolcube1 camera 
(Zeiss) at 40x magnification.  Automated Rad51 foci quantification was carried out using the Metafer 4 
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software (Metasystems).  At least 300 cells were counted per trial.   
 
P. PCNA-Bard1 and PCNA-Brca1 staining and colocalization 
Immortalized MEFs were seeded onto poly-L-lysine (Sigma) coated coverslips in 6-well plates.  
48 hours after seeding, the cells were treated with either 2 mM hydroxyurea (HU, Sigma) or PBS for 1.5 
hours.  After treatment, the cells were harvested by washing three times with ice cold CSK buffer (10 mM 
piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES), 100 mM NaCl, 300 mM sucrose, and 3 mM MgCl2).  
Cells were then permeabilized with ice cold 0.5% triton/CSK for 5 minutes at 4˚C.  Permeabilization buffer 
was washed off by rinsing twice with ice-cold CSK buffer and twice with 1X PBS.  Cells were then fixed by 
incubating with ice cold 100% methanol at –20˚C for 10 minutes.  After fixation, the cells were rinsed 
twice with 1X PBS and washed three times with 1X PBS on a platform shaker for 5 minutes each.  
Blocking was performed by incubating the cells in 5% BSA, 0.1% triton/PBS for 30 minutes on a platform 
shaker at room temperature.  Cells were then stained with the following primary antibodies: PCNA 
(mouse monoclonal, Santa Cruz Biotechnology PC10, 1:200 dilution) and either Brca1 (rabbit polyclonal 
57J, 1:250 dilution) (Shakya et al., 2011) or Bard1 (rabbit polyclonal 1734R, 1:500 dilution) (E. E. 
McCarthy et al., 2003) diluted in 1% BSA 0.1% triton/PBS for 1 hour at room temperature.   Following 
primary antibody application, cells were rinsed twice with 0.1% triton/PBS and then washed three times 
with 0.1% triton/PBS for 5 minutes each on a platform shaker.  Cells were then incubated with secondary 
antibodies (goat anti-rabbit Alexa Fluor 488, ThermoFischer Scientific, 1:1000 dilution; and goat anti-
mouse Alexa Fluor 568, ThermoFischer Scientific, 1:400 dilution) diluted in 1% BSA, 0.1% triton/PBS for 
30 minutes at room temperature while protected from light.  Once again, the cells were rinsed twice with 
0.1% triton/PBS and then washed three times with 0.1% triton/PBS for 5 minutes each on a platform 
shaker while protected from light.  Following the wash steps, the cells were rinsed twice with 1X PBS and 
then dehydrated using successive rinses of 70%, 90%, and 100% ethanol.  The cells were then mounted 
onto a glass slide with Vectashield hard set mounting medium with 4’, 6-diamidino-2-phenylindole (DAPI; 
Vector Laboratories).  The mounting media was allowed to dry for 20 minutes before sealing the 
coverslips to the glass slides with clear nail polish. 
The cells were imaged on an Eclipse 80i fluorescent microscope (Nikon) with CoolSNAP HQ2 
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camera (Photometrics) at 40x magnification.  Blue, red, and green channel images were merged and 
analyzed using imageJ software. At least 200 cells were counted by hand per trial.  A “Brca1-positive” cell 
was defined as a cell containing 5 or more Brca1 foci.  A “Bard1-positive” cell was defined as a cell 
containing 5 or more Bard1 foci.  A “PCNA-positive” cell was defined as a cell containing 5 or more PCNA 
foci.  PCNA and Bard1 (or Brca1) were scored as “co-localizing” if over half of the Bard1 (or Brca1) foci 
overlapped with PCNA foci.  Percent co-localization was defined as the number of co-localizing cells over 
total number of PCNA-positive cells (Figure 33).   
 
Table 2: Antibody dilutions 
Antibody Species Source Western blot Immunocytochemistry 
Bard1 (1734) Rabbit polyclonal (E. E. McCarthy et al., 2003) 1:2000 1:500 






Brca1 (57) Rabbit polyclonal (Shakya et al., 2011) 1:2000 1:250 
Ctip (14-1) Mouse monoclonal (Yu & Baer, 2000) 1:50  





Rad51 Rabbit polyclonal Calbiochem (Ab-1)  1:200 
α-Tubulin Mouse monoclonal Calbiochem (DM1A) 1:10,000  
 
 
Q. Analysis of metaphase spreads using Giemsa stain or Telomere fluorescent in situ 
hybridization (T-FISH) 
For T-FISH analysis, metaphase spreads were prepared from passage 3 (P3) or earlier primary 
MEFS.  The day prior to drug treatment, the primary MEFs were plated on 0.2% gelatin-coated plates and 
allowed to attach overnight.  For Giemsa stain analysis, metaphase spreads were prepared from 
immortalized MEFs plated one day prior to genotoxin exposure.  For genotoxin exposure in both T-FISH 
and Giemsa stain analysis, cells were treated the day after plating with either 40 ng/mL mitomycin C 
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(MMC, Sigma) or mock treatment with 1X PBS for 16 hours (overnight).  Four hours prior to the end of 
genotoxin treatment, Karyomax colcemid solution (Invitrogen) was added at a concentration of 0.1 µg/mL.  
Following the colcemid treatment, the cell media was collected in order to preserve any mitotic 
cells that may have become detached.  The cells were then washed with 1X PBS and trypsinized, saving 
the wash and trypsinized cells along with the cell media.  The media/wash/cell mixture was then 
centrifuged at 1000 RPM for 5 minutes.  The supernatant was aspirated, the resulting cell pellet was 
washed with 10 mL of 1X PBS, and then centrifuged again at 1000 RPM for 5 minutes.  The cell pellet 
was then resuspended in 0.4% KCl (w/v) solution by adding the solution dropwise while gently vortexing.  
The cells were then allowed to swell by incubating in the KCl solution for 20 minutes at room temperature 
while gently inverting the tubes every 5 minutes.  At the end of the incubation period, 10 drops of 3:1 
methanol/glacial acetic acid fixative solution was added to the tube before centrifuging for 10 min at 800 
RPM.  The resulting supernatant was then removed and the cells were resuspended in 10 mL of fixative 
solution by adding the fixative dropwise while gently vortexing.  Again, the cells were centrifuged at 800 
RPM and the resulting supernatant was aspirated.  The fixative wash and centrifugation steps were then 
repeated an additional three times, before resuspending the cells in 10 mL of fixative and incubating at –
20˚C overnight.   
 The next day, the fixative wash process was repeated three more times before resuspending the 
cells in a volume of 250µL – 1 mL depending on the confluency of the culture at the time of harvest.  A 
volume of 10 µL of each cell suspension was dropped from a height of approximately 0.3 m onto glass 
slides.  To facilitate the spreading of the cells across the slide, the slide was held over a 95˚ C steam bath 
for 5 seconds, approximately 10 seconds after dropping the cell suspension. The cells were allowed to 
dry overnight before staining with either Giemsa stain or telomere probe for T-FISH.   
 To stain the slides for Giemsa stain analysis, cells were incubated with Karyomax Giemsa stain 
(Gibco) diluted 1:10 in 1X Gurr Buffer (Gibco) for 3 minutes.  The slides were then rinsed with ddH20 to 
remove excess stain.  The metaphase spreads were then imaged using a Nikon Eclipse E600 light 
microscope using a Nikon DS-Fi1 camera at 100X magnification.  Twenty-five metaphases were analyzed 
for gross structural abnormalities per condition. 
 To stain the slides for T-FISH analysis, they were first washed in 1x PBS for 15 minutes followed 
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by fixation in 4% formaldehyde/PBS for 2 minutes.  The slides were then washed three times in 1X PBS 
for five minutes each.  After the washes, the cells were digested for 10 minutes at 37˚C in pre-warmed 
acidified pepsin (2500 units/mL Sigma and 10 M HCl).  Two washes for 5 minutes in 1X PBS were then 
performed followed by a second fixation step in 4% formaldehyde/PBS for two minutes, after which an 
additional three washes for 5 min each in 1X PBS were performed.  The slides were then dehydrated 
using successive washes in 70% ethanol, 90% ethanol, and 100% ethanol for five minutes each before 
allowing the slides to air dry for 20 minutes.  Probe mix (10 mM Tris Cl pH 7.2, 2 mM MgCl2, 0.75 mM 
citric acid, 7 mM Na2HPO4, 70% deionized formamide, 0.5 µg/µL telomere probe, and 0.25% blocking 
reagent for nucleic acid hybridization and detection (Sigma)) was added to the slides and incubated at 
80˚C for three minutes to denature the DNA.  Following the denaturation step, the slides (with probe mix 
still present) were transferred to a humidified chamber and incubated at room temperature for 2 hours.  
The slides were then incubated with wash buffer (70% formamide, 10 mM Tris pH 7.2, 0.1% BSA) on a 
shaking incubator twice for 15 minutes each.  Next, the slides were washed in 0.08% TBS-T (20 mM Tris-
Cl pH 7.6, 0.137 M NaCl, 0.08% Tween 20) three times for five minutes each.  After the washes, the 
slides were dehydrated using successive washes in 70% ethanol, 90% ethanol, and 100% ethanol for five 
minutes each before allowing to air dry for 20 minutes.  Finally, glass coverslips were mounted onto the 
slides using Prolong Gold Antifade with DAPI (Thermo Fisher Scientific) and sealed with clear nail polish.   
 The T-FISH metaphase spreads were imaged on an Axio Imager Z2 fluorescent microscope with 
Coolcube1 camera (Zeiss). Metafer software version 3.10.6 (Metasystems) was used to automatically 
locate metaphases at 10x magnification and then automatically capture images at 63x magnification.  The 
metaphases were then analyzed on Isis fluorescent imaging system software (Metasystems).  At least 25 
metaphases were counted per experimental condition.   
 
R. DNA Fiber Assay 
 Forty-eight hours after seeding in 6-well plates, exponentially growing immortalized MEFs were 
pulse labeled with 200 µM 5-iodo-2’-deoxyuridine (IdU, Sigma) for 20 minutes at 37˚C.  After IdU 
treatment, the cells were washed three times with warm (37˚C) 1X PBS and pulse labeled with 100 µM 5-
chloro-2’-deooxyridine (CldU, Sigma) for 20 minutes at 37˚C.  The cells were again washed with warm 1X 
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PBS three times and then either harvested (untreated control) or treated with 2 mM hydroxyurea (HU, 
Sigma) for 1.5 hours followed by harvest (Figure 27A).  To inhibit the Mre11 nuclease, cells were treated 
with 50 µM mirin (Sigma) during pulse labeling with IdU and CldU, as well as during the subsequent 
hydroxyurea treatment. To harvest the cells, 0.5 mL of 1X trypsin-EDTA (0.25% trypsin/2.21 mM EDTA in 
Hank’s Balanced Salt Solution without sodium bicarbonate, calcium, and magnesium; Cellgro) was added 
to each well of the 6-well plate and incubated at 37˚C for 3 min.  The trypsin was then neutralized with 2.5 
mL immortalized MEF media (DMEM supplemented with 10% FBS, 100 µg/mL penicillin/streptomycin, 
and 2 mM L-glutamine), transferred to a 15-mL falcon tube, and centrifuged at 1200 RPM for 2 minutes.  
After centrifugation, the cell pellet was resuspended in 500 µL ice-cold 1X PBS and kept on ice thereafter 
to prevent further DNA synthesis or degradation.  The concentration of cells in 1X PBS was then 
determined with a hemocytometer and adjusted to 0.3 x 106 cells/mL. Two microliters of the cell mixture 
was pipetted onto precleaned glass microscope slides and allowed to partially dry for 5 minutes.  After 
partial drying, the cells were lysed using pre-warmed spreading buffer at 37˚C (0.5% sodium dodecyl 
sulfate, 20 mM Tris-Cl pH 7.4, and 50 mM EDTA) for 10 minutes in a humidified chamber at room 
temperature.  Spreading of the DNA was then achieved by tilting the slides at a 15˚ angle relative to 
horizontal and allowing the cell lysis buffer mixture to run down the slide for 3 minutes.  Following 
spreading, the slides were dried for 20 minutes in a fume hood and then fixed by incubating in an ice cold 
(–20˚C) 3:1 methanol:acetic acid mixture at room temperature for 2 minutes.  The slides were once again 
allowed to dry for approximately 20 minutes and then denatured in a 2.5 M HCl solution for 45 minutes at 
room temperature.  The slides were then rinsed 5 times with 1X PBS to remove all residual HCl.  After 
rinsing, the slides were blocked for 1 hour at room temperature in 3% bovine serum albumin (BSA), 0.1% 
triton X-100/PBS. To stain the slides with primary antibody, the slides were incubated with rat anti-BrdU to 
detect CldU (Abcam ab6326, diluted 1:100) and mouse anti-BrdU to detect IdU (BD biosciences, BD 
347580, 1:100 dilution) diluted in blocking solution for 1 hour at room temperature in a humidified 
chamber.  The slides were then rinsed three times with 1X PBS and stained with anti-mouse Alexa Fluor 
488 (ThermoFischer Scientific, 1:300 dilution) and anti-rat Alexa Fluor 594 (ThermoFischer Scientific, 
1:300 dilution) diluted in blocking solution for 30 min at room temperature in a humidified chamber.  
Following secondary antibody staining, the slides were washed three times with 1X PBS, dried for 45 
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minutes in a fume hood, and then mounted in Prolong Gold Antifade (ThermoFischer Scientific).  The 
slides were kept at 4˚C until ready for imaging.  Imaging of fibers was carried out on an Eclipse 80i 
fluorescent microscope (Nikon) with CoolSNAP HQ2 camera (Photometrics) at 40x magnification.  
Analysis was performed using imageJ software.  At least 150 individual fibers were measured per 
experimental condition.   
 
S. Genotoxin sensitivity assays 
 For all genotoxin sensitivity assays, immortalized MEFs were used to seed 6-well plates with 
1000 cells/well for both drug-treated and control plates.  Each experimental condition was plated in 
triplicate (3 wells per condition).  In the case of mitomycin C treatment (MMC; Sigma) treatment, 48 hours 
after plating, the immortalized MEFs were exposed to varying doses of MMC (0 ng/mL, 50 ng/mL, 100 
ng/mL, 200 ng/mL, 400 ng/mL, and 800 ng/mL) for 4 hours.  In the case of camptothecin (CPT; Sigma) 
treatment, 48 hours after plating the immortalized MEFs were exposed to varying doses of CPT (0 µM, 
0.05 µM, 0.1 µM, 0.2 µM, 0.4µM, and 1.0 µM) for 1 hour.  After drug treatment the cells were washed two 
times with 1X PBS, given fresh media, and allowed to grow until harvest 5-7 days post treatment.   
 In the case of PARP inhibitor (PARPi) treatment, at 24 hours after plating, immortalized MEFs 
were exposed to various concentrations of olaparib (SelleckChem; 0 µM, 0.064 µM, 0.16 µM, 0.4 µM, 1.0 
µM, 2.5 µM, and 5.0 µM).  The media containing olaparib was replaced with fresh media containing 
olaparib every 48 hours until cell harvest 6-8 days after initial drug treatment.  
 In the case of ionizing radiation (IR) treatment, immortalized MEFS were irradiated 48 hours after 
plating with varying doses of IR (0 Gy, 2 Gy, 4 Gy, 6 Gy, 8 Gy, and 10 Gy) with an Atomic Energy of 
Canada Gammacell 40 Cesium unit.  After irradiation, the cells were allowed to grow undisturbed until 
harvest 5-7 days later. 
 In all cases, the immortalized MEFs were harvested approximately 7 – 9 days after seeding, 
when the colonies in the untreated control plate were judged to be large enough to count.  For harvest, 
the cells were washed twice with 1X PBS and then stained with a 0.5% crystal violet, 50% methanol 
solution for 20 minutes.  Excess stain was removed by washing the plates with H20 three times and drying 
overnight.  The following day, the surviving colonies of cells were counted using a light box and 
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magnifying glass.  A colony was only counted if it contained 50 or more cells.     
 
T. Alkaline comet assays 
 One day prior to performing the assay, precleaned glass microscope slides (Fisher Scientific) 
were coated with two layers of molten 1% agarose/PBS.  The slides were allowed to dry for at least 5 
hours between the first and second agarose coat.  Immortalized MEFs were seeded onto 12-well plates 
and then treated the following day with 2 mM hydroxyurea (HU, Sigma), 100 nM camptothecin (CPT, 
Sigma), PBS mock treatment, or DMSO mock treatment for 5 hours at 37˚C.  Immediately following the 
drug treatment, the cells were harvested using 0.25 mL of 1X trypsin-EDTA (0.25% trypsin/2.21 mM 
EDTA in Hank’s Balanced Salt Solution without sodium barconbanate, calcium, and magnesium; Cellgro) 
for 5 min at 37˚C, inactivated with 1.5 mL immortalized MEF media media (DMEM supplemented with 
10% FBS, 100 µg/mL penicillin/streptomycin, and 2 mM L-glutamine), and centrifuged at 1200 RPM for 5 
minutes.  The cells were then resuspended in 0.5 mL ice cold 1X PBS and kept on ice thereafter to 
prevent DNA repair.  The cells were centrifuged again at 1200 RPM for 5 minutes at 4˚C to remove any 
residual media and resuspended in 20 µL of ice cold 1X PBS.  Ten µL of the cell/PBS mixture were then 
added to 75 µL of 0.5% low melting agarose/PBS and pipetted onto the agarose-coated slides.  
Spreading of the cell/low melting agarose mixture was facilitated by application of a glass coverslip.  The 
low melting agarose was then allowed to solidify for 10 minutes at room temperature before removal of 
the coverslip. 
After solidification of the low melting agarose, the slides were incubated with pH 10.0 lysis buffer 
(25 mM NaCl, 100 mM EDTA, 10 mM trisma base, and 1% triton X-100) at 4˚C overnight while protected 
from light.  The following the day, the slides were equilibrated in pre-chilled (4˚C) electrophoresis buffer 
(300 mM NaOH, 1 mM EDTA) for 20 minutes.  After equilibration, electrophoresis was performed at 0.6 
V/cm (20 V) in a horizontal chamber (FischerScientific) for 20 minutes.  The slides were then neutralized 
by washing with neutralization buffer (0.4 M Tris-Cl, pH 7.5) three times for five minutes each and then 
rinsed with ddH20 three times.  Following the washing steps, the slides were fixed in ice cold 100% 
ethanol for 20 minutes at room temperature and then allowed to dry completely in a fume hood.  
Following drying of the slides, the comets were stained by pipetting 90 µL of a fluorescent dye 
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(GelRed, Biotium, dilution 1:1000 in H20) onto the slide and placing a coverslip over the dye.  The comets 
were then imaged on an Eclipse 80i fluorescent microscope (Nikon) with CoolSNAP HQ2 camera 
(Photometrics) at 20x magnification.  Comet tail moment values were determined using CometScore 
Sofware Version 1.5.  At least 75 tails were analyzed per experimental condition.  Apoptotic cells (small 

















PHOSPHO-RECOGNITION BY THE BARD1 BRCT DOMAIN IS DISPENSABLE FOR BRCA1/BARD1-






 Approximately 12% of women in the general population will develop breast cancer at some point 
during their lives (Siegel et al., 2017). In contrast, women who inherit a single pathogenic allele of the 
BRCA1 gene have a 50-80% lifetime risk of breast cancer (Antoniou et al., 2003; Roy et al., 2011).  
BRCA1 has been implicated in a myriad of cellular functions, including transcriptional regulation, 
chromatin remodeling, protein ubiquitination, cell cycle checkpoint activation, stalled fork protection, 
centrosome duplication, maintenance of genome stability, and homology directed repair (Jiang & 
Greenberg, 2015; Moynahan & Jasin, 2010; Nagaraju & Scully, 2007; Roy et al., 2011; Venkitaraman, 
2014).  Despite decades of BRCA1 research, it is not known which of these function(s) is required for the 
tumor suppressor activity of BRCA1, and how its loss accounts for the staggering increase in breast 
cancer risk.  Two aspects of BRCA1 function, homology-directed repair (HDR) and stalled replication fork 
protection (SFP), have received special attention, in part because they are critical for genome stability 
and in part because they are also dependent on BRCA2.  In particular, this chapter will focus on the role 
of BRCA1, and its associated protein BARD1, in HDR. 
BRCA1 is required for homology-directed repair (HDR), a cellular pathway that repairs double-
strand DNA breaks (DSBs) with high fidelity in S and G2 phase cells.  Fluorescent staining studies 
demonstrated that BRCA1 colocalizes with other HDR components at the sites of DSBs, and subsequent 
DR-GFP reporter studies demonstrated that BRCA1-mutant cells display a profound deficiency in HDR 
(Jin et al., 1997; Moynahan et al., 1999; Scully, Chen, Ochs, et al., 1997; Scully, Chen, Plug, et al., 1997).  
Consequently, cells harboring pathogenic BRCA1 lesions have a reduced capacity for HDR and 
accumulate high levels of chromosomal abnormalities. 
The BRCA1 gene encodes a polypeptide of 1863 amino acids that contains an N-terminal RING 
domain and two tandem C-terminal BRCT repeats (Figure 3).  In vivo, BRCA1 exists as a heterodimer 
with the structurally related protein BARD1 (Baer & Ludwig, 2002; Jin et al., 1997; L. C. Wu et al., 1996).  
Most of the cellular pool of BRCA1 polypeptides exists in complex with BARD1 and multiple lines of 
evidence indicate that these proteins function as an obligate stoichiometric heterodimer (Joukov et al., 
2006; Yu & Baer, 2000).  Of note, cellular loss of BARD1 results in HDR deficiencies and chromosomal 
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abnormalities similar to the phenotype of BRCA1-mutant cells (Baer & Ludwig, 2002; Fabbro et al., 2002; 
Joukov et al., 2006; Laufer et al., 2007; E. E. McCarthy et al., 2003; Westermark et al., 2003).  
Importantly, the tumor suppression activity of BRCA1 also appears to be mediated by the BRCA1/BARD1 
heterodimer, since mammary-specific inactivation of either Brca1 or Bard1 elicits basal-like triple-negative 
breast carcinomas in mice that are phenotypically indistinguishable (Shakya et al., 2008).  In addition, 
germline mutations of human BARD1 have been identified as the pathogenic lesion in some families with 
hereditary breast and ovarian cancer (De Brakeleer et al., 2016; De Brakeleer et al., 2010; Ratajska et al., 
2012; Sabatier et al., 2010).  Together, these results argue that BARD1 makes unknown, but essential, 
contributions to the tumor suppression activity of the BRCA1/BARD1 heterodimer. 
Most of the pathogenic BRCA1 lesions associated with familial breast and ovarian cancer are 
frameshift or nonsense mutations that would eliminate the potential to encode an intact BRCT domain.  
However, in some families, tumor susceptibility can be attributed to a single amino acid substitution, often 
involving residues within the BRCT domain.  Moreover, structural studies have shown that one of these 
residues (S1655) forms a hydrogen bond with the phosphate group of BRCA1 phospho-ligands, and that 
the pathogenic S1655F mutation disrupts the interaction of BRCA1 with its known BRCT phospho-ligands 
(Figure 4) (Botuyan et al., 2004; Clapperton et al., 2004; Shiozaki et al., 2004; Varma, Brown, Birrane, & 
Ladias, 2005; Williams et al., 2004).  Previously, our laboratory observed that the corresponding mutation 
in murine Brca1 (S1598F) abrogates HDR and renders mice susceptible to basal-like triple-negative 
mammary tumors reminiscent of those that arise in human BRCA1 mutation carriers (Shakya et al., 
2011).  These observations indicate that BRCT phospho-recognition is required for BRCA1-mediated 
tumor suppression and suggest that HDR is a critical component of this process.  
Structural studies show that the 3-dimensional fold of the BARD1 BRCT repeats contains a 
hydrophilic cleft that is strikingly similar to the BRCT phosphate-binding pockets of BRCA1 and MDC1 
(Figure 5) (Birrane et al., 2007) (Edwards et al., 2008).  Nonetheless, proteins that bind the BARD1 BRCT 
domain in a phospho-dependent manner have not as yet been reported.  Instead, Li and Yu (2013) 
showed that this domain specifically recognizes poly(ADP-ribose) (PAR), a nucleic acid-like polymer that 
rapidly assembles at DNA breaks and stalled replication forks (M. Li & Yu, 2013).  Moreover, they found 
that the BARD1/PAR interaction was ablated by missense mutations predicted to disrupt the phosphate-
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binding cleft of the BARD1 BRCT domain.  Interestingly, this interaction was specifically required for early 
recruitment of the BRCA1/BARD1 heterodimer to sites of DNA damage, whereas the BRCT domain of 
BRCA1 mediated a subsequent phase of gH2AX-dependent BRCA1/BARD1 recruitment (M. Li & Yu, 
2013).  However, it is unknown whether the ability of the BARD1 BRCT domain to specifically bind PAR 
and/or any as yet undiscovered phosphoprotein ligands (hereafter these properties of the BRCT domain 
will be described as “phospho-recognition”) is required for BRCA1/BARD1 maintenance of genome 
stability and HDR.  This chapter will describe the characterization of novel Bard1-BRCT mutant mice and 




1. Generation and phenotype of Bard1 BRCT-mutant mice 
i.  Structure of the Bard1 knock-in constructs and the phenotype of Bard1-mutant mice 
Although phosphoprotein ligands for the BRCT domain of BARD1 have not yet been identified, 
structural studies indicate that these sequences have the potential to form a phosphate-binding cleft 
similar to the BRCT domains of BRCA1 and MDC1 (Figure 5) (Birrane et al., 2007; Edwards et al., 2008), 
and biochemical analyses confirm that this cleft specifically recognizes the phosphate-rich PAR polymer 
(M. Li & Yu, 2013).  Each of the four amino acids of human BRCA1 that form direct contacts with 
phosphoserine (S1655, G1656, T1700, K1702) is conserved in the BRCT sequences of human (S575, 
G576, T617, K619) and mouse (S563, G564, T605, K607) BARD1.  Therefore, to evaluate the function of 
phospho-recognition by the BARD1 BRCT domain, our laboratory introduced the S563F and K607A 
missense mutations into the mouse Bard1 gene.  The corresponding mutations of human BARD1 (S575F 
and K619A) have been shown to abrogate BARD1 recognition of PAR and to disrupt gH2AX-independent 
recruitment of the BRCA1/BARD1 heterodimer to sites of DNA damage (M. Li & Yu, 2013).  Structural 
studies also predict that mutations of the mouse Bard1 residues S563 or K607 would disrupt the 
phospho-binding activity of its BRCT domain.  Moreover, the Bard1-S563F mutation is structurally 
analogous to the pathogenic Brca1-S1598F mutation that ablates the HDR and tumor suppression 
activities of Brca1 (Shakya et al., 2011). 
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For my dissertation research, I studied the phenotypes of mice harboring the Bard1S563F and 
Bard1K607A alleles.  These mutant alleles had been previously generated in our laboratory as follows.  A 
S563F knock-in targeting vector containing mouse Bard1 genomic DNA was constructed by inserting a 
neomycin-resistance gene cassette flanked by loxP sites (loxP-neo-loxP) into intron 7 and the S563F 
missense mutation into exon 8 (Figure 6).  Likewise, a K607A targeting construct was generated by 
inserting the loxP-neo-loxP cassette into intron 8 and the K607A missense mutation into exon 9 (Figure 
7).  These vectors were then electroporated into ES cells, properly recombined neomycin-resistant ES 
clones were identified, and the presence and correct integration of the desired mutations confirmed by 
nucleotide sequence and Southern blot analyses (data not shown).  Two independent clones of both 
Bard1S563F-neo/+ and Bard1K607A-neo/+ ES cells were injected into blastocysts for the production of germline-
transformed mice. 
To excise the loxP-neo-loxP cassette from the targeted alleles, chimeric male Bard1S563F-neo/+ and 
Bard1K607A-neo/+ mice were mated with females carrying a ubiquitously expressed Cre transgene (E2A-Cre) 
to produce offspring with the desired Bard1S563F (Figure 6D) or Bard1K607A alleles (Figure 7D).   For 
convenience, the Bard1S563F and Bard1K607A alleles will be abbreviated hereafter as Bard1SF and Bard1KA, 
respectively, and the Brca1S1598F allele as Brca1SF (Shakya et al., 2011).  Genomic DNA from Bard1SF/+ 
and Bard1KA/+ was then examined by nucleotide sequence and Southern blot analyses to confirm the 
presence of the BRCT mutation and proper excision of the neomycin cassette (Figure 8).   
I began my dissertation research by analyzing the phenotypes of homozygous Bard1SF/SF and 
Bard1KA/KA mice.  To assess the viability, I first conducted intercrosses of the heterozygous mutant 
animals (Bard1SF/+ x Bard1SF/+ and Bard1KA/+ x Bard1KA/+).  Bard1SF/SF and Bard1KA/KA mice were born at 
the expected Mendelian ratios (~25%) and displayed no obvious developmental abnormalities (Figure 9).  
This is in sharp contrast to Bard1-null (Bard1–/–) and Brca1-null (Brca1–/–) animals, which display identical 
phenotypes of embryonic lethality between embryonic days E7.5 and E8.5 as a result of an impairment in 
cell proliferation (Hakem et al., 1996; Ludwig et al., 1997; E. E. McCarthy et al., 2003).  The absence of a 
developmental phenotype in Bard1SF/SF and Bard1KA/KA mice also contrasted with previously-described 
mice harboring hypomorphic mutations that alter (Brca1SF/SF) or remove (Brca1tr/tr) the Brca1 BRCT 



















are born at sub-Mendelian ratios (5-20%, depending on genetic background).  Also, Bard1SF/SF and 
Bard1KA/KA mice, unlike Brca1SF/SF and Brca1tr/tr mice, do not display other developmental abnormalities 
characteristic of mice homozygous for hypomorphic Brca1 mutations, such as growth retardation, kinked 
tails, and white spots on the belly and hind feet (Ludwig et al., 2001; Shakya et al., 2011).  Together, 
these data imply that phospho-recognition by the Bard1 BRCT domain is largely dispensable for mouse 
development.   
 
ii. Bard1SF/SF and Bard1KA/KA mice display a defect in spermatogenesis distinct from that of 
Brca1SF/SF mice 
While Bard1 homozygous mice initially appeared normal, we observed that Bard1SF/SF and 
Bard1KA/KA males, but not females, are sterile.  Male sterility is a commonly observed trait of Brca1 
hypomorphic mice, including the Brca1SF/SF and Brca1tr/tr mutants (Shakya et al., 2011) (Ludwig et al., 
2001).  Furthermore, sterility or reduced fertility is also frequently observed in male mice harboring 
mutations in other HDR and DNA damage response genes, such as Brca2, Fancd2, Palb2, and H2AX 
(Celeste et al., 2002; Houghtaling et al., 2003; Sharan et al., 2004; Simhadri et al., 2014).      
To assess the fertility defect in males, testes from 6-week-old Bard1SF/SF, Bard1KA/KA and 
Brca1SF/SF mice were subjected to histological analysis.  As shown in Figure 10A, the testes of Bard1SF/SF, 
Bard1KA/KA and Brca1SF/SF mice are markedly smaller than those of their wildtype and heterozygous-
mutant littermates.  As expected, in wild type mice, histological staining revealed normal spermatogenesis 
in the seminiferous tubules (Figure 10B and C).  Briefly, spermatogenesis occurs in the seminiferous 
tubules beginning in the outermost region of the tubule with the diploid spermatogonia and proceeding 
through several intermediate differentiation steps (primary spermatocyte, secondary spermatocyte, round 
spermatid, elongated spermatid), eventually yielding mature haploid spermatozoa near the lumen of the 
tubule (J. M. Turner, 2007).    In contrast, histological staining of Bard1SF/SF and Bard1KA/KA testes 
revealed a complete absence of mature spermatozoa in the seminiferous tubules (Figure 10B and C).  
Closer examination revealed a mosaic pattern in which Bard1SF/SF and Bard1KA/KA seminiferous tubules 
displayed either of two distinct abnormalities: that is, roughly half of the tubules were almost entirely 







the arrow in Figure 10B), while the remaining tubules showed maturation arrest and accumulation of 
primary spermatocytes, characterized by scant cytoplasm and large, dark-staining nuclei (indicated by an 
asterisk in Figure 10B).  Histological analysis suggests that the primary spermatocytes are specifically 
stalled during the pachytene stage of meiosis I, as the arrested cells display the characteristic coarse 
chromatin pattern representing the “thick threads” of chromosomal tetrads in pachytene.  In any case, the 
Bard1SF/SF and Bard1KA/KA tubules displayed a complete absence of all subsequent stages of sperm 
development, including secondary spermatocytes, round spermatids, elongated spermatids, and mature 
spermatozoa, thus explaining the observed fertility defect.  As the Bard1SF/SF and Bard1KA/KA mice aged, 
testes from mice older than one year became increasingly dominated by the first seminiferous tubule 
phenotype (i.e., entirely devoid of germ cells) indicative of stem cell exhaustion (data not shown).     
The phenotype of the Bard1SF/SF and Bard1KA/KA testes was distinct from that of 6-week-old 
Brca1SF/SF mice in that Brca1SF/SF tubules displayed a uniform pattern of maturation arrest without the 
empty tubules observed in Bard1SF/SF and Bard1KA/KA testes (Figure 10B and C).  Furthermore, the stage 
of arrest during spermatogenesis was different in Brca1SF/SF tubules compared to Bard1SF/SF and 
Bard1KA/KA tubules.  Specifically, spermatogenesis in Brca1SF/SF tubules was able to proceed past the 
stage of the primary spermatocyte, where the arrest occurred in Bard1SF/SF and Bard1KA/KA tubules, to the 
stage of the round spermatid.  Thus, Brca1SF/SF seminiferous tubules completely lacked elongated 
spermatids but contained all prior stages of germ cell development, including secondary spermatocytes 
and round spermatids.  However, no elongated spermatids or mature spermatozoa were observed, 
accounting for the male sterility.  These observations imply that Bard1 BRCT phospho-recognition 
mediates functions in spermatogenesis that are distinct from those of Brca1 BRCT phospho-recognition. 
 
iii. Bard1KA/KA mice are not sensitive to ionizing radiation 
 Mice with HDR defects have previously been reported to be sensitive to ionizing radiation, 
including mice deficient for Abraxas, one of the phospho-dependent binding partners of the BRCA1 BRCT 
domain (Castillo et al., 2014).  To determine whether phospho-recognition by the Bard-BRCT domain is 
required for in vivo resistance to ionizing radiation, cohorts of 5-week-old Bard1+/+, Bard1KA/+, and 
Bard1KA/KA mice were exposed to a sub-lethal dose (7.5 Gy) of ionizing radiation.  The survival of the mice 
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was then monitored for 60 days after radiation treatment.  At the end of the monitoring period, 14 of 16 
Bard1+/+ mice were still alive compared with 17 of 18 Bard1K607A/+ and 11 of 11 Bard1KA/KA mice (Figure 
11).  Therefore, there was no statistical difference in survival between the homozygous, heterozygous, 
and wild type Bard1 mice.  These data suggest that phospho-recognition by the Bard-BRCT domain is 
dispensable for in vivo resistance to ionizing radiation. 
 
2. Generation and characterization of Bard1-SF and Bard1-KA cell lines  
i.  Generation of Bard1-SF and Bard1-KA ES cells and MEFs 
To evaluate the function of Bard1 BRCT phospho-recognition at the cellular level, heterozygous 
mutant mice (e.g., Bard1SF/+) were intercrossed, and isogenic panels of mouse embryonic fibroblasts 
(MEFs) were derived from wildtype, heterozygous-mutant, and homozygous-mutant embryos at 
embryonic day E13.5.  The cell lines were then immortalized with SV40 large-T antigen and their 
genotypes verified by PCR (Figure 12A and B).  A comprehensive list of the Bard1 cell lines described in 
this thesis can be found in Table 3.   Additionally, Brca1SF/+ mice were intercrossed to create isogenic 
panels of immortalized MEFs as described above, and the genotypes of these lines were verified as 
shown in Figure 12C.  A comprehensive list of the Brca1 cell lines described in this thesis can be found in 
Table 4.   Additionally, embryonic stem (ES) cell lines were derived by intercrossing heterozygous Bard1 
mice and harvesting embryos at embryonic day E3.5.  Genotypes of the ES cell lines were also confirmed 
by PCR (data not shown).  
 
ii. Expression and subcellular localization of Brca1 and Bard1 in Bard1SF/SF and Bard1KA/KA cells 
To determine whether the Bard1SF and Bard1KA mutant proteins were expressed, lysates from 
wild type, heterozygous, and homozygous Bard1-BRCT mutant MEF lines were fractionated by SDS-
PAGE.  Immunoblotting with a Bard1-specific antiserum revealed that Bard1SF/SF and Bard1KA/KA cells 
expressed the mutant Bard1 protein at levels comparable to wild type and heterozygous MEFs, albeit with 
modest inter-clonal variation of steady-state Bard1 levels that did not correlate with mutation status 
(Figure 13).  Immunoblotting with a Brca1-specific antiserum also revealed that Brca1 expression was 














comparable to wild type MEFs.  Given that Brca1 and Bard1 are dependent on their interaction with each 
other for stability, the comparable expression levels imply that the Bard1KA and Bard1SF mutations have 
no effect on their interaction with Brca1 or the stability of the Brca1/Bard1 heterodimer.  Furthermore, 
Western analysis of cytoplasmic and nuclear subcellular fractions demonstrated that Brca1 and Bard1 are 
both properly localized to the nucleus in Bard1KA/KA and Bard1SF/SF cells.  Once again, this result suggests 
that the interaction of Brca1 and Bard1 is preserved in the Bard1KA and Bard1SF mutant proteins, as the 
association of Bard1 with Brca1 masks a nuclear export signal found in Brca1 (Fabbro et al., 2002).   
 
iii. Brca1/Bard1 heterodimerization is preserved in Bard1SF/SF and Bard1KA/KA cells 
Since formation of the BRCA1/BARD1 heterodimer is facilitated by sequences encompassing 
their respective RING domains, mutations in the Bard1-BRCT domain are not predicted to affect the 
interaction of Brca1 and Bard1 (Brzovic et al., 2001; L. C. Wu et al., 1996).  Nonetheless, to ascertain 
whether the mutant Bard1 polypeptides retain the ability to heterodimerize with Brca1, cell lysates from 
Bard1KA/KA and Bard1SF/SF mutants were immunoprecipitated with a mouse Bard1-specific antiserum (IP: 
Bard1) or the corresponding pre-immune serum (IP: Pre), fractionated by PAGE, and immunoblotted with 
monoclonal antibodies that recognize Brca1 or its associated protein Ctip.  As shown in Figure 14, Brca1 
was efficiently co-immunoprecipitated with Bard1 from the lysates of both wildtype (Bard1+/+) and mutant 
(Bard1SF/SF and Bard1KA/KA) MEFs, demonstrating that phospho-recognition by the Bard1 BRCT domain is 
not required for formation of the Brca1/Bard1 heterodimer.  
While the BARD1 and BRCA1 BRCT domains share significant sequence and structural 
homology, they are not predicted to bind the same phospho-ligands due to important differences in their 
hydrophobic binding pockets (Figure 5B) (Birrane et al., 2007; Edwards et al., 2008).  As such, the 
phospho-recognition function of the Bard1 BRCT domain is not believed to interact directly with any of the 
known BRCA1 phospho-ligands, including Ctip.  Indeed, the efficient co-immunoprecipitation of Ctip with 
Bard1 from Bard1SF/SF and Bard1KA/KA cell lysates demonstrates that the in vivo association of Ctip with 
the Brca1/Bard1 heterodimer is not dependent on phospho-recognition by the Bard1 BRCT domain 





3. Bard1SF/SF and Bard1KA/KA cells display a pattern of genotoxin sensitivity distinct from that of 
Brca1SF/SF cells 
i.  Bard1SF/SF and Bard1KA/KA cells are highly sensitive to MMC 
To determine whether Bard1 BRCT phospho-recognition affects the cellular response to DNA 
damage, we used clonogenic survival assays to evaluate the sensitivity of Bard1-mutant immortalized 
MEFs to various genotoxic agents.  In these clonogenic survival assays, isogenic wild type, 
heterozygous, and homozygous MEFs harboring phospho-recognition mutations in the Bard1-BRCT 
domain were exposed to varying concentrations of a DNA-damaging agent, after which the cells were 
then allowed to recover and the surviving colonies quantified. 
A hallmark of BRCA1-mutant cells is their exquisite sensitivity to DNA interstrand crosslinking 
reagents (ICL), such as cisplatin and Mitomycin C (MMC) (Moynahan, Cui, et al., 2001).  Indeed, cisplatin 
is a component of standard chemotherapeutic regimens for certain malignancies, including BRCA1-
mutant ovarian tumors.  Crosslinking reagents damage DNA by preventing the Watson and Crick DNA 
strands from separating, resulting in stalled replication forks and DNA double strand breaks, and thereby 
activating both the SFP and HDR pathways.  Indeed, cells that are mutant for other SFP and HDR 
factors, such as RAD51, BRCA2, and FancD2, are highly sensitive to ICL reagents (N. Liu et al., 1998; 
Schlacher et al., 2012).  However, recent evidence suggests that the ability of BRCA1 to repair ICLs is 
independent of its function in HDR (Bunting et al., 2012).   
To determine whether phospho-recognition by the Bard1 BRCT domain is required for resistance 
to DNA interstrand crosslinking reagents, Bard1SF/SF and Bard1KA/KA immortalized MEFs were exposed to 
varying concentrations of MMC for 4 hours and then allowed to recover for 7-10 days post treatment.  As 
shown in Figure 15, two independent clones each of Bard1SF/SF and Bard1KA/KA MEFs were hypersensitive 
to MMC compared to isogenic wild type and heterozygous cell lines.  Additionally, as had been previously 
reported by Shakya et al., Brca1SF/SF MEFs are also hypersensitive to MMC compared to their wild type 
control (Shakya et al., 2011).  Taken together, Bard1SF/SF and Bard1KA/KA MEFs are hypersensitive to the 
DNA inter-strand crosslinking agent mitomycin C (MMC), to an extent that is comparable to or even 






ii. Bard1SF/SF and Bard1KA/KA MEFs display an intermediate hypersensitivity to PARP inhibition. 
BRCA1-mutant cells and tumors are exquisitely sensitive to poly(ADP-ribose) polymerase 
inhibitors (PARPi) (Bryant et al., 2005) (Farmer et al., 2005) (Fong et al., 2009).  This extreme 
hypersensitivity may reflect the combined deficiencies of these cells for both HDR and SFP.  PARPi, 
which is required for single-strand break repair (SSB), was originally proposed to exploit the HDR defect 
of BRCA1/2-mutant cells through a synthetic lethal interaction. Thus, since BRCA1-deficient cells are 
already deficient in DSB repair by HDR, inhibition of SSB repair by PARPi would lead to a toxic 
accumulation of DNA damage as unrepaired SSBs are converted into DSBs during DNA replication.  
Supporting this hypothesis is the clinical observation that BRCA1 tumors often evolve resistance to 
PARPi treatment by restoring HDR function (Lord & Ashworth, 2013).  However, PARPi treatment is also 
thought to stall replication forks by generating DNA-protein adducts (Helleday, 2011).  Indeed, recent 
reports suggest that restoration of the SFP pathway in BRCA1-deficient cells is an alternative mechanism 
for PARPi resistance (Ray Chaudhuri et al., 2016; Taglialatela et al., 2017). 
To determine whether Bard1 BRCT phospho-recognition is required for PARPi resistance, 
Bard1SF/SF and Bard1KA/KA MEFs were exposed to continuous treatment with the PARP inhibitor olaparib 
for 7-10 days.  Compared to their isogenic wild type and heterozygous controls, two independent clones 
each of Bard1SF/SF and Bard1KA/KA MEFs displayed hypersensitivity to the PARP inhibitor (Figure 16). 
However, the degree of hypersensitivity of the Bard1-mutant MEFs is reproducibly less than that 
observed with Brca1SF/SF MEFs (Figure 16), suggesting that Bard1 BRCT phospho-recognition is partially 
required for resistance to PARP inhibitors. 
 
iii.  Bard1SF/SF and Bard1KA/KA MEFs are not hypersensitive to ionizing radiation 
 Ionizing radiation (IR) induces many different types of DNA damage, including, most notably, 
DNA double strand breaks.  These DSBs may subsequently be repaired by HDR, non-homologous end 
joining (NHEJ), or microhomology mediated end joining (MMEJ).  Cells deficient in BRCA1 and other 
HDR factors typically display a moderate hypersensitivity to IR (Abbott et al., 1999; N. Liu et al., 1998).  
As shown in Figure 17, Bard1 and Brca1 mutant MEFs were exposed to varying doses of ionizing 







moderate hypersensitivity to IR compared to their wild type controls.  However, Bard1SF/SF and Bard1KA/KA 
MEFs showed no difference in survival when compared to their wild type and heterozygous controls.  
Therefore, phospho-recognition by the Bard1 BRCT domain is dispensable for resistance to IR.  This 
observation is consistent with the IR resistance of Bard1KA/KA mice shown in Figure 11.   
 
iv. Bard1SF/SF and Bard1KA/KA MEFs are not hypersensitive to camptothecin 
 Camptothecin generates DNA damage by stabilizing the covalent linkage of type I topoisomerase 
to DNA ends.  Under normal cellular conditions, type I topoisomerases relieve the supercoils generated 
from DNA replication by inducing transient single-stranded breaks in S-phase cells.  By stabilizing the 
covalent linkage of topoisomerase to DNA ends, camptothecin prevents the proper re-ligation of these 
ssDNA breaks, which can be subsequently converted to dsDNA breaks upon DNA replication (Helleday, 
2011; Pommier et al., 2003; Strumberg et al., 2000).  Indeed, mutations in HDR components like BRCA1, 
BRCA2, and CtIP have been shown to sensitize cells to camptothecin treatment (Scully, 2011) (Sartori et 
al., 2007).   
 To determine whether Bard1-BRCT phospho-recognition is required for resistance to 
camptothecin, Bard1SF/SF and Bard1KA/KA immortalized MEFs were exposed to varying concentrations of 
camptothecin for 1 hour and then allowed to recover for 7-10 days.  As shown in Figure 18, two 
independent clones of both Bard1SF/SF and Bard1KA/KA MEFs displayed no hypersensitivity to 
camptothecin compared to their isogenic wild type and heterozygous controls.  On the other hand, 
Brca1SF/SF MEFs were moderately hypersensitive to camptothecin compared to a Brca1+/+ cell line.  
Therefore, phospho-recognition by the Bard1-BRCT domain is dispensable for resistance to 
camptothecin. 
 In summary, cells harboring the Bard1SF/SF or Bard1KA/KA mutations displayed identical patterns of 
sensitivity or resistance to genotoxic stress, which supports the structural predictions that both of these 
mutations will result in identical functional consequences (i.e., disruption of BRCT phosphoprotein 
recognition and PAR binding).  Although each of the agents tested can, to some extent, induce a variety 
of genotoxic lesions, the Bard1 mutant cells appear to be more hypersensitive to drugs that induce stalled 




breaks (e.g., IR).  On the other hand, Brca1SF/SF cells are hypersensitive to all the genotoxins tested 
(MMC, olaparib, IR, and CPT), suggesting defects in both SFP and HDR.  
 
4. Bard1SF/SF and Bard1KA/KA cells exhibit chromosomal instability in response to genotoxic stress 
i. Giemsa karyotype analysis suggest chromosomal instability in MMC-treated Bard1SF/SF 
immortalized MEFs 
 The hypersensitivity of the Bard1 and Brca1 BRCT domain mutants to certain genotoxins 
(Section 3) suggests the presence DNA repair deficiencies in these cell lines.  Indeed, deficiencies in 
DNA repair may lead to gross chromosomal rearrangements, which can be detected through cytogenetic 
analysis.  Relative to wild type cells, Brca1- and Bard1-null cells accumulate increased levels of both 
spontaneous and genotoxic-induced chromosomal abnormalities (E. E. McCarthy et al., 2003) (Xu et al., 
1999) (A. McCarthy et al., 2007) (X. Liu et al., 2007) (Shakya et al., 2008) (Shakya et al., 2011).  Since 
genome instability is a hallmark of cancer in general (Hanahan & Weinberg, 2011), the chromosomal 
instability of BRCA1/BARD1-mutant cells may be a critical factor in the formation of hereditary breast 
cancer. 
 Thus, to determine whether phospho-recognition by the Bard1-BRCT domain is required for 
chromosomal stability, two independent clones of Bard1SF/SF immortalized MEFs, along with an isogenic 
Bard1+/+ MEF clone, were cultured in the presence or absence of 40 ng/mL MMC for 16 hours.  
Metaphases stained with Giemsa were then examined for structural chromosome abnormalities.  In 
parallel, immortalized lines of Brca1SF/SF and Brca1+/+ MEFs were also subjected to the same analysis.  
 By examining the prevalence of chromosomal aberrations in untreated cell lines, we could 
determine whether the Bard1- or Brca1-BRCT mutant MEF lines spontaneously accumulate chromosomal 
rearrangements (Figure 19A and C).  The Bard1+/+ clone displayed abnormalities in 44% of mock-treated 
karyotypes examined.  In comparison, we observed a similar percentage of abnormal karyotypes in two 
independent Bard1SF/SF MEF clones, with abnormalities in 44% (clone A) and 48% (clone C) of 
metaphases, respectively.   The burden of abnormalities appeared to be modestly higher in the two 
Bard1SF/SF cell lines (0.80 and 0.88 aberrations per metaphase) compared to the Bard1+/+ cell line (0.68 







that the Bard1SF/SF cells do not accumulate spontaneous chromosomal abnormalities at a markedly 
heightened rate.   Similarly, the Brca1 wild type cell line showed abnormalities in 52% of untreated 
karyotypes as compared with 56% in the Brca1SF/SF cell line.  While at first glance there does not appear 
to be much difference between the Brca1+/+ and Brca1SF/SF cell lines, closer examination revealed that the 
Brca1SF/SF cells carry a greater burden of chromosomal abnormalities, with 36% of Brca1SF/SF metaphases 
displaying two or more abnormalities (0.96 aberrations per metaphase) compared to just 14% of Brca1+/+ 
metaphases (0.64 aberrations per metaphase).  Therefore, the Brca1SF/SF mutation may predispose to 
spontaneous genome instability, but again the results do not achieve statistical significance.  Moreover, 
the interpretation of this experiment is limited by the relatively high burden of spontaneous abnormalities 
in all cell lines (ranging from 44%-56%).  This high background level of genome instability may be a 
product of the MEF immortalization process, in which expression of the SV40 large-T antigen abrogates 
several cellular activities, including the p53 pathway.   
 In contrast to untreated cells, both Bard1SF/SF clones displayed an increase in MMC-induced 
chromosomal rearrangements compared to their isogenic Bard1+/+ control (Figure 19A and C). Sixty-eight 
percent of karyotypes from Bard1SF/SF clone A and 72% from Bard1SF/SF clone C displayed abnormalities 
compared with 48% from Bard1+/+ clone E.  Moreover, the total burden of chromosomal rearrangements 
was higher in the Bard1SF/SF mutants, as 56% (clone A) and 48% (clone C) of metaphases displayed two 
or more aberrations (1.68 and 1.44 aberrations per metaphase) compared to 32% in the Bard1 wild type 
clone (0.88 aberrations per metaphase).  Comparing the treated and untreated Bard1SF/SF cells, the 
increase in aberrations was largely accounted for by a greater number of chromosome and chromatid 
breaks, as the number of exchanges/fusions stayed relatively constant in the two conditions.  Brca1SF/SF 
cells also displayed an increase in the percentage of abnormal metaphases after MMC treatment (72%, 
1.68 aberrations per metaphase) compared to Brca1+/+ cells (56%, 1.12 aberrations per metaphase).  
Once again, the Brca1SF/SF clone carried a greater burden of abnormalities with 48% of cells displaying 
two or more aberrations compared with 40% in the Brca1+/+ clone.  However, likely due to the low number 
of metaphases analyzed, we were not able to demonstrate statistical significance in these observations.   
 Together, these data suggest that phospho-recognition by the Bard1 BRCT domain may be 
dispensable for suppression of spontaneous chromosomal rearrangements but required for suppression 
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of MMC-induced rearrangements.  Consistent with the results in Shakya et al. (2011), Brca1 BRCT 
phospho-recognition appears to be required for suppression of both spontaneous and MMC-induced 
chromosomal rearrangements.  However, the interpretation of these experiments is limited by the high 
background of chromosomal aberrations in the untreated condition.  As a result, rather than carrying out 
further trials in immortalized MEFs to demonstrate statistical significance, we decided to instead examine 
primary MEFs.   
 
ii. Telomere fluorescent in situ hybridization (T-FISH) reveals MMC-induced chromosomal 
instability in Bard1SF/SF and Bard1KA/KA primary MEFs 
 As the interpretation of the karyotyping in Figure 19 was limited by the high background 
chromosomal instability present in wild type immortalized MEFs, we performed another experiment in low 
passage primary MEFs, which, unlike immortalized MEFs, still retain a functional p53 pathway.  As such, 
primary MEFs should also have a lower baseline level of chromosome instability in the wild type clones.  
Additionally, since aberrations observed in the experiment above included many chromosome/chromatid 
breaks, we examined the metaphases using telomere fluorescent in situ hybridization (T-FISH) rather 
than conventional Giemsa-stained cytogenetics, as T-FISH is more sensitive to chromosome/chromatid 
breaks.   
 Three independent clones of early passage Bard1SF/SF primary MEFs, along with two isogenic 
Bard1+/+ primary MEF clones, were cultured in the presence or absence of 40 ng/mL MMC for 16 hours 
and the resulting metaphases analyzed by T-FISH.  As shown in Figure 20A, in contrast to immortalized 
MEFs, the two Bard1+/+ clones displayed low levels of spontaneous chromosomal rearrangements, with 
only 4.6% of metaphases from clone E and 1.8% of metaphases from clone I harboring abnormalities.  
These wild type clones also displayed a low burden of chromosomal abnormalities, with an average of 
0.04 abnormalities per metaphase in clone E and 0.01 abnormalities per metaphase in clone I.  Thus, the 
use of primary MEFs solved the problem of high background abnormalities in wild type cells observed in 
the immortalized MEFs shown in Figure 19A.  The three independent Bard1SF/SF clones did not display a 
significant increase in spontaneous chromosomal rearrangements compared to the isogenic wild type 







6.1% of metaphases, respectively, as well as a low burden of chromosomal aberrations with averages of 
0.07, 0.01, and 0.13 abnormalities per metaphase.  If the results from the two Bard1+/+ clones (E and I) 
and the three Bard1SF/SF clones are pooled (A, C, and H), no statistically significant difference is observed 
between wild type and mutant cells with regards to either the percent of abnormal metaphases (3.3% vs 
5.0%) or the average abnormalities per metaphase (0.03 vs 0.07) (Figure 20B, Table 5B).   
 However, when treated with MMC, the three independent Bard1SF/SF clones showed marked 
increases in the percentage of abnormal metaphases (55.7%, 72.9%, and 54.0%) compared to the wild 
type clones (35.7% and 27.9%) (Figure 20A, Table 5A).  Furthermore, three Bard1SF/SF clones displayed a 
higher burden of abnormalities as reflected by the average number of abnormalities per metaphase (1.5, 
2.3, and 1.2 abnormalities per metaphase) compared to the two wild type clones (0.62 and 0.72 
abnormalities per metaphase).  This result is statistically significant when each of the wild type clones (E 
and I) was compared to two of the Bard1SF/SF clones (A and C), but not to clone H.  However, if the results 
from the two independent wild type clones (E and I) and the three independent Bard1SF/SF clones (A, C, 
and H) are separately pooled, then statistically significant differences in the percentage of abnormal 
metaphases (30.9% in wild type vs. 59.7% in Bard1SF/SF) and average abnormalities per metaphase (0.68 
in Bard1+/+ vs 1.62 in Bard1SF/SF) are observed (Figure 20B, Table 5B).   
 Similar to the Bard1SF/SF cell lines, three independent Bard1KA/KA primary MEF lines (clones J, L, 
and M) did not display an increase in spontaneous chromosomal rearrangements when compared to two 
wild type isogenic controls (I and N) in either the percentage of abnormal metaphases (1.6% and 0% in 
Bard1+/+ vs 8.3%, 4.7%, and 6.9% in Bard1KA/KA) or the average aberrations per metaphase (0.03 and 
0.00 in Bard1+/+ vs 0.08, 0.063, and 0.103 in Bard1KA/KA) (Figure 21A, Table 6A).  However, as was the 
case with Bard1SF/SF lines, the Bard1KA/KA cells displayed a significant increase in chromosomal instability 
when treated with mitomycin C as reflected in both the percentage of abnormal metaphases (20.3% and 
21.1% in Bard1+/+ vs 50.6%, 51.4%, and 27.5% in Bard1KA/KA) and the average number of aberrations per 
metaphase (0.29 and 0.37 in Bard1+/+ vs 1.14, 1.12, and 0.63 in Bard1KA/KA) (Figure 21A, Table 6A).  
When comparing the average number of aberrations per metaphase, Bard1KA/KA clone M (0.63 
aberrations per metaphase) was not statistically significant compared to the corresponding wild type 







clones (J, L, and M) pooled together, a significant difference between the Bard1+/+ and Bard1KA/KA cells in 
the average number of abnormalities per metaphase after MMC treatment (0.31 in Bard1+/+ vs 1.03 in 
Bard1KA/KA) is observed (Figure 21B, Table 6B).   
 In contrast to the Bard1SF/SF and Bard1KA/KA cell lines, untreated Brca1SF/SF primary MEFs 
displayed a substantial increase in chromosomal aberrations compared to their wild type isogenic 
controls, thus confirming the data obtained by giemsa-stained karyotypes of immortalized Brca1SF/SF 
MEFs in Figure 19A and by Shakya et al. (Shakya et al., 2011).  Pooled data from Brca1+/+ clones (Q and 
T) displayed spontaneous chromosomal rearrangements in 3.8% of metaphases with an average of 0.05 
aberrations per metaphase compared to 33.8% abnormal metaphases and 0.60 aberrations per 
metaphase in the pooled Brca1SF/SF clones (P and R) (Figure 22).  Furthermore, there was a drastic 
increase in MMC-induced aberrations in Brca1SF/SF cells compared to wild type cells, with 85.7% 
abnormal metaphases and 3.7 abnormalities per metaphase in the Brca1SF/SF clones compared with 
27.5% abnormal metaphases and 0.8 abnormalities per metaphase in the Brca1+/+ clones (Figure 22).   
 In summary, the data suggest that phospho-recognition by the Bard1 BRCT domain is not 
required for suppression of spontaneous chromosomal rearrangements, as the baseline level of 
aberrations in wild type primary MEFs is similar to that of Bard1SF/SF and Bard1KA/KA cells.  However, in 
accord with the MMC hypersensitivity shown in Figure 15, Bard1SF/SF and Bard1KA/KA cells displayed 
significant increases in chromosomal aberrations, implying that Bard1 BRCT phospho-recognition is 
required for suppression of MMC-induced chromosomal instability.  Furthermore, our data confirms 
previous studies that the phospho-recognition ability of the BRCA1 BRCT domain is required for 
suppression of both spontaneous and MMC-induced chromosomal instability (Shakya et al., 2011).  While 
direct comparisons between the Bard1-mutant and Brca1-mutant MEF lines is fraught by their different 
genetic backgrounds (Bard1 lines were derived from C57Bl/6J mice, while the Brca1 lines were obtained 
from mice on a mixed m129 and c57Bl/6J background), Brca1SF/SF cells appear to be more prone to 








5. Bard1SF/SF and Bard1KA/KA cells are proficient for HDR 
i.  Bard1SF/SF and Bard1KA/KA cells are proficient for Rad51 focus formation  
 Multiple lines of evidence of implicate BRCA1 as a key component in homology-directed repair 
(HDR) of double-strand DNA breaks (Moynahan et al., 1999; Scully, Chen, Ochs, et al., 1997; Scully, 
Chen, Plug, et al., 1997).  Like BRCA1-null cells, BARD1-null cells are deficient in HDR (Baer & Ludwig, 
2002; Fabbro et al., 2002; Joukov et al., 2006; Laufer et al., 2007; E. E. McCarthy et al., 2003; 
Westermark et al., 2003).  Moreover, the phospho-recognition property of the Brca1 BRCT domain is 
essential for HDR, as Brca1SF/SF cells have been shown to possess a clear HDR defect (Shakya et al., 
2011).  Therefore, on the basis of these findings, we hypothesized that Bard1 BRCT phospho-recognition 
would also be required for BRCA1/BARD1-mediated HDR.  
To test this hypothesis, we first examined the ability of Bard1KA/KA and Bard1SF/SF cell lines to form 
Rad51 foci after treatment with ionizing radiation.  During HDR, Rad51 polypeptides are assembled onto 
the resected ends of DSBs to form ssDNA/Rad51 nucleoprotein filaments.  In cells treated with ionizing 
radiation (IR), this process is manifested cytologically by the appearance of Rad51 nuclear foci.  Cells 
with defects in HDR, including Brca1SF/SF cells, do not form Rad51 foci as efficiently as HDR-competent 
cells (Shakya et al., 2011).   To ascertain whether ssDNA/Rad51 filaments are assembled efficiently in 
response to DNA damage in the Bard1-mutant MEFs, we examined Rad51 focus formation by 
immunofluorescent microscopy.  Immortalized MEFs were treated with 10 Gy of IR, harvested one hour 
later, and stained with a Rad51 specific antibody.  The number of cells with ≥10 Rad51 foci was quantified 
to detect the presence or absence of an HDR defect.  As shown in Figure 23A, isogenic Bard1+/+, 
Bard1SF/+, and two independent Bard1SF/SF clones displayed a significant increase in Rad51 foci after IR 
treatment.  Furthermore, the percentage of cells with ≥10 Rad51 foci were comparable between the 
Bard1+/+ clone (I – 52.6%) and the two Bard1SF/SF clones (A – 57.0% and C – 51.3%).  In accord with 
previous studies, Rad51 focus formation was markedly reduced in Brca1SF/SF cells relative to Brca1+/+ 
control cells.   Specifically, 53.6% of Brca1+/+ cells had ≥10 Rad51 foci compared to only 31.4% of 
Brca1SF/SF cells (Figure 23A).  
Similar to the Bard1SF/SF cells, the levels of Rad51 focus formation in Bard1KA/KA cells were 







(Bard1KA/KA clone L) of cells displaying more than 10 Rad51 foci compared 50.6% of cells in the Bard1+/+ 
clone (I) (Figure 23B).  Once again, a Brca1SF/SF cell line treated in parallel with the Bard1KA/KA cell lines 
displayed a defect in Rad51 focus formation compared to its isogenic wild type control (32.6% - Brca1SF/SF 
vs. 54.1% - Brca1+/+) (Figure 23B).  
 Moreover, the Rad51 foci levels in Bard1SF/SF and Bard1KA/KA cells were also similar to those of 
wild type controls beyond one-hour post treatment.  As shown in Figure 24, we performed a time-course 
experiment in which cells were treated with 10 Gy of ionizing radiation and then harvested at 1, 2, 4, 6, 8, 
and 10 hours post treatment.  Upon quantifying the percentage of cells with ≥10 Rad51 foci, it was 
observed that Rad51 foci levels remained elevated hours after IR induction and only approached baseline 
levels near the end of the time course in both wildtype and Bard1-mutant MEFs.  This observation 
indicates that the Bard1 mutations do not significantly affect the kinetics of Rad51 focus resolution.  As 
expected, Brca1SF/SF cells displayed a decreased ability to form Rad51 foci across all time points (Figure 
24A and B).  Therefore, phospho-recognition by the Bard1 BRCT domain is not required for Rad51 focus 
formation after IR treatment.  These data suggest that the Bard1 BRCT domain is dispensable for 
BRCA1/BARD1-mediated HDR.   
 
ii. Bard1SF/SF and Bard1KA/KA cells display gene-targeting efficiencies similar to those of wild type 
cells 
 To further investigate the role of the Bard1 BRCT domain in HDR, we compared gene-targeting 
efficiencies in cells that do or do not harbor the Bard1 BRCT mutations.  Although the precise 
mechanisms by which gene targeting through homologous recombination (HR) occurs are unclear, it is 
believed to entail many of the same components as homology-directed repair (HDR) of DSBs.  In support 
of this notion, BRCA1-mutant cells display severe defects in gene targeting compared to wild type cells 
(Moynahan et al., 1999).   
To quantitate gene targeting into the Pim1 locus on mouse chromosome 17, Bard1SF/SF, 
Bard1KA/KA, or Bard1+/+ embryonic stem (ES) cells were electroporated with the XhoI-linearized p59xDR-
GFP6 targeting vector.  The p59xDR-GFP6 targeting vector is a plasmid that contains the DR-GFP 




flanked by Pim1 genomic DNA sequences (Moynahan, Pierce, et al., 2001; Pierce & Jasin, 2001).  The 
ES cells were then selected with hygromycin and proper homologous integration into the Pim1 locus was 
assessed by Southern blot analysis of the individual hygromycin-resistant subclones.  As shown in 
Figures 25A and B, the p59xDR-GFP6 plasmid was properly targeted to the Pim1 locus in 47 of 48 
(97.9%) of Bard1SF/SF clones compared to 40 of 47 (85.1%) of isogenic Bard1+/+ clones.  Similarly, correct 
targeting was observed in 29 of 30 (96.7%) of Bard1KA/KA clones compared to 22 of 25 (88.0%) of isogenic 
Bard1+/+ clones (Figure 25C and D).  Therefore, the Bard1SF/SF and Bard1KA/KA ES cells do not display a 
defect in gene targeting and, in fact, appear to be slightly more efficient than their isogenic wild type 
controls.  
 
iii. Bard1SF/SF and Bard1KA/KA cells do not display a defect in double-strand break repair by HDR 
Using the DR-GFP reporter system, we next determined whether phospho-recognition by the 
Bard1 BRCT domain is required for HDR of an induced double-strand break (DSB) in vivo.  The DR-GFP 
reporter is a DNA construct that consists of two non-functional GFP genes (Figure 26A).  One of the GFP 
genes harbors both an in-frame stop codon and a restriction site for the I-SceI endonuclease, whereas 
the coding sequences of the second GFP gene is truncated at both the N and C-termini (iGFP).  A DNA 
DSB can be induced within the first GFP gene by transfection of the I-SceI restriction enzyme into cells 
possessing the DR-GFP reporter.  In cells that are competent for HDR, the DSB can be repaired using 
iGFP as a template for homologous recombination, resulting in the formation of a functional GFP gene.  
Successful HDR repair can then be quantified by detection of GFP-positive cells using fluorescent 
activated cell sorting (FACS).  Previous studies using the DR-GFP reporter have shown that Brca1-null, 
Bard1-null, and Brca1SF/SF cells all display a marked decrease in GFP-positive cells compared to wild type 
controls (Laufer et al., 2007; Moynahan et al., 1999; Moynahan, Cui, et al., 2001; Shakya et al., 2011) 
To measure repair of an I-SceI-induced chromosomal DSB within the DR-GFP reporter, the Bard1SF/SF, 
Bard1KA/KA   and their isogenic Bard1+/+ controls (targeted at the Pim1 locus as described in the previous 
Section 5-ii) were transiently transfected with either an expression vector encoding the I-SceI 
meganuclease or an empty vector (EV), and the proportions of GFP-positive ES cells were quantified by 










(Brca1SF/SF) ES cell lines harboring DR-GFP integrated into the same position of the Pim1 locus (Shakya 
et al., 2011).   The percentage of GFP-positive cells was normalized to transfection efficiency as 
determined by the percentage of GFP-positive cells after transfection with a GFP expression vector.  In all 
cell lines transfected with the empty vector (EV), the percent of GFP-positive cells was very low (<0.1%), 
indicating that spontaneous gene conversion within the HDR reporter is exceedingly rare (Figure 26B and 
C).  In contrast, the percent of GFP-positive cells in wild type sublcones was markedly elevated upon 
expression of I-SceI, indicating that HDR within the reporter is induced by DSB formation (Figure 26B and 
C) (Pierce & Jasin, 2001).  As expected, when transfected with I-SceI, the proportion of GFP-positive cells 
was markedly reduced (approximately 9-fold) in Brca1SF/SF cells relative Brca1+/+ cells (Figure 26B and C) 
(Shakya et al., 2011).  In contrast, no significant difference was observed upon analysis of multiple 
independent isogenic subclones of wildtype (Bard1+/+) and Bard1-mutant (Bard1SF/SF and Bard1KA/KA) ES 
cells (Figure 26B and C).  These results, together with the analysis of Rad51 focus formation (Figures 23 
and 24) and gene targeting efficiency (Figure 25), indicate that HDR is dependent on the phospho-
recognition potential of the Brca1 BRCT domain, but not that of the Bard1 BRCT domain. 
 
C. Discussion 
BRCA1 polypeptides exist primarily in a nuclear complex with the BARD1 tumor suppressor, and 
the resulting BRCA1/BARD1 heterodimer mediates many of the functions ascribed to BRCA1, including 
HDR and tumor suppression (L. C. Wu et al., 1996) (Laufer et al., 2007) (Westermark et al., 2003) 
(Shakya et al., 2008).  Like BRCA1, BARD1 harbors two tandem C-terminal BRCT repeats that form a 
phosphate binding cleft.  Although BRCA1 uses its BRCT domain to recognize particular 
phosphoproteins, several of which have been implicated in HDR, no phosphoprotein ligands have yet 
been identified for the BARD1 BRCT domain.  Nonetheless, the BARD1 BRCT domain can bind in a 
phospho-dependent manner to poly(ADP-ribose) (PAR), a nucleic acid polymer that is rapidly assembled 
at sites of DNA breaks and stalled replication forks (M. Li & Yu, 2013), but the functional relevance of 
BARD1 BRCT phospho-recognition has remained unclear. 
To address this question, we examined novel mouse strains harboring either of two missense 
mutations predicted to disrupt the BRCT phosphate-binding cleft of Bard1 (Bard1SF and Bard1KA), 
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including one that is structurally analogous to the Brca1-S1598F mutation.  Homozygous Bard1SF/SF and 
Bard1KA/KA mice are born at the expected Mendelian ratios (Figure 9) and, apart from male infertility, they 
appear to develop normally.  As such, Bard1SF/SF and Bard1KA/KA mice are considerably more robust than 
Brca1SF/SF mice, which are born at reduced Mendelian ratios (dependent on the genetic background) and 
exhibit, in addition to male infertility, growth retardation and mild developmental defects (Shakya et al., 
2011).  Since cells harvested from Bard1SF/SF and Bard1KA/KA mice are competent for homology-directed 
repair (HDR) while Brca1SF/SF cells display a clear HDR defect, this implies that the loss of HDR function 
is, at least in part, responsible for the developmental defects observed in Brca1-mutant mice.  Indeed, it 
has been proposed that loss of HDR function leads to an accumulation of DNA damage during the rapid 
cell divisions that occur during embryogenesis, and that the resultant DNA damage induces premature 
cellular senescence, which can be partially bypassed by deletion of p53 or p16 (Hakem et al., 1996) 
(Cressman et al., 1999) (Xu et al., 2001).   
 Nevertheless, the Bard1 mutations elicit a more severe defect with respect to male germ cell 
development than the Brca1SF/SF mutation, with the Bard1 mutations resulting in maturation arrest at 
significantly earlier stages of spermatogenesis (Figure 10).  As mentioned above, spermatogenesis 
occurs in the seminiferous tubules beginning with the diploid germ cells (spermatogonia) which undergo a 
series of mitotic divisions. The developing germ cells then enter meiosis and proceed through several 
intermediate differentiation steps in the following order: primary spermatocyte, secondary spermatocyte, 
round spermatid, elongated spermatid before finally becoming mature haploid spermatozoa (de Rooij, 
2001; J. M. Turner, 2007) (Kotaja & Sassone-Corsi, 2007) (Ahmed & de Rooij, 2009).  Specifically, 
spermatogenesis in Bard1SF/SF and Bard1KA/KA seminiferous tubules appears to arrest at the stage of the 
primary spermatocytes, as shown by the accumulation of cells with large, dark staining nuclei and scant 
cytoplasm, compared to arrest at the round spermatid stage in Brca1SF/SF tubules (Figure 10 B and C).   
Together, these observations indicate that the developmental functions of BRCT phospho-recognition by 
BRCA1 and BARD1 are at least partly distinct.  
Clearly, the testes of Bard1-BRCT and Brca1-BRCT mutant mice display maturation arrests at 
distinct stages of spermatogenesis.  In the Bard1-BRCT mutant mice arrest occurs at the level of primary 
spermatocytes, which would normally undergo meiosis I, during which the homologous chromosomes 
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align, DNA double-strand breaks are induced by the Spo11 enzyme, and crossing over (also known as 
synapsis) occurs to facilitate the exchange of DNA sequences between homologous chromosomes 
before their eventual separation  However, in the Brca1-BRCT mutant mice arrest take place at the level 
of round spermatids, at a point in which both meiotic divisions should be complete (de Rooij, 2001; J. M. 
Turner, 2007) (Kotaja & Sassone-Corsi, 2007) (Ahmed & de Rooij, 2009).  Therefore, the Bard1SF/SF and 
Bard1KA/KA mutants, in contrast to the Brca1SF/SF mutants, appear unable to complete meiosis as reflected 
by their different stages of arrest and their distinct correlation with meiotic events.  
Taking a closer look at the stages of meiosis I, where the Bard1-BRCT mutants appear to be 
arrested as primary spermatocytes, prophase of meiosis I can be broken down into four distinct stages 
that correspond with events in homologous recombination.  These stages are: leptotene (when the DNA 
DSBs are generated), zygotene (when the homologous chromosomes align), pachytene (when crossing 
over facilitated by Rad51 occurs), and diplotene (when the synapsis between homologous chromosomes 
begins to dissolve).  Histological analysis suggests that the primary spermatocytes are specifically stalled 
during the pachytene stage of meiosis I, as the arrested cells display the characteristic coarse chromatin 
pattern representing the “thick threads” of chromosomal tetrads in pachytene.  However, further staining 
experiments are necessary to fully support this assertion.  Interestingly, pachytene arrest has also been 
observed in other Brca1 hypomorphic mutations, including Brca1∆11, which deletes exon 11 and the 
majority of the coding sequence of Brca1 (Xu, Aprelikova, Moens, Deng, & Furth, 2003).   
Given the role of homologous recombination in the production of mature germ cells during 
meiosis, it is tempting to speculate that a deficiency in HDR is responsible for the sterility defect seen in 
Brca1 pathway mutant mice.  However, since homologous recombination occurs in both male and female 
gametogenesis and the sterility defect is only observed in males, a deficiency in HDR cannot completely 
explain the phenotype.  Furthermore, our data demonstrating the absence of an HDR defect in Bard1SF/SF 
and Bard1KA/KA mutant cells argues that the sterility defect observed in our Bard1-mutant mice is 
independent of HDR function.  While HDR and homologous recombination in meiosis involve many of the 
same components, the two processes differ considerably.  Thus, it is feasible that some aspects of 
protein function required for meiosis may be dispensable for HDR and vice versa.  It is also possible that 
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there are HDR-independent and meiosis-independent functions of the BRCA1/BARD1 heterodimer that 
are required for production of mature sperm. 
Taking into consideration the likely pachytene arrest and male-specific infertility of the Bard1-
BRCT mutants, it is possible that the defect in spermatogenesis stems from a failure of meiotic sex 
chromosome inactivation (MSCI).  MSCI is a process whereby the unsynapsed regions of the X and Y 
chromosomes in developing male gametes are transcriptionally silenced during prophase of meiosis I.   
The transcriptionally silenced, highly condensed, X and Y chromosomes are visible as a compact 
structure termed the XY body or sex body beginning in zygotene and persisting into meiosis II.  Indeed, 
failure to silence the Y chromosome is believed to lead to inappropriate expression of Y chromosome 
genes that are toxic to the spermatocyte during pachytene (J. M. Turner, 2007).  Brca1 is believed to 
facilitate MSCI, as Brca1 is recruited to the X and Y chromosomes during zygotene, resulting in the 
recruitment of the ATR kinase, phosphorylation of histone H2AX, chromatin compaction, and finally 
transcriptional silencing (J. M. Turner et al., 2004).  The Brca1 hypmorphic mutant Brca1∆11/∆11, which also 
displays pachytene arrest of spermatocytes, has been shown to have a defect in MSCI (Xu et al., 2003).  
Surprisingly, another Brca1-BRCT phospho-recognition mutant (Brca1M1717R), which also has a male 
fertility defect similar to Brca1SF/SF mice, is competent for XY body formation (Baer Lab, unpublished 
data).  This suggests that the phospho-recognition function of the Brca1 BRCT domain is not required for 
MSCI.  Interestingly, deletion of poly(ADP-ribose) polymerase 2 (PARP2), an enzyme that synthesizes 
PAR polymers, leads to defects in XY body formation (Dantzer et al., 2006).  Therefore, it is tempting to 
speculate that the PAR-binding function of the Bard1-BRCT domain is responsible for the initial 
recruitment of Brca1 to the X and Y chromosomes during MSCI and that failure of this recruitment is 
responsible for the male fertility defects observed in the Bard1SF/SF and Bard1KA/KA mice.  However, further 
studies are necessary to confirm this hypothesis.   
 Given the well-established roles of BRCA1 and BARD1 in HDR, we initially hypothesized that 
phospho-recognition by the BARD1 BRCT domain is required for HDR (Baer & Ludwig, 2002; Fabbro et 
al., 2002; Joukov et al., 2006; Laufer et al., 2007; E. E. McCarthy et al., 2003; Moynahan et al., 1999; 
Scully, Chen, Ochs, et al., 1997; Scully, Chen, Plug, et al., 1997; Westermark et al., 2003).  To test this 
hypothesis, we created isogenic panels of MEF and ES cell lines, representing a clean genetic system 
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compared to siRNA-mediated knockout/reconstitution experiments.  Surprisingly, Bard1SF/SF and 
Bard1KA/KA cells showed no discernable defects in three separate assays designed to detect HDR 
deficiencies.  First, the Bard1-BRCT mutants were competent for Rad51 focus formation (Figures 23 and 
24), a key step in the repair of DSBs by HDR.  As expected, Brca1SF/SF cells did not form Rad51 foci as 
efficiently as their wild type controls or Bard1SF/SF and Bard1KA/KA cell lines.  Second, we tested the gene 
targeting efficiency of our Bard1 cell lines (Figure 25).  While the connection between gene targeting and 
HDR is still unclear, many HDR components, including BRCA1, are believed to be vital to both processes 
(Moynahan et al., 1999).  Both Bard1-BRCT mutants displayed gene targeting efficiencies comparable to, 
or even slightly greater than, isogenic Bard1+/+ ES cell lines.  Finally, we used the DR-GFP reporter 
system to measure in vivo repair of a DSB by HDR (Figure 26).  Neither Bard1SF/SF or Bard1KA/KA ES cells 
displayed a decrease in GFP-positive cells when compared to their isogenic wild type control, while 
Brca1SF/SF cells were clearly defective for HDR in the same assay (Shakya et al., 2011).  Taken together, 
these data strongly suggest that phospho-recognition by the Bard1 BRCT domain is dispensable for 
BRCA1/BARD1-mediated HDR. 
 The lack of a role for the Bard1-BRCT domain in HDR is in line with previous experiments utilizing 
the DR-GFP reporter and involving reconstitution of a Bard1-null mouse carcinoma line with human 
BARD1-BRCT phospho-recognition mutants (S575F, K619A) (Laufer et al., 2007).  Our data, performed 
in mouse ES cells harvested from transgenic Bard1-BRCT mutants, represents a clean genetic system 
and confirms the previous result.  Furthermore, recent data suggests that, apart from stabilizing the 
BRCA1 protein, BARD1 may not have a unique role in HDR.  This data derives from the analysis of 
“RING-less” BRCA1 polypeptides harboring an N-terminal truncation that disrupts BRCA1 binding to 
BARD1 while preserving BRCA1 stability through deletion of a nuclear export signal required for BRCA1 
proteolysis (M. Li et al., 2016).  As a result, these mutant cells express the RING-less BRCA1 polypeptide 
but have essentially no detectable levels of BARD1.  Surprisingly, these cells were competent for HDR as 
confirmed by Rad51 focus formation after IR treatment, but still displayed genome instability associated 
with replication fork defects.  Together these data imply that the Bard1-BRCT domain, and possibly the 
entire Bard1 protein, is not required for BRCA1/BARD1-mediated HDR.   
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 Despite the absence of an HDR defect in the Bard1 BRCT phospho-recognition mutants, the 
Bard1SF/SF and Bard1KA/KA cell lines displayed a distinct pattern of genotoxin sensitivity, as indicated by 
clonogenic survival assays with immortalized MEFs (Figures 15-18).  Although each of the genotoxins 
investigated (MMC, PARPi, IR, camptothecin) can cause multiple types of DNA damage which activate a 
number of DNA repair pathways, broadly the Bard1-BRCT mutants appear to be more sensitive to DNA 
damaging agents that had the capacity to stall replication forks (MMC, PARPi) and less sensitive to 
agents that primarily generate DSBs (IR).  The resistance of Bard1SF/SF and Bard1KA/KA cells to agents that 
generate DSBs fits with the data showing that these same mutations do not result in an HDR defect.  
Instead, these data raise the possibility that phospho-recognition by the Bard1-BRCT domain may be 
required for stalled replication fork protection. 
 While sensitivity to MMC and PARPi are thought to stem, at least in part, from defects in HDR, 
there is ample evidence that sensitivity to these agents is also partially HDR-independent in BRCA1-
mutant cells.  Specifically, rescue of HDR function in BRCA1-mutant cells by deletion of the non-
homologous end joining (NHEJ) protein 53BP1 failed to rescue MMC sensitivity (Bunting et al., 2012), 
implying that sensitivity to DNA inter-strand crosslinking reagents is HDR-independent.  Inter-strand 
crosslinks (ICLs) are repaired during replication through a series of steps involving the Fanconi Anemia 
(FA) proteins.  Repair of the lesion is thought to be stimulated by replication fork stalling and some of the 
FA proteins have also been implicated in the SFP pathway (Raschle et al., 2008) (Schlacher et al., 2012).  
However, repair of ICLs is a special case of replication fork stalling, as it requires removal of a physical 
lesion.  As such, BRCA1 has been shown to facilitate helicase unloading and FA protein ubiquitylation 
which stimulate excision of the ICL (Long, Joukov, Budzowska, & Walter, 2014).  Thus, it is possible that 
phospho-recognition by the BARD1 BRCT domain is required for an ICL repair-specific function, in 
addition to its role in the canonical SFP pathway.  Further experiments will be necessary to fully 
investigate this possibility. 
Furthermore, while double-mutant Brca1–/– 53BP1–/– cells are not as sensitive as Brca1–/– cells to 
PARPi, the 53BP1 deletion did not completely restore their PARPi resistance to wild type levels (Bunting 
et al., 2012).  This result also suggests that the PARPi sensitivity of BRCA1-mutant cells is not completely 
mediated by loss of its HDR function.  Indeed, supporting this are recent observations that restoration of 
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the SFP pathway in HDR-deficient cells can mediate partial resistance to PARPi treatment, implying that 
SFP defects are, at least partly responsible for PARPi sensitivity (Ray Chaudhuri et al., 2016) 
(Taglialatela et al., 2017).  
 In addition to MMC sensitivity, Bard1SF/SF and Bard1KA/KA cells are also prone to MMC-induced 
chromosomal rearrangements.  This suggests that the inability to repair MMC-induced crosslinks leads 
directly to chromosomal instability.  Consistent with their hypersensitivity to MMC, rescue of HDR in 
Brca1-mutant cells did not restore resistance to MMC-induced genome stability (Bunting et al., 2012). 
Together, these results support the conclusion that MMC hypersensitivity and MMC-induced genome 
instability are independent of HDR function.  Furthermore, cells expressing the “RING-less” Brca1 
polypeptide, which fails to bind Bard1, show an increase in cisplatin-induced (another DNA crosslinking 
reagent) chromosomal aberrations compared to wild type cells (M. Li et al., 2016).  This suggests that 
BARD1, and specifically the phospho-recognition function of its BRCT domain, make a unique 
contribution to the DNA crosslink repair functions of the BRCA1/BARD1 heterodimer.   
 On the other hand, Bard1SF/SF and Bard1KA/KA primary MEFs did not display spontaneous 
chromosomal abnormalities when compared to their isogenic wild type controls (Figures 20 and 21).  In 
contrast, as had been previously reported, significant spontaneous genomic instability was observed in 
Brca1SF/SF cells (Figure 22) (Shakya et al., 2011).  This suggests that the suppression of spontaneous 
chromosomal rearrangements is dependent upon HDR function.  In line with this reasoning, rescue of 
HDR function in BRCA1-mutant cells by 53BP1 loss suppressed spontaneous chromosomal 
rearrangements, as did cells expressing the “RING-less” BRCA1 polypeptide, which lack BARD1 
expression but appear to be competent for HDR (Bunting et al., 2012) (M. Li et al., 2016).     
 Taken together, the hypersensitivity to MMC and PARPi, the susceptibility to MMC-induced 
genome instability, and the male sterility phenotype imply that the BARD1-BRCT domain makes unique 
contributions towards BRCA1/BARD1-mediated functions, rather than simply stabilizing BRCA1.  
Additionally, the pattern of genotoxin sensitivity implies that phospho-recognition by the Bard1 BRCT 
domain may be required for protection of stalled replication forks.  This hypothesis will be investigated in 
















PHOSPHO-RECOGNITION BY THE BARD1 BRCT DOMAIN IS REQUIRED FOR BRCA1/BARD1-








 Homology-directed repair (HDR) and stalled fork protection (SFP) are thought to be critical for 
BRCA1-mediated genome stability and tumor suppression (Kolinjivadi, Sannino, de Antoni, Techer, et al., 
2017; Moynahan et al., 1999; Schlacher et al., 2012).  However, given the many functions of BRCA1, it is 
difficult to determine the exact contributions that HDR or SFP make to these aspects of BRCA1 function.  
Further complicating matters is the significant overlap between the molecular components that serve in 
these two pathways (Kolinjivadi, Sannino, de Antoni, Techer, et al., 2017), making separation-of-function 
mutants valuable tools to investigate the relative contributions of HDR and SFP to genome stability and 
tumor suppression.    
 Stalled fork protection promotes genome stability by preventing the degradation and subsequent 
collapse of replication forks that have encountered a replication block and are unable to proceed with 
DNA replication (Figure 2) (Ciccia & Elledge, 2010; Cortez, 2015; Errico & Costanzo, 2012; Zeman & 
Cimprich, 2014).  Since collapsed replication can lead to aberrant chromosomal rearrangements, it is not 
surprising that a deficiency in the SFP pathway is associated with genomic instability (Schlacher et al., 
2011; Schlacher et al., 2012).  Replication fork stalling is induced by replication stress, which can arise 
from many endogenous and exogenous sources.   Exogenous sources include chemotherapeutic agents 
that deplete nucleotide pools or induce the formation of protein-DNA adducts or DNA inter-strand 
crosslinks.   Replication stress can also occur from endogenous sources, such as oncogene activation, 
collision of the replication fork with transcriptional machinery, or encounters with DNA adducts created by 
byproducts of cellular metabolism (Ciccia & Elledge, 2010; Cortez, 2015; Errico & Costanzo, 2012; 
Zeman & Cimprich, 2014).  Given the many sources of replication stress, replication fork stalling is likely a 
fairly common cellular event, thereby highlighting the importance of the SFP pathway in maintaining 
genome stability.   
 BRCA1 and BRCA2 are both required for an intact SFP pathway, and given that SFP is one of 
the activities common to both BRCA1 and BRCA2, SFP may be important for their tumor suppressor 
functions (Lomonosov et al., 2003; Schlacher et al., 2011; Schlacher et al., 2012; Ying et al., 2012).  
BRCA2 has been shown to protect stalled forks from degradation by MRE11 by promoting the assembly 
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of RAD51 onto DNA (Schlacher et al., 2011).  While BRCA1-deficient cells show a defect in SFP, it is not 
clear mechanistically how BRCA1 contributes to the protection of stalled forks.  Despite this, the role of 
BRCA1 in SFP has been firmly established, as BRCA1 colocalizes with the DNA replication machinery 
upon application of fork stalling reagents like hydroxyurea (Dungrawala et al., 2015; Scully, Chen, Ochs, 
et al., 1997). 
 BRCA1 binds with BARD1 to form an obligate stoichiometric heterodimer (Jin et al., 1997; L. C. 
Wu et al., 1996).  Indeed, many of the functions of BRCA1, including tumor suppression and HDR, are 
mediated by the BRCA1/BARD1 heterodimer (Baer & Ludwig, 2002; Joukov et al., 2006; Yu & Baer, 
2000).  Indeed, conditional Bard1-null mice have been shown to develop mammary tumors at the same 
rate and of the same phenotype as those that arise in conditional Brca1-null mice (Shakya et al., 2008). 
Furthermore, Bard1-null cells display chromosome instability and HDR defects reminiscent of Brca1-null 
cells (Baer & Ludwig, 2002; Fabbro et al., 2002; Joukov et al., 2006; Laufer et al., 2007; E. E. McCarthy 
et al., 2003; Westermark et al., 2003).  
Given that BRCA1 and BARD1 are dependent upon their heterodimerization for their stability, 
experiments using cells and mouse models that result in the complete inactivation of either Brca1 or 
Bard1 are largely uninformative in sorting out which functions of the heterodimer are mediated by BRCA1 
or BARD1 individually.  Furthermore, since null mutations disrupt all functions associated with the 
heterodimer, they cannot reveal which protein domains of BRCA1 and BARD1 are responsible for 
individual BRCA1/BARD1 functions like tumor suppression, HDR, or SFP.  Illustrative of this point, while 
Bard1-null cells are defective for HDR, our data show that Bard1 BRCT phospho-recognition is 
dispensable for HDR (Chapter 3).  On the other hand, the phospho-recognition by the Brca1-BRCT 
domain is required for both HDR and tumor suppression (Shakya et al., 2011).  However, whether the 
Brca1SF/SF mutation leads to SFP defects has not been examined.   
 Furthermore, whether BARD1 plays a role in the SFP pathway is currently unknown.  Despite 
this, there are some lines of evidence suggesting that BARD1 also functions in SFP.  Like BRCA1, 
BARD1 colocalizes with the replication fork machinery after induction of replication stress by hydroxyurea 
(Scully, Chen, Ochs, et al., 1997).  More recently, BARD1 has been shown to be highly enriched at 
stalled replication forks using a biochemical method called isolation of proteins on nascent DNA (iPOND) 
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(Dungrawala et al., 2015).  Moreover, the sensitivity of the Bard1SF/SF and Bard1KA/KA mutants to agents 
that are known to stall replication forks (Chapter 3, MMC and PARPi) imply that phospho-recognition by 
the Bard1 BRCT domain is required for SFP.  However, once again, it is unknown whether BARD1 is 
actually required for BRCA1/BARD1-mediated SFP, or if its role is largely to stabilize BRCA1.   
Germline mutations of BRCA1 account for a significant proportion of the familial cases of breast 
and ovarian cancer (Easton, 1999).  Furthermore, most BRCA1-mutant breast tumors display a “triple-
negative” immunophenotype, meaning they lack expression of the estrogen receptor (ER), progesterone 
receptor (PR), and HER2/Neu growth factor receptor.  The triple-negative immunophenotype corresponds 
to a “basal-like” molecular subtype as determined by gene expression profiling (Perou et al., 2000; Sorlie 
et al., 2001).  Clinically, patients with ER-positive or HER2-positive breast cancers can be treated with 
tamoxifen and trastuzumab, respectively, two targeted therapies that have been shown to improve patient 
survival and decrease disease recurrence (Early Breast Cancer Trialists' Collaborative, 2005; Engel & 
Kaklamani, 2007; Piccart-Gebhart et al., 2005).  However, since most BRCA1-mutant tumors do not 
express these markers, they are typically resistant to these targeted therapies and must be treated with 
standard chemotherapeutic agents (Foulkes et al., 2010).  In part due to the lack of targeted therapy 
options, triple-negative and basal-like breast cancers are associated with poor clinical outcomes (Hennigs 
et al., 2016; Liedtke et al., 2008). 
 Given that a mutation in BRCA1 increases a woman’s lifetime risk of breast cancer approximately 
10-30 fold, there is keen interest in determining how loss of BRCA1 and its associated functions lead to 
tumorigenesis (Antoniou et al., 2003; Roy et al., 2011).  Indeed, determining the mechanism of tumor 
formation in BRCA1 mutants may help to reveal universally applicable concepts regarding malignant 
transformation.  Additionally, mechanistic insights into BRCA1-mutant cancers may yield new targets for 
rational drug design that could be used in cancer treatment or even prevention.  As proof of this concept, 
poly(ADP-ribsose) polymerase inhibitors (PARPi) have arisen as an effective treatment for BRCA1/2-
mutant tumors in recent years (Fong et al., 2009).  Their deployment in the clinical setting can be traced 
back to basic science research that revealed deficiencies in homology-directed repair (HDR) of DNA 
double-strand breaks (DSB) in BRCA1-mutant cells (Moynahan et al., 1999).  It was hypothesized that 
PARPi treatment, which inhibits the repair of single-strand DNA (ssDNA) breaks, would result in a 
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synthetic lethal interaction in cells with an HDR defect.  Specifically, the inhibition of PARP would lead to 
an accumulation of ssDNA breaks, which would then be converted to DSBs during DNA replication 
leading to a toxic overload of DNA damage in HDR-deficient cells (Bryant et al., 2005; Farmer et al., 
2005).  Interestingly, sensitivity to PARPi has since been shown to stem, at least in part, from their ability 
to stall replication forks, indicating the stalled fork protection (SFP) pathway may also be important for 
BRCA1/2-mediated resistance to PARP inhibition (Pommier et al., 2016).  Despite the clinical benefit 
offered by PARPi treatment, BRCA1/2-mutant tumors rapidly evolve resistance, often through restoration 
of the SFP or HDR pathway (Lord & Ashworth, 2013; Ray Chaudhuri et al., 2016; Taglialatela et al., 
2017).  Therefore, the identification of new drug targets, as well as how to combat therapy resistance, 
remains a high priority of BRCA1/2 research. 
 BRCA1 has been implicated in a wide spectrum of cellular activities, thus complicating the search 
for BRCA1 functions that are actually required for tumor suppression.  As alluded to in the previous 
discussion of PARPi usage, the functions of BRCA1 in SFP and HDR are proposed to be important for 
tumor suppression.  Supporting this hypothesis, loss of SFP and HDR functions have been shown to lead 
to genome instability, a hallmark of cancer that may also be a key initiating event in tumorigenesis 
(Moynahan et al., 1999; Schlacher et al., 2011; Schlacher et al., 2012).  Furthermore, BRCA2 has also 
been implicated in both HDR and SFP, suggesting the possibility that BRCA1 and BRCA2 promote tumor 
suppression by common mechanisms (Couch et al., 2015; Schlacher et al., 2011). 
Despite the evidence implicating SFP and HDR in the maintenance of genome stability, it has 
never been formally proven whether these aspects of BRCA1 function are required, either individually or 
together, for BRCA1-mediated tumor suppression.  Additionally, since the SFP and HDR pathways share 
common components, it is difficult to assess the unique contributions of each pathway to tumor 
suppression (Kolinjivadi, Sannino, de Antoni, Techer, et al., 2017).   Indeed, while mammary-specific 
conditional knockout mouse models have been instrumental in establishing BRCA1 and BARD1 as tumor 
suppressors (Shakya et al., 2008), they have been largely uninformative regarding the specific 
contributions of SFP and HDR to tumor suppression.  Nonetheless, mechanistic insights can be obtained 
by incorporating mutations that target specific aspects of Brca1/Bard1 function into mouse models of 
hereditary breast cancer.  As proof of this principle, our laboratory previously showed that a separation-of-
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function mutation (Brca1I26A) that ablates the E3 ubiquitin ligase activity of Brca1 without disrupting its 
interaction with Bard1 did not impair tumor suppression in mice (Shakya et al., 2011).  Therefore, the E3 
ubiquitin ligase activity appears to be dispensable for the tumor suppression activity of the 
BRCA1/BARD1 heterodimer.  In contrast, the phospho-recognition function of the BRCA1 BRCT domain 
is required for both HDR and tumor suppression, implying that the HDR functions of BRCA1 contribute to 
its tumor suppression activity (Shakya et al., 2011).  However, as discussed above, the contribution of the 
BRCA1 BRCT domain is to SFP is unknown, therefore it is unclear whether loss of HDR alone, or loss of 
HDR and SFP together is required for tumor formation.   
In this chapter, we evaluate the roles of the Bard1 BRCT domain and the Brca1 BRCT domain in 




1. The BRCT domains of Brca1 and Bard1 are required for stalled fork protection 
i.  Bard1 BRCT phospho-recognition is required to protect stalled forks from nucleolytic 
degradation. 
Since BRCA1 is required for stalled fork protection (SFP), and SFP is critical for genome integrity, 
we next examined SFP in Bard1SF/SF and Bard1KA/KA cells (Schlacher et al., 2011; Schlacher et al., 2012).  
To this end, we performed DNA fiber analysis with mutant and wild type immortalized MEFs.  Isogenic cell 
lines were subjected to two sequential 20-minute pulses with the nucleoside analogs 5’-iodo-2-
deoxyuridine (IdU) and 5’-chloro-2-deoxyuridine (CldU) (Figure 27A).  The track lengths of single DNA 
fibers were then measured immediately following CldU treatment (–HU condition) or after a 90-minute 
treatment with hydroxyurea (HU, +HU condition) at a dose known to stall replication forks (Schlacher et 
al., 2011).  As a reversible inhibitor of ribonucleotide reductase, HU can induce replication fork stalling by 
depleting cellular nucleotide pools.  Mre11-dependent fork degradation in BRCA1/2-mutant cells occurs in 
a directional manner such that the most recently synthesized DNA of the nascent strands is degraded first 





CldU and ldU replication tracts.  In the presence of an SFP defect, the CldU tract would be degraded first 
by Mre11, resulting in a decreased CldU/IdU ratio.   
As expected, the median CldU/IdU ratios approximate unity in the untreated Bard1+/+ (clone I, 
1.03) and the two untreated Bard1SF/SF (G, 1.05 and H, 1.01) isogenic cell lines (Figure 27B).   
Furthermore, when the wild type cell line was exposed to 2 mM HU for 1.5 hours, there was no significant 
change in the median CldU/IdU ratios (1.05 +HU, 1.03 untreated), indicating an intact SFP pathway.  In 
contrast, CldU/IdU ratios were significantly reduced after HU treatment in the two independent Bard1SF/SF 
clones (0.80 and 0.77) compared to both untreated Bard1SF/SF cells and HU-treated Bard1+/+ cells.  Thus, 
Bard1 BRCT phospho-recognition is required for the stability of HU-stalled forks.  Importantly, the 
CldU/IdU ratios of the two Bard1SF/SF clones were fully restored by culturing these HU-treated cells in the 
presence of mirin, an inhibitor of Mre11 nuclease activity (1.01 in clone G and 0.98 in clone H) (Dupre et 
al., 2008).  Thus, the DNA degradation occurring during HU treatment of Bard1SF/SF cells is mediated by 
the MRE11 nuclease.  
Similarly, the median CldU/IdU ratios of untreated isogenic clones of Bard1+/+ (clone N, 1.03) and 
Bard1KA/KA (J, 0.88 and L, 0.89) were close to 1 (Figure 28B).  As expected, upon treatment of the 
Bard1+/+ clone with HU, there was no significant reduction in the median CldU/IdU ratio (1.00) compared 
to the untreated Bard1+/+ cells (1.03).  Consistent with the results from Bard1SF/SF cells, upon HU 
exposure, Bard1KA/KA clones J and L showed significant reductions in the median CldU/IdU ratio (0.45 and 
0.47, respectively), which were largely restored by treatment with mirin (0.89 and 0.85).  Taken together, 
these data demonstrate that phospho-recognition by the Bard1 BRCT domain is required for protection of 
stalled replication forks from Mre11 degradation.   
 
ii. Brca1SF/SF cells also fail to protect stalled replication forks 
Although stalled fork protection (SFP) is clearly dependent on BRCA1, the functional domains of 
BRCA1 that mediate SFP have not yet been defined (Schlacher et al., 2012). Although Brca1SF/SF cells 
are defective for HDR (Shakya et al., 2011), their ability to protect stalled forks is not known.  Therefore, 
to ascertain whether the BRCT phospho-recognition activity of BRCA1 contributes to SFP, isogenic 





analysis after sequential pulse labeling with IdU and CldU.  As shown in Figure 29B, the median CldU/IdU 
ratios were close to 1 in both untreated Brca1+/+ (0.92 and 0.93) and untreated Brca1SF/SF (0.92 and 0.97) 
clones.   Likewise, the median CldU/IdU ratios of the HU-treated Brca1+/+ clones also approached unity 
(0.93 and 0.93).  In contrast, however, both Brca1SF/SF clones displayed a significant decrease in their 
median CldU/IdU ratios upon HU exposure (0.54 and 0.57), suggesting a defect in SFP.  Once again, 
these stalled replication forks were shown to be degraded in an Mre11-dependent fashion, as application 
of the Mre11 inhibitor mirin to HU-treated Brca1SF/SF cells rescued the median CldU/IdU ratio (0.89 and 
0.91).  Thus, the phospho-recognition property of the Brca1 BRCT domain is required for not only HDR 
(Shakya et al., 2011), but also for SFP. 
 
2. Treatment with agents that create replication stress induce DNA damage in Bard1 and Brca1 
BRCT-mutant cells 
i. Bard1SF/SF, Bard1KA/KA, and Brca1SF/SF cells display an increase in DNA damage after HU 
treatment 
 While the DNA fiber assay demonstrated that stalled replication forks are susceptible to Mre11-
mediated degradation in Bard1SF/SF, Bard1KA/KA, and Brca1SF/SF cells, the assay does not reveal whether 
this degradation translates into an increased burden of DNA damage and genome instability.  Therefore, 
we used the alkaline comet assay to determine whether replication stress induces increased levels of 
DNA damage in Bard1SF/SF and Bard1KA/KA cells.  In the alkaline comet assay, which detects single-strand 
and double-strand DNA breaks, cells are treated with a DNA damaging agent, embedded in agarose, and 
incubated in an alkaline denaturing buffer before being subjected to gel electrophoresis.  Single-strand 
and double-strand DNA breaks will cause the damaged DNA to migrate though the gel faster than 
undamaged DNA.  Upon staining with a fluorescent nucleic acid dye (GelRed); the damaged DNA can be 
visualized as a “comet tail” trailing the undamaged DNA (i.e., the “comet head”).  The amount of DNA 
damage can then be quantified from the tail moment, a measurement of the length and amount of DNA 
present in the comet tail.   
 Thus, isogenic clones of Bard1+/+ (E and I) and Bard1SF/SF (A, C, and H) immortalized MEFs, in 





hours (Figure 30A).  After HU treatment, the amount of DNA damage was quantified through 
measurement of the tail moment.  As shown in Figure 30A, all three Bard1SF/SF cell lines displayed a 
significant increase in DNA damage after HU exposure when compared with their isogenic wild type 
controls.  Specifically, the Bard1SF/SF clones (A, C, and H) displayed average tail moments of 10.1, 10.6, 
and 7.33, respectively, compared to averages of 2.43 and 2.57 in the two Bard1+/+ clones.  Additionally, 
the Brca1SF/SF cell line also displayed an increase in average tail moment (7.10) compared to its isogenic 
wild type control (3.10).   
 Similarly, isogenic clones of Bard1+/+ (I and N) and Bard1KA/KA (J, L, and M) immortalized MEFs, in 
parallel with an isogenic pair of Brca1+/+ (Q) and Brca1SF/SF (P) cell lines, were treated and analyzed as 
described above.  As shown in Figure 30B, the three Bard1KA/KA clones all displayed higher levels of DNA 
damage after HU exposure as reflected by a significant increase in average tail moment (11.5, 10.2, and 
9.17) when compared to the two Bard1+/+ clones (2.96 and 3.47).  Once again, the Brca1SF/SF cell line also 
displayed an increase in average tail moment over its Brca1+/+ isogenic control (10.5 vs 4.11). Therefore, 
these data indicate that the SFP defects of Bard1SF/SF and Bard1KA/KA cells lead to DNA damage upon 
induction of replication stress.   
 
ii.  Bard1SF/SF, Bard1KA/KA, and Brca1SF/SF cells also display an increase in DNA damage after 
camptothecin treatment 
 To confirm that Bard1SF/SF and Bard1KA/KA cells are susceptible to replication stress-induced DNA 
damage, we performed the alkaline comet assay with camptothecin (CPT), a topoisomerase I (TopI) 
inhibitor that can block progression of the replication fork by stabilizing TopI-DNA adducts.  Thus, the 
mechanism of fork stalling by camptothecin is very different from that of hydroxyurea, which creates 
replication stress without a physical block by the depletion of nucleotide pools.  Indeed, CPT has been 
shown to lead to MRE11-mediated fork degradation in cell lines deficient for SFP (Seiler, Conti, Syed, 
Aladjem, & Pommier, 2007; Taglialatela et al., 2017).   
 Bard1+/+ (E and I) and Bard1SF/SF (A, C, and H) isogenic cell lines were treated with 100 nM CPT 
for 5 hours to induce replication stress.  An isogenic pair of Brca1+/+ (Q) and Brca1SF/SF (P) immortalized 








embedded in agarose, incubated in denaturing buffer, electrophoresed, and stained with a DNA dye.  As 
shown in Figure 31A, the average tail moments of the Bard1SF/SF cell lines (6.18, 5.84, and 4.78) were 
significantly higher than those of the two Bard1+/+ cell lines (1.65 and 1.70).  Additionally, the Brca1SF/SF 
cell line also displayed a significant increase in average tail moment compared to its isogenic wild type 
control (6.00 vs. 1.59).  
 Three Bard1KA/KA clones (J, L, and M) and their isogenic wild type controls (I and N) were also 
treated with CPT under the same conditions as above, along with an isogenic pair of Brca1+/+ (Q) and 
Brca1SF/SF (P) immortalized MEF lines.  Similar to those of Bard1SF/SF cells, the average tail moments of 
Bard1KA/KA clones (4.40, 4.83, and 4.87) were markedly increased compared to those of the Bard1+/+ 
clones (1.79 and 1.05).  The Brca1SF/SF cell line also displayed an increase in DNA damage, as its 
average tail moment (6.70) was significantly larger than that of its isogenic wild type control (1.95).  
Therefore, the phospho-recognition functions of the both the Bard1 and Brca1 BRCT domains are 
required for resistance to camptothecin-mediated replication stress.  Indeed, if the results from both the 
hydroxyurea and camptothecin alkaline comet assays are taken into consideration, then both Bard1 and 
Brca1 BRCT phospho-recognition are required for resistance to multiple types of replication stress. 
   
3. Localization of the BRCA1/BARD1 heterodimer to stalled forks is impaired in Bard1SF/SF and 
Bard1KA/KA cells  
i. Bard1 foci formation in Bard1KA/KA cells  
 A potential function for BRCA1 at stalled replication forks first emerged from studies of the 
nuclear distribution of BRCA1 and BARD1 polypeptides in S phase cells (Nagaraju & Scully, 2007; Scully, 
Chen, Ochs, et al., 1997).  In particular, Scully et al. used immunoflourescent microscopy to show that, in 
unperturbed S phase cells, a fraction of the BRCA1/BARD1 pool resides in discrete nuclear foci that are 
clearly distinct from sites of DNA replication marked by PCNA immunostaining (Scully, Chen, Ochs, et al., 
1997).  However, upon HU treatment these S phase foci dissipate, and focal BRCA1/BARD1 
immunostaining reappears within the PCNA-staining DNA replication structures of late S phase cells.  
Recently, the notion that BRCA1 and BARD1 are recruited to stalled forks was established biochemically 







associate with HU-stalled, but not unstressed, DNA replication forks (Dungrawala et al., 2015).  To 
ascertain whether the SFP defect of Bard1SF/SF and Bard1KA/KA cells reflects a failure of mutant 
BRCA1/BARD1 heterodimers to mobilize at stalled forks, we compared HU-induced recruitment of Brca1 
and Bard1 polypeptides to PCNA-staining replication foci in isogenic wildtype and mutant MEFs.  Thus, 
cells cultured for 90-minutes in the presence or absence of HU were harvested, co-stained with PCNA- 
and Bard1-specific antibodies, and visualized by immunoflourescent microscopy. 
 First, we analyzed the capacity of Bard1KA/KA cells to form Bard1 foci under both HU-treated and 
untreated conditions.  Scully et al. (1997) reported that Brca1 and Bard1 form foci in S phase cells under 
both unperturbed and HU-treated conditions, however the total number of cells expressing Brca1 or 
Bard1 foci decreases substantially in HU-treated cells (Scully, Chen, Ochs, et al., 1997).  The function of 
the BRCA1/BARD1 nuclear foci of unperturbed cells is currently unknown, but may represent recruitment 
of the heterodimer to spontaneous sites of DNA damage, or, alternatively, the sequestration of these 
proteins into discrete domains to prevent their interference with normal replication.    
Thus, to see whether Bard1 foci dynamics are preserved in Bard1KA/KA cells, we cultured mutant 
cell lines and their isogenic wild type controls for 1.5 hours in the presence or absence of 2mM HU and 
quantified the percentage of cells that displayed five or more Bard1 nuclear foci (Figure 33A).  As 
previously reported by Scully et al., treatment with hydroxyurea led to a decrease in percentage of cells 
displaying Bard1 foci when compared to the untreated cells (Figure 32) (Scully, Chen, Ochs, et al., 1997).   
This decrease was observed in the both the Bard1KA/KA clones (J and L) and their wild type control (I). 
Furthermore, Bard1 foci levels in Bard1KA/KA clones were comparable to their wild type control in both 
untreated (53.0% and 55.5% in Bard1KA/KA clones vs. 53.5% in the Bard1+/+ clone) and HU-treated (29.0% 
and 27.2% in Bard1KA/KA clones vs. 24.7% in the Bard1+/+ control) conditions (Figure 32).  Therefore, it is 
unlikely that Bard1-BRCT phospho-recognition is required for formation of Bard1 foci during S phase.   
 
ii. Bard1SF/SF and Bard1KA/KA cells show a defect in the recruitment of Bard1 to PCNA foci in HU-
treated cells 
  A recent study demonstrated that the PAR-binding ability of the Bard1-BRCT domain is required 





laser microirradiation (M. Li & Yu, 2013).  Given that PAR chains are also rapidly assembled at stalled 
replication forks, and that SFP is dependent on PARP1 activity (Ying et al., 2012), we hypothesized that 
Bard1 BRCT phospho-recognition may be required for proper recruitment of the BRCA1/BARD1 
heterodimer to stalled replication forks.  To test this hypothesis, we examined the ability of Bard1 to 
localize to PCNA-staining replication structures after HU treatment in wild type and Bard1 BRCT-mutant 
cells (Figure 33A).  To quantify this localization event, we first identified cells that exhibit the late S phase 
pattern of nodular PCNA staining (PCNA+ cells, Figure 33B).  Of this PCNA+ population, cells could be 
further subdivided into three separate populations: cells that did not display Bard1 nuclear foci (Bard1– 
PCNA+), cells that displayed Bard1 foci that colocalized with PCNA (Bard1+ PCNA+ colocalized), and cells 
that displayed Bard1 foci that were spatially independent of PCNA (Bard1+ PCNA+ non-colocalized).  We 
then defined the percent colocalization in PCNA+ cells as the number of Bard1+ PCNA+ colocalized cells 
divided by the total number of nodular-staining PCNA+ cells (i.e., the sum of the Bard1– PCNA+, Bard1+ 
PCNA+ non-colocalized, and Bard1+ PCNA+ colocalized populations).  Therefore, we interpreted the 
Bard1– PCNA+ and Bard1+ PCNA+ non-colocalized cells as populations in which Bard1 had failed to 
mobilize to the stalled replication fork.  
 Thus, two independent Bard1SF/SF clones (A and C) and an isogenic Bard1+/+ clone (E) were 
incubated with or without 2 mM HU for 1.5 hours (Figure 33A).  As was observed by Scully et al., Bard1 
and PCNA rarely colocalized in untreated cells (Scully, Chen, Ochs, et al., 1997).  This was true of the 
two Bard1SF/SF clones (A, 3.3%; C, 2.6% colocalization) as well as the isogenic Bard1+/+ control clone (E, 
7.8% colocalization) (Figure 34A).  As expected, upon HU treatment, the proportion of PCNA-staining late 
S-phase nuclei that harbor co-localizing PCNA and Bard1 foci increased approximately 10-fold in wild 
type cells (81.8% colocalization in +HU vs 7.8% colocalization in –HU condition) (Figure 34A), once again 
confirming the observations of Scully et al., (Scully, Chen, Ochs, et al., 1997). Significantly, however, we 
observed a marked reduction in the proportion of nuclei with co-localizing PCNA and Bard1 foci in the 
HU-treated Bard1SF/SF clones (22.2% and 24.5% colocalization compared to 81.8% colocalization in 
Bard1+/+) (Figure 34A).  These results suggest that the recruitment of Bard1 to stalled forks is impaired by 














 To confirm this result for the Bard1KA mutant, we subjected two independent Bard1KA/KA clones (J 
and L) along with an isogenic Bard1+/+ clone (I) to the same analysis.  Once again, colocalization between 
Bard1 and PCNA was exceedingly rare in untreated cells in both the Bard1KA/KA clones (2.0% and 1.6% 
colocalization) and the Bard1+/+ clone (2.3% colocalization) (Figure 34B).  Upon HU treatment of the 
Bard1+/+ clone, colocalization of Bard1 with PCNA was observed in the overwhelming majority of PCNA+ 
cells (87.3% colocalization).  In sharp contrast, in the HU-treated Bard1KA/KA clones Bard1 colocalized with 
PCNA-staining replication structures in only a fraction of PCNA+ cells (42.3% and 35.2% colocalization in 
PCNA+) (Figure 34B).  Therefore, the Bard1KA mutation also impairs the recruitment of Bard1 to HU-
stalled replication forks.  Together, these results indicate that Bard1 BRCT phospho-recognition is 
required for recruitment of Bard1 to stalled replication forks. 
 
iii. Brca1 focus formation in Bard1KA/KA cells  
 Since Bard1 and Brca1 form an obligate heterodimer and colocalize in nuclear foci, we 
hypothesized that Brca1 would also display a recruitment defect to PCNA-staining replication structures 
(Baer & Ludwig, 2002; Jin et al., 1997; L. C. Wu et al., 1996).  We first examined the formation of Brca1 
nuclear foci in HU- and mock-treated clones of both Bard1+/+ and Bard1KA/KA cells (Figure 35).  As had 
been observed with Bard1 foci in Figure 32, the percentage of cells harboring ≥5 Brca1 foci decreased 
upon HU treatment in the two independent Bard1KA/KA clones (L: 55.3% in untreated vs. 31.3% in HU-
treated; M: 64.2% in untreated vs. 22.8% in HU-treated) and their isogenic Bard1+/+ control (I: 57.8% in 
untreated vs. 22.5% in HU-treated) (Figure 35B).  Furthermore, consistent with the Bard1 focus formation 
data, there was no difference in the percentage of cells harboring five or more Brca1 foci between the 
Bard1KA/KA and Bard1+/+ clones in the untreated (55.3% and 64.2% in Bard1KA/KA vs. 57.8% in Bard1+/+) or 
HU-treated (31.3% and 22.8% in Bard1KA/KA vs. 22.5% in Bard1+/+) conditions.  Therefore, Bard1 BRCT 
phospho-recognition does not appear to be required for the formation of Brca1/Bard1 foci under either 







iv. Bard1SF/SF and Bard1KA/KA cells show a defect in the recruitment of Brca1 to PCNA foci in HU-
treated cells 
 Next, we sought to confirm whether the defect in Bard1 recruitment to HU-stalled replication forks 
observed in Bard1SF/SF and Bard1KA/KA cell is accompanied by a corresponding defect in Brca1 
recruitment.  Therefore, we examined the ability of Brca1 to localize to PCNA-staining replication 
structures of late S phase in HU-treated wild type and Bard1 BRCT-mutant cells.  As above, we defined 
the percent colocalization as the number of Brca1+ PCNA+ colocalized cells divided by the total number of 
PCNA+ cells (i.e., the sum of Brca1– PCNA+, Brca1+ PCNA+ non-colocalized, and Brca1+ PCNA+ 
colocalized cells) (Figure 33B).  Consistent with our analysis of Bard1-PCNA colocalization, we 
interpreted the Brca1– PCNA+ and Bard1+ PCNA+ non-colocalized cells as populations where Brca1 had 
failed to localize at stalled replication forks.  
 As such, we cultured two independent Bard1SF/SF clones (A and C) along with their isogenic 
Bard1+/+ control (E) in the presence or absence of 2 mM HU for 1.5 hours (Figure 33A).  Brca1 
localization to PCNA-staining replication structures was highly uncommon in untreated cells in both the 
isogenic Bard1SF/SF mutants (4.6% and 6.0% colocalization in PCNA+ cells) and the Bard1+/+ isogenic 
clone (9.5% colocalization in PCNA+ cells) clones (Figure 36A).  Upon HU treatment, Brca1 was efficiently 
recruited to PCNA-staining replication structures in the wild type cell line (66.1% colocalization in PCNA+ 
cells).  However, in both Bard1SF/SF clones, localization of Brca1 to PCNA-staining replication structures 
was significantly disrupted compared to the wild type cell line, as only 23.8% and 21.6% colocalization 
was observed in PCNA+ cells in Bard1SF/SF clones A and C, respectively. 
 Consistent with what was observed in Bard1SF/SF cells, colocalization between Brca1 and PCNA 
was exceedingly rare in untreated Bard1KA/KA cells (clone J: 2.1% and clone L: 1.9% colocalization in 
PCNA+ cells) and an isogenic Bard1+/+ cell line (clone I: 2.1% colocalization in PCNA+ cells) (Figure 
36B).  Upon treatment with HU, Brca1 localized to PCNA-staining replication structures in the vast 
majority of PCNA+ cells in the Bard1+/+ clone (94.7% colocalization).  In sharp contrast, the two Bard1KA/KA 
clones displayed a defect in the recruitment of Brca1 to stalled replication forks as Brca1 localization to 
PCNA-staining replication structures was only observed in 30.4% and 41.3% of PCNA+ cells.  Therefore, 







Bard1KA/KA cells.  Indeed, if the Bard1 and Brca1 co-staining experiments are taken together, the data 
indicates that Bard1 BRCT phospho-recognition is required for recruitment of the Brca1/Bard1 
heterodimer to HU-stalled replication forks. 
 
4. Tumorigenesis in Bard1 BRCT mutants 
 
Although Brca1-null and Bard1-null animals undergo embryonic lethality, mice homozygous for 
certain hypomorphic Brca1 mutations (e.g., Brca1SF/SF or Brca1tr/tr) are viable.  As these mice age, they 
develop a broad spectrum of tumor types at increased rates relative to their wildtype and heterozygous 
littermates (Ludwig et al., 2001; Shakya et al., 2011).  Since Brca1SF/SF cells are defective for both HDR 
and SFP, it is not possible to conclude whether the tumor susceptibility of these Brca1-mutant mice 
reflects the loss of HDR, SFP, or both.  In contrast, Bard1SF and Bard1KA are separation-of-function alleles 
that abrogate SFP without affecting HDR.  Therefore, we generated cohorts of Bard1SF/SF and Bard1KA/KA 
mice and monitored them for tumor formation (Figure 37A).    Although some of these animals developed 
tumors at an advanced age, the kinetics of tumor formation in Bard1SF/SF and Bard1KA/KA mice were 
statistically indistinguishable from that of their wild type littermate controls (Bard1SF/SF vs. Bard1+/+ p = 
0.9854; Bard1KA/KA vs. Bard1+/+ p = 0.8387).  When the Kaplan-Meier curve of tumor-free survival for 
Brca1SF/SF mice (Shakya et al., 2011) is superimposed on those of the Bard1 cohorts, it is clear that the 
kinetics of tumor formation occur with a markedly increased frequency and decreased latency in 
Brca1SF/SF mice relative to Bard1SF/SF and Bard1KA/KA mice (Figure 37B).  Indeed, the kinetics of tumor 
formation in the Brca1SF/SF mice was significantly greater when compared to either the Bard1SF/SF, 
Bard1KA/KA, or Bard1+/+ cohorts (p < 0.0001 for all comparisons).  Therefore, the Bard1SF/SF and Bard1KA/KA 
mice are not tumor prone. 
 In the Bard1SF/SF cohort, only 7 of 39 mice developed neoplasms.  Of the seven mice that 
developed neoplasms, the average age at the time of tumor detection was 724 days, which was well past 
the T50 of Brca1SF/SF mice (575 days) (Shakya et al., 2011).  Given the advanced age of Bard1SF/SF mice at 




seven neoplasms were mammary tumors.  Instead, most were hematological malignancies, specifically 
monocytoid leukemias and lymphomas.  A squamous cell carcinoma was the only solid tumor detected in 
the Bard1SF/SF cohort.  Similarly, only a small fraction of the Bard1KA/KA cohort developed tumors (4 of 34 
mice).  As was the case with the Bard1SF/SF tumors, the average appearance of malignancies occurred at 
an advanced age (657 days).  Three of the four tumors observed in the Bard1KA/KA mice were leukemias 
or lymphomas and the lone solid tumor was a hepatic adenoma.  In the Bard1+/+ cohort, 3 of 28 mice 
developed tumors at an average age of 786 days.  The three tumors consisted of a hepatocellular 
carcinoma, a renal cell carcinoma, and a monocytoid lymphoma.  Thus, many of the malignancies 
observed in the Bard1KA/KA and Bard1SF/SF mice were also observed in the Bard1+/+ control cohort.  This 
supports the conclusion that the tumors observed in the Bard1 BRCT mutant mice were likely the result of 
spontaneous tumor formation and not due to the Bard1-BRCT mutation.   These results indicate that 
simultaneous loss of Brca1/Bard1-mediated HDR and SFP, but not loss of Brca1/Bard1-mediated SFP 
alone, renders mice susceptible to spontaneous tumor formation. 
 
C. Discussion  
The ability of BRCA1 to promote genome stability is thought to be a central aspect of its tumor 
suppression activity.  BRCA1 and BRCA2 both promote genome stability through at least two distinct 
pathways: homology directed repair (HDR) of DSBs and stalled fork protection (SFP).  Early studies 
established that BRCA1 and BRCA2 are both required for HDR and that cells deficient for either protein 
readily accumulate chromosomal abnormalities (Moynahan et al., 1999; Moynahan, Pierce, et al., 2001).  
More recently, both proteins have also been implicated in the protection of stalled forks from nuclease 
degradation (Kolinjivadi, Sannino, de Antoni, Techer, et al., 2017; Schlacher et al., 2011; Schlacher et al., 
2012; Ying et al., 2012).  Since fork progression can be stalled in a transient manner by a variety of 
obstacles, cells employ specific mechanisms to stabilize stalled forks and restore their replication 
competence.  For example, upon stress-induced stalling of DNA replication, the conventional three-way 
replication fork can be converted via branch migration into a four-way structure in which the two nascent 
DNA strands anneal to form a fourth arm (Figure 2) (Neelsen & Lopes, 2015).  Through further 
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remodeling of this “reversed fork”, DNA synthesis can proceed past the obstacle by using the 
complementary nascent DNA strand as a template, allowing scheduled DNA synthesis to resume.   
In 2003, Lomonosov et al. reported that the HU-induced stalled forks of wildtype cells, which can 
be detected as Y-shaped DNA junctions on 2D gel electrophoretograms, are specifically absent from 
BRCA2-mutant cells, suggesting that BRCA2 is required for the formation and/or stability of stalled forks 
(Lomonosov et al., 2003).  In support of this notion, DNA fiber analyses revealed that the HU-induced 
stalled forks of BRCA2-mutant cells are degraded by the nuclease activity of MRE11 (Schlacher et al., 
2011; Ying et al., 2012).  Moreover, Schlacher et al. identified a BRCA2 mutation that specifically ablates 
SFP without affecting HDR, and further showed that cells bearing this mutation undergo chromosomal 
instability upon HU treatment (Schlacher et al., 2011).  These findings support two critical notions: first, 
that SFP and HDR are separable aspects of BRCA2 function and, second, that SFP is itself an important 
contributor to genome integrity, especially in cells subjected to replication stress.  In a subsequent study, 
Schlacher et al. reported that SFP is also dependent on BRCA1, FANCD2, and RAD51, suggesting the 
existence of a “stalled fork protection” pathway that preserves genome integrity by preventing nucleolytic 
degradation of stalled forks (Schlacher et al., 2012).  Indeed, multiple components (PTIP, MLL3/4, CHD4, 
and PARP1) of an opposing pathway that promotes fork degradation by recruiting the MRE11 nuclease to 
stalled forks have also been identified (Ding et al., 2016; Ray Chaudhuri et al., 2016), and recent studies 
have established that the four-way reversed fork is the likely substrate for nucleolytic degradation in 
BRCA1/2-deficient cells (Kolinjivadi, Sannino, De Antoni, Zadorozhny, et al., 2017; Vujanovic et al., 
2017). 
The experiments discussed above demonstrated that BRCA1 is required for SFP, however, they 
made use of null BRCA1 alleles and were thus largely uninformative as to what functional domains of 
BRCA1 are necessary for SFP.  Therefore, to determine whether the phospho-recognition function of the 
BRCA1 BRCT domain is required for SFP, we performed the DNA fiber assay on Brca1SF/SF cells.  The 
Brca1 phospho-recognition mutant was clearly defective in SFP, showing Mre11-dependent degradation 
of stalled forks (Figure 29B).  Furthermore, we observed extensive DNA damage upon treatment of 
Brca1SF/SF cells with replication stress-inducing agents like hydroxyurea and camptothecin (Figures 30 
and 31).  Previous studies demonstrated that the Brca1SF mutation renders mice prone tumor formation, 
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implying that the SFP function may contribute to Brca1-mediated tumor suppression.  However, as the 
Brca1SF mutation is also defective in HDR, it is still unclear which of these BRCA1 functions (HDR and/or 
SFP) are actually required for tumor suppression.     
While a role for BRCA1 in SFP had been firmly established by previous work, it was unknown 
whether BARD1 is also required.  Previous studies had shown that BARD1 localizes, together with 
BRCA1, to PCNA-staining replication structures upon hydroxyurea treatment (Scully, Chen, Ochs, et al., 
1997), and a subsequent biochemical assay demonstrated that BARD1 is highly enriched at HU-stalled 
replication forks (Dungrawala et al., 2015).  However, given that BRCA1 is reliant upon 
heterodimerization with BARD1 for its stability and nuclear localization, and that deletion of BARD1 would 
result in deficiency of BRCA1, it was unclear whether BARD1 contributes unique functions to 
BRCA1/BARD1-mediated SFP or instead supports SFP indirectly through stabilization of BRCA1.  
Nonetheless, DNA fiber analyses revealed that Bard1SF/SF and Bard1KA/KA cells display Mre11-mediated 
degradation of stalled forks, indicating that Bard1 BRCT phospho-recognition is required for SFP (Figures 
27 and 28).  Significantly, as shown in Figures 13 and 14, Bard1SF/SF and Bard1KA/KA cells stably express 
Brca1 polypeptides, readily form Brca1/Bard1 heterodimers, and localize to the nucleus.  Thus, the role of 
BARD1 in BRCA1/BARD1-mediated SFP cannot simply be attributed to its ability to stabilize BRCA1.  
In Chapter 3, we showed that Bard1 BRCT phospho-recognition is dispensable for HDR.  
Specifically, Bard1SF/SF and Bard1KA/KA cells showed no defect in the ability to form Rad51 foci after IR 
treatment (Figures 23 and 24) and efficiently repaired induced DSBs within the DR-GFP reporter by HDR 
(Figure 26).  Therefore, Bard1SF and Bard1KA are separation-of-function mutants that are competent for 
HDR but defective for SFP (i.e., they confer a “SFP–HDR+ phenotype”).  In contrast to Brca1-null and 
Brca1SF mutants, which are defective in both HDR and SFP (conferring a “SFP–HDR– phenotype”), the 
Bard1SF and Bard1KA mutants can be used to determine which functions of the BRCA1/BARD1 
heterodimer are mediated by SFP specifically, including, as discussed further below, tumor suppression.  
While the DNA fiber assay demonstrated that the Bard1SF/SF and Bard1KA/KA cells are prone to 
Mre11-mediated stalled fork degradation, it was unclear whether this degradation event actually led to 
functional consequences such as the accumulation of DNA damage.  To test this hypothesis, we 
employed the alkaline comet assay, which can detect the presence of single-strand and double-strand 
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DNA breaks.  The assay revealed significant accumulation of DNA damage in Bard1SF/SF and Bard1KA/KA 
cells, as well as Brca1SF/SF cells in response to replication stress.  Given that the Bard1 BRCT mutants 
are competent for HDR, this observation implies that SFP defects are sufficient to generate DNA damage.  
Significantly, Bard1SF/SF and Bard1KA/KA cells accumulated DNA damage in response to at least two 
distinct types of replication stress: hydroxyurea (Figure 30), which stalls forks by depleting nucleotide 
pools, as well as camptothecin (Figure 31), which stalls forks by generating protein-DNA adducts.  
Interestingly, although an accumulation of DNA damage was seen in the Bard1SF/SF and Bard1KA/KA cells 
in response to camptothecin treatment, the same cells were not overtly sensitive to camptothecin (Figure 
18).  Since Brca1SF/SF cells, which are defective for both SFP and HDR, are hypersensitive to 
camptothecin, it is possible that the cytotoxic effects of camptothecin depend on combined deficiencies in 
both pathways.  Alternatively, since a shorter camptothecin exposure was used in the sensitivity assay (1 
hour vs. 5 hours in the comet assay), it is possible that the shorter treatment is sufficient to cause 
cytotoxicity in the SFP– HDR– cells, but not SFP– HDR+ cells.    
Regardless, the DNA fiber assays combined with the comet assays demonstrated that the Bard1 
BRCT domain is required for SFP-mediated resistance to genome instability.  Indeed, this conclusion is 
supported by experiments involving a BRCA2 separation-of-function mutant (Brca2S3291A) reported by 
Schlacher at al. (2011), which also displays an SFP–HDR+ phenotype.  Significantly, cells harboring the 
Brca2S3291A mutation displayed chromosomal instability upon induction of replication stress with 
hydroxyurea.  Additionally, Schlacher et al. (2011) showed that the chromosomal stability of V-C8 cells, 
which express a grossly truncated Brca2 polypeptide defective for both HDR and SFP, is fully rescued by 
exogenous expression of wildtype Brca2, but only partly rescued by the Brca2S3291A polypeptide 
(Schlacher et al., 2011).  These observations suggest that both HDR and SFP contribute to chromosome 
integrity and that a defect in SFP alone is sufficient to induce some degree of chromosomal instability, 
albeit not as the genome instability observed in SFP– HDR– cells.  Consistent with this interpretation, 
although both the Bard1 and Brca1 BRCT mutant cells displayed an increase in chromosomal aberrations 
after treatment with the DNA interstrand crosslinking reagent MMC, Brca1SF/SF cells displayed significantly 
more aberrations in response to the same treatment compared to the Bard1SF/SF and Bard1KA/KA cell lines 
(Figures 20, 21, and 22).  Furthermore, Brca1SF/SF cells displayed spontaneous chromosomal 
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rearrangements which were not observed in Bard1SF/SF and Bard1KA/KA cells, suggesting that HDR, but not 
SFP alone, is required for suppression of spontaneous genome instability (Figures 20, 21, and 22).  One 
explanation for these results is that endogenous fork stalling may not occur often enough under 
unstressed conditions to generate significant accumulation of DNA damage in SFP– HDR+ cells, as the 
intact HDR pathway can act to repair any stalled forks that collapse into DSBs.  However, under 
conditions of significant replication stress (e.g., HU or MMC treatment), the SFP-deficient Bard1SF/SF and 
Bard1KA/KA cells may experience a greater load of fork collapse, overwhelming the capacity of the HDR 
pathway to act as an error-free backup mechanism and thereby leading to the accumulation of DNA 
damage.  On the other hand, in untreated SFP–HDR– cells, the moderate levels of endogenous fork 
stalling and collapse may be sufficient to generated DNA damage, as any fork collapse that does occur is 
instead shunted to error-prone mechanisms of repair (e.g., MMEJ or NHEJ) in the absence of a functional 
HDR pathway.  Thus, both HDR and SFP likely work together to prevent genome stability, and loss of 
both pathways leads to a more severe phenotype than loss of SFP alone.   
The fact that Bard1SF/SF and Bard1KA/KA cells are deficient for SFP while proficient for HDR sheds 
light on the mechanism of PARPi sensitivity and resistance in BRCA1-mutant tumors.  Hypersensitivity to 
PARP inhibitors is thought to arise as a result of the HDR and SFP defects of BRCA1, although how 
much each individual defect contributes to overall sensitivity is unclear.  Since the PARP1 and PARP2 
enzymes are required for repair of single-strand DNA breaks (SSBs), PARPi should increase the load of 
SSBs that can be converted, upon DNA replication, to DSBs; thus, it was proposed that although these 
toxic DSBs can be repaired by HDR in normal cells, in BRCA1-mutant cells the combined defects in SSB 
repair and HDR result in synthetic lethality.  Subsequent studies revealed that the sensitivity of BRCA1-
mutant cells to PARPi often correlates with the ability of the inhibitor to stabilize toxic PARP1-DNA or 
PARP2-DNA complexes that would generate stalled forks during DNA replication (Pommier et al., 2016).  
Two further observations suggest that loss of SFP may constitute a significant factor in the targeted 
cytotoxicity of PARPi in BRCA1/2-mutant cells.  First, PARP enzymatic activity is itself required for 
protection of stalled forks from Mre11-dependent degradation (Ying et al., 2012).  Second, in recent 
studies, a partial resistance to PARPi was observed in BRCA1/2-mutant cells when SFP, but not HDR, 
was restored by diverse mechanisms, including depletion of PTIP, SMARCAL1, EZH2, or RADX (Ray 
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Chaudhuri et al., 2016) (Dungrawala et al., 2015; Rondinelli et al., 2017; Taglialatela et al., 2017). The 
availability of Bard1 separation-of-function mutants has now allowed us to ask directly whether 
Brca1/Bard1-mediated SFP contributes to PARPi resistance.  Importantly, Bard1SF/SF and Bard1KA/KA cells, 
which display the HDR+/SFP– phenotype, are clearly hypersensitive to olaparib, but to a qualitatively 
lesser degree than Brca1SF/SF cells with the HDR–/SFP– phenotype (Figure 16).  These results indicate 
that loss of Brca1/Bard1-mediated HDR and Brca1/Bard1-mediated SFP can both contribute to the 
PARPi-induced cytotoxicity of Brca1-mutant cells.   
We also propose a mechanistic explanation for the SFP defect seen in Bard1SF/SF and Bard1KA/KA 
cells.  Using iPOND (isolation of proteins on nascent DNA) technology, Dungrawala et al. demonstrated 
that BRCA1 and BARD1 are present at HU-stalled, but not unstressed, DNA replication forks 
(Dungrawala et al., 2015).  Therefore, the ability of the BARD1 BRCT domain to bind poly(ADP-ribose) 
(PAR) in a phospho-dependent manner suggested a possible mechanism for the SFP defect in Bard1SF/SF 
and Bard1KA/KA cells (M. Li & Yu, 2013).  Previous studies have shown that PAR chains are assembled at 
sites of stalled DNA replication by PAR polymerase 1 (PARP1) and that SFP is dependent on PARP1 
activity (Ying et al., 2012).  Therefore, to ascertain whether Bard1 BRCT phospho-recognition is required 
for the recruitment of Brca1/Bard1 heterodimer to stalled forks, we examined the ability of Brca1/Bard1 to 
localize within PCNA-staining replication factories of HU-treated cells in a series of immunostaining 
experiments (Scully, Chen, Ochs, et al., 1997).  Notably, the co-localization of Brca1/Bard1 and PCNA in 
late S phase cells was markedly reduced in HU-treated Bard1SF/SF and Bard1KA/KA cells relative to wildtype 
cells.  Indeed, preliminary experiments in our laboratory using the iPOND method biochemically confirm 
that the Brca1/Bard1 heterodimers of Bard1SF/SF and Bard1KA/KA cells fail to associate with HU-stalled 
replication forks (Michiko Horiguchi, personal communication).  Together, these observations indicate that 
Bard1 BRCT phospho-recognition promotes SFP, at least in part, by mediating the recruitment of 
Brca1/Bard1 heterodimers to stalled replication forks. 
Using the dynamics of Brca1/Bard1 and PCNA foci in untreated and HU treated cells, a rough 
picture of the events leading to BRCA1/BARD1 recruitment to stalled replication forks emerges.  In 
untreated cells, Brca1/Bard1 form foci that rarely colocalize with PCNA-staining replication structures.  
Although the function of these S phase Brca1/Bard1 foci are not known, it has been hypothesized that 
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they may represent localization of the heterodimer to spontaneously-formed DSBs or stalled replication 
forks.  However, given that the S phase Brca1/Bard1 foci of untreated cells do not colocalize with PCNA, 
it seems unlikely that these foci represent fork stalling events.  It is also possible that the foci of 
unperturbed cells represent a normal process of Brca1/Bard1 sequestration during S phase, particularly if 
normal DNA replication is compromised by inappropriate activation of the SFP or HDR pathways.  In any 
case, upon induction of replication fork stalling by hydroxyurea, these Brca1/Bard1 foci dissipate, leading 
to a transient decrease in Brca1/Bard1-staining cells.  Since this phenomenon occurs in both wild type 
and Bard1-BRCT mutant cells, Bard1 BRCT phospho-recognition is likely to be dispensable for HU-
induced dissipation of S-phase Brca1/Bard1 foci (Figures 32 and 35).  Indeed, this process is 
accompanied by HU-induced hyper-phosphorylation of BRCA1 (Cortez et al., 1999; Scully, Chen, Ochs, 
et al., 1997).  As such, the HU-induced dissipation of S phase BRCA1/BARD1 foci may entail the 
activation of DNA damage sensors, like ATM and ATR. 
In HU-treated wild type cells, the Brca1/Bard1 heterodimer is recruited to stalled replication forks, 
as represented by the localization of Brca1 and Bard1 polypeptides to the nodular PCNA-staining 
replication structures during late S phase.  However, the assembly of Brca1/Bard1 to these PCNA-
staining structures is largely abrogated in HU-treated Bard1KA/KA and Bard1SF/SF cells, suggesting that the 
recruitment of Brca1/Bard1 to stalled replication forks is dependent on Bard1 BRCT phospho-recognition 
(Figures 34 and 36) . The failure of Brca1/Bard1 to localize to PCNA-staining replication structures is 
manifested cytologically in either of two patterns: 1.) Brca1/Bard1 foci are present but do not overlap with 
PCNA foci, and 2.) Brca1/Bard1 foci are absent in cells with PCNA foci.  In the first case (Brca1/Bard1+ 
PCNA+ non-colocalizing cells), this population might represent Bard1KA/KA and Bard1SF/SF cells in which 
HU treatment was insufficient to induce significant replication fork stalling and thus activation of the SFP 
pathway.  However, this seems unlikely given that fork stalling appears to occur in the majority of late S 
phase Brca1+/+ cells (as reflected by the high percentage of wild type cells that display HU-induced 
colocalization between Bard1/Brca1 and PCNA).  Another possibility is that the Brca1/Bard1 foci of HU-
treated Bard1KA/KA and Bard1SF/SF cells represents sites of DSBs that arise from collapsed replication forks 
that no longer associate with PCNA, rather than the stalled forks of PCNA-staining replication factories.   
Li and Yu demonstrated that phospho-recognition by the Bard1 BRCT domain is dispensable for late 
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recruitment to DSBs (M. Li & Yu, 2013), thus even in the presence of the Bard1SF/SF and Bard1KA/KA 
mutations, the Brca1/Bard1 heterodimer should be able to eventually localize to DSBs.  Accordingly, the 
altered staining patterns of Bard1SF/SF and Bard1KA/KA cells may reflect both the cause of the SFP defect 
(i.e., unprotected forks, as represented by PCNA foci that do not colocalize with Brca1/Bard1), as well as 
the consequences of SFP defects (i.e., collapsed forks, as represented by Brca1/Bard1 foci that do not 
colocalize with PCNA). 
At present, it is unknown how phospho-recogntion by the Brca1 BRCT domain contributes, if at all 
to this recruitment process.  It is possible that the Brca1 BRCT domain mediates an aspect of recruitment 
that is distinct from the event facilitated by the Bard1 BRCT domain, similar to what was observed in the 
context of a DSB by Li and Yu (M. Li & Yu, 2013).  Alternatively, the Brca1 BRCT domain may facilitate a 
non-recruitment aspect of SFP through binding to one of its phospholigands.  However, the identity of the 
phospholigand, or the mechanism of fork protection are currently unknown.  Further studies are 
necessary to fully explore these possibilities.    
Since the HDR and SFP functions of BRCA1/BARD1 both contribute to chromosomal stability, it 
is conceivable that BRCA1/BARD1-mediated tumor suppression activity is dependent on HDR, SFP, or 
both.  To discriminate among these possibilities, it would be helpful to evaluate tumorigenesis in mice 
harboring Brca1 separation-of-function mutations that yield either the HDR–SFP+ or HDR+SFP– 
phenotype.  A number of mouse strains exist that harbor Brca1 alleles modeled after human pathogenic 
BRCA1 mutations associated with hereditary breast and ovarian cancer.  A subset of these, including the 
Brca1SF allele, encode polypeptides that retain at least some Brca1 function.  Thus, unlike Brca1-null 
animals, which invariably undergo embryonic lethality, mice that are homozygous for these hypomorphic 
mutations (Brca1SF/SF) can survive as adults, but develop a wide spectrum of tumor types at increased 
rates relative to their wild type and heterozygous littermates.  However, since Brca1SF/SF cells are deficient 
for both the HDR and SFP pathways, this observation does not illuminate the relative contributions of 
HDR or SFP to BRCA1-mediated tumor suppression.  In contrast, Bard1SF/SF and Bard1KA/KA mice, which 
exhibit the HDR+SFP– phenotype, do not display increased tumor formation relative to their littermates 
(Figure 37), suggesting that abrogation of BRCA1/BARD-mediated SFP alone is not sufficient to elicit 
tumor susceptibility.  While some of the Bard1SF/SF and Bard1KA/KA mice did develop tumors at a highly 
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advanced age, none of these were mammary tumors, and most also arose with the same kinetics in the 
control Bard1+/+ cohort.  Therefore, tumor formation in the Bard1SF/SF and Bard1KA/KA cohorts likely 
represents the appearance of spontaneous malignancies associated with advanced age.  Together, the 
tumor cohort data suggests that the tumor suppression activity of BRCA1/BARD1 is dependent on its 






































THE BARD1 BRCT AND BRCA1 BRCT PHOSPHO-RECOGNITION MUTANTS ARE 













































1. Stalled fork protection is also defective in heterozygous cells harboring BRCT mutations in 
either Brca1 or Bard1 
i. Stalled fork protection is defective in Brca1SF/+ cells 
Although cells that are heterozygous for pathogenic BRCA1 mutations retain most BRCA1-
mediated functions, including HDR, Pathania et al. observed a defect in stalled fork protection in 
heterozygous-mutant (BRCA1mut/+) human mammary epithelial cells (Pathania et al., 2014).  To determine 
whether heterozygosity for the Brca1 BRCT mutation also impairs SFP, we conducted DNA fiber analysis 
of immortalized MEFs according to the conditions described in Chapter 4.  Briefly, immortalized MEFs 
were subjected to two sequential 20-minute pulses with the nucleoside analogs 5’-iodo-2-deoxyuridine 
(IdU) and 5’-chloro-2-deoxyuridine (CldU) (Figure 38A).  The track lengths of single DNA fibers were then 
measured immediately following CldU treatment (–HU condition) or after a 90-minute treatment with 
hydroxyurea (HU, +HU condition).  SFP was once again assessed by calculating the ratio of the lengths 
of adjacent CldU and ldU replication tracts, with a decrease in the CldU/IdU ratio indicating stalled fork 
degradation and thus an SFP defect.  
Two independent Brca1SF/+ MEF clones (O and V), along with an isogenic Bard1+/+ (Q) and an 
isogenic Brca1SF/SF clone (P) were treated as described above.  As expected, in all untreated (-HU) 
clones the median ratio of CldU/IdU was close to 1 (Figure 38B).  Additionally, when Brca1+/+ cells were 
exposed to HU, the median CldU/IdU ratio was statistically indistinguishable from that of untreated 
Brca1+/+ cells (0.87 in the –HU condition vs. 0.89 in the +HU condition), indicating that stalled replication 
forks are stable in wild type cells.  Consistent with the results shown in Chapter 4 (Figure 29), HU-treated 
Brca1SF/SF cells showed a significant reduction in the CldU/IdU ratio compared to untreated Brca1SF/SF 
cells (0.89 –HU vs. 0.47 +HU).  Notably, in both heterozygous-mutant Brca1SF/+ clones, HU treatment also 
induced a marked decrease in the CldU/IdU ratio (clone O: 0.88 –HU vs 0.49 +HU; clone V: 0.90 –HU vs. 
0.49 +HU), indicating a profound defect in SFP.   Interestingly, the SFP defect observed in the 
heterozygous Brca1SF/+ cell lines appears to be qualitatively similar to that of homozygous Brca1SF/SF cells.  
Furthermore, exposure to the Mre11 nuclease inhibitor mirin rescued the CldU/IdU ratio in the HU-treated 





+HU +mirin).  Therefore, the degradation of HU-stalled forks observed in Brca1SF/+ cells is also mediated 
by the Mre11 nuclease.  Taken together, these results show that the Brca1 BRCT phospho-recognition 
mutation is haploinsufficient for the SFP pathway. 
 
ii. Stalled fork protection is also defective in Bard1SF/+ and Bard1KA/+ cells 
To determine whether the Bard1 BRCT mutations are also haploinsufficient for SFP, we 
performed the DNA fiber assay with two independent heterozygous Bard1SF/+ clones (B and D), along with 
an isogenic Bard1+/+ clone (E) and an isogenic Bard1SF/SF clone (A).  As expected, in all untreated (–HU) 
clones, the CldU/IdU approached unity (Figure 39).  Additionally, when Bard1+/+ cells were exposed to 
HU, the median CldU/IdU ratio was statistically indistinguishable from that of untreated Bard1+/+ cells 
(1.04 –HU vs. 1.00 +HU), confirming that stalled replication forks are stable in wild type cells.  Consistent 
with the results of Chapter 4 (Figure 27), Bard1SF/SF cells showed a significant reduction of the CldU/IdU 
ratio upon HU treatment (1.04 –HU vs. 0.81 +HU), indicative of an SFP defect.  Notably, in both 
heterozygous-mutant Bard1SF/+ clones, HU treatment also induced a marked decrease in the CldU/IdU 
ratio (B: 1.04 –HU vs. 0.82 +HU; D: 1.02 –HU vs. 0.79 +HU), indicating a profound defect in SFP.  Again, 
the SFP defect observed in the heterozygous Bard1SF/+ clones appears to be qualitatively similar to that of 
homozygous Bard1SF/SF cells, and treatment with the Mre11 nuclease inhibitor mirin restored the CldU/IdU 
ratio to levels similar to untreated Bard1SF/+ cells (B: 0.82 +HU vs. 1.02 +HU +mirin; D: 0.79 +HU vs. 1.00 
+HU +mirin). 
Similarly, we performed the DNA fiber assay on a heterozygous Bard1KA/+ MEF clone (K), along 
with an isogenic Bard1+/+ clone (I) and an isogenic Bard1KA/KA clone (J).  As expected, HU treatment 
induced a significant decrease in the CldU/IdU ratio in the Bard1KA/KA cells (0.89 –HU vs. 0.49 +HU) but 
not Bard1+/+ cells (0.88 –HU vs 0.88 +HU) (Figure 40).  Consistent with the Bard1SF/+ and Brca1SF/+ 
heterozygotes, heterozygous Bard1KA/+ cells also displayed a significant decrease in the CldU/IdU ratio in 
response to HU treatment (0.91 –HU vs. 0.51 +HU) that was qualitatively similar to that of homozygous 
Bard1KA/KA cells.  Furthermore, Mre11 inhibition restored the CldU/IdU to close to unity in both HU-treated 
Bard1KA/+ and Bard1KA/KA cells.  Together, these results indicate that the Bard1 BRCT phospho-recognition 








2. Replication stress induces DNA damage in heterozygous Bard1 and Brca1 BRCT-mutant cells 
 While the DNA fiber assay demonstrated that stalled replication forks are susceptible to Mre11-
mediated degradation in Bard1SF/+, Bard1KA/+, and Brca1SF/+ cells, the assay does not reveal whether this 
degradation translates into an increased burden of DNA damage and genome instability.  Therefore, we 
used the alkaline comet assay to determine whether replication stress induces increased levels of DNA 
damage in Bard1SF/SF and Bard1KA/KA cells.  As described in Chapter 4, the alkaline comet assay detects 
single-strand and double-strand DNA breaks.  Briefly, cells are treated with a DNA damaging agent, 
embedded in agarose, and incubated in an alkaline denaturing buffer before being subjected to gel 
electrophoresis.  Single-strand and double-strand DNA breaks will cause the damaged DNA to migrate 
though the gel faster than undamaged DNA.  Upon staining with a fluorescent nucleic acid dye (GelRed); 
the damaged DNA can be visualized as a “comet tail” trailing the undamaged DNA (i.e., the “comet 
head”).  The amount of DNA damage can then be quantified from the tail moment, a measurement of the 
length and amount of DNA present in the comet tail.   
 Thus, isogenic clones of Brca1+/+ (Q), Brca1SF/+ (O), and Brca1SF/SF (P) immortalized MEFs were 
exposed to 2mM HU for 5 hours (Figure 41).  After HU treatment, the average amount of DNA damage 
per cell was quantified through measurement of the tail moment.  Consistent with the data shown in 
Figure 30, the Brca1SF/SF clone showed a significant increase in the average tail moment (10.45), and 
thus an increase in the DNA damage burden, when compared to its isogenic Brca1+/+ control (4.11).  
Interestingly, the Brca1SF/+ clone also displayed a significant increase in the average tail moment (7.09) 
when compared to the wild type clone.  Of note, the level of DNA damage observed in the heterozygous 
clone (7.09) was modestly, but significantly lower, than what was observed in the corresponding 
homozygous-mutant clone (10.45).  
 Similarly, isogenic clones of Bard1+/+ (E), Bard1SF/+ (B),, and Bard1SF/SF (A) immortalized MEFs 
were treated and analyzed as described above,  As shown in Figure 41, consistent with the data shown in 
Figure 30A, the Bard1SF/SF clone displayed a high level DNA damage after HU exposure as reflected by a 
significant increase in the average tail moment (12.19) when compared to its isogenic Bard1+/+ control 






average tail moment (7.66) that was significantly increased compared to the Bard1+/+ clone, but 
significantly less than the Bard1SF/SF clone.  
 Finally, we also performed the alkaline comet assay using isogenic clones of Bard1+/+ (I), 
Bard1KA/+ (K), and Bard1KA/KA (J) immortalized MEFs (Figure 41).  Consistent with our previous data, 
Bard1KA/KA cells showed a significant increase in DNA damage after HU treatment (8.94, average tail 
moment) when compared to its isogenic Bard1+/+ control 3.42).  Once again, the heterozygous Bard1KA/+ 
cell line showed an average tail moment 5.37) that was significantly more than its isogenic Bard1+/+ 
control but significantly less than an isogenic Bard1KA/KA clone.  Together, these results indicate that both 
the heterozygous Brca1 BRCT phospho-recognition mutant as well as the heterozygous Bard1 BRCT 
phospho-recognition mutants accumulate DNA damage during replication stress. 
 




































































































































































































































This model also predicts that women who carry BARD1 mutations that are functionally 
comparable to Bard1SF or Bard1KA/+ would not display susceptibility to breast and ovarian cancer.  
Although Bard1SF/+ and Bard1KA/+ cells would be deficient for SFP and likely accumulate low levels of 
genome instability, loss of the wild type allele would not “uncover” an HDR defect, since homozygous 
cells harboring the Bard1-BRCT mutations are competent for HDR.  Thus, even Bard1SF/–  and Bard1KA/– 
mammary epithelial cells would not be able to acquire the “mutator” phenotype necessary to drive 
malignant transformation.  The differential tumor susceptibility of the Bard1KA/KA and Bard1SF/SF mice 
compared to that of the Brca1SF/SF mice supports this hypothesis.  In principle, the best test of this model 
would be to compare tumor formation in heterozygous Bard1KA/+ and Bard1SF/+ mice to that of 
heterozygous Brca1SF/+ mice.  Unfortunately, however, unlike women, mice heterozygous for a Brca1 null 
mutation (Brca1+/–) do not develop tumors (X. Liu et al., 2007).  This difference between human and 
mouse BRCA1-mediated mammary tumorigenesis may be due to the shorter lifespan of mice and the 
markedly fewer mammary epithelial cell divisions that occur in mice relative to humans.  Therefore, the 
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lifetime risk of a loss-of-heterozygosity event at the mouse Brca1 locus is sufficiently low to be essentially 
non-existent.  Nevertheless, heterozygous Brca1 mice have been shown to be tumor prone when treated 
with genotoxic stress such ionizing radiation (Jeng et al., 2007).  Thus, it is possible that this model could 
be tested by applying genotoxic stress to heterozygous Bard1 and Brca1-BRCT mutants and monitoring 
for tumor formation.   
Furthermore, the model presented above might be consistent with the tissue specificity of 
BRCA1/2 pathway cancers.  Even though a human BRCA1/2 mutation carrier harbors the mutation in 
every cell type, tumors almost exclusively arise in the breast and ovaries.  The most obvious connection 
between these two tissues is that they are hormonally responsive to estrogen and progesterone.  
Strikingly, estrogen and its metabolites have been reported to induce DNA damage through adduct 
formation in mammary cells (Savage et al., 2014).  Furthermore, estrogen may also generate replication 
stress by inducing rapid cell proliferation (Caldon, 2014; Musgrove & Sutherland, 2009) or increased R-
loop formation (Stork et al., 2016).  Consistent with the idea that estrogen can contribute to breast cancer 
formation, conditions that increase lifetime estrogen exposure, such as early menarche, late menopause, 
nulliparity, and treatment with exogenous estrogen, are all associated with an increased breast cancer 
risk (Clemons & Goss, 2001; Foulkes et al., 2010).  Furthermore, oophorectomy has been shown to 
reduce breast cancer risk in BRCA1-mutant carriers (Rebbeck et al., 2002).  Another recent paper 
reported that progesterone signaling through the RANKL pathway induces aberrant proliferation and 
accumulation of DNA damage in BRCA1mut/+ cells (Nolan et al., 2016).  Thus, it is possible that estrogen 
and progesterone act as replication stress-inducing agents, and that mammary epithelial cells responsive 
to these hormones would experience a significant increase in replication stress compared to other cell 
types.  In BRCA1mut/+ cells that harbor an SFP defect, this stress would lead to genetic instability and 































































Abbott, D. W., Thompson, M. E., Robinson-Benion, C., Tomlinson, G., Jensen, R. A., & Holt, J. T. (1999). 
BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through 
enhancement of transcription-coupled DNA repair. J Biol Chem, 274(26), 18808-18812.  
Achar, Y. J., Balogh, D., & Haracska, L. (2011). Coordinated protein and DNA remodeling by human 
HLTF on stalled replication fork. Proc Natl Acad Sci U S A, 108(34), 14073-14078. 
doi:10.1073/pnas.1101951108 
Ahmed, E. A., & de Rooij, D. G. (2009). Staging of mouse seminiferous tubule cross-sections. Methods 
Mol Biol, 558, 263-277. doi:10.1007/978-1-60761-103-5_16 
Ali, A. A. E., Timinszky, G., Arribas-Bosacoma, R., Kozlowski, M., Hassa, P. O., Hassler, M., . . . Oliver, 
A. W. (2012). The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks. Nat 
Struct Mol Biol, 19(7), 685-692. doi:10.1038/nsmb.2335 
Allred, D. C. (2010). Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and 
HER2 in breast cancer. Mod Pathol, 23 Suppl 2, S52-59. doi:10.1038/modpathol.2010.55 
Antoniou, A., Pharoah, P. D., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., . . . Easton, D. F. 
(2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations 
detected in case Series unselected for family history: a combined analysis of 22 studies. Am J 
Hum Genet, 72(5), 1117-1130. doi:10.1086/375033 
Atkinson, J., & McGlynn, P. (2009). Replication fork reversal and the maintenance of genome stability. 
Nucleic Acids Res, 37(11), 3475-3492. doi:10.1093/nar/gkp244 
Baer, R., & Ludwig, T. (2002). The BRCA1/BARD1 heterodimer, a tumor suppressor complex with 
ubiquitin E3 ligase activity. Curr Opin Genet Dev, 12(1), 86-91.  
Bartek, J., Lukas, J., & Bartkova, J. (2007). DNA damage response as an anti-cancer barrier: damage 
threshold and the concept of 'conditional haploinsufficiency'. Cell Cycle, 6(19), 2344-2347. 
doi:10.4161/cc.6.19.4754 
Bennett, L. M., Haugen-Strano, A., Cochran, C., Brownlee, H. A., Fiedorek, F. T., Jr., & Wiseman, R. W. 
(1995). Isolation of the mouse homologue of BRCA1 and genetic mapping to mouse chromosome 
11. Genomics, 29(3), 576-581.  
Birrane, G., Varma, A. K., Soni, A., & Ladias, J. A. (2007). Crystal structure of the BARD1 BRCT 
domains. Biochemistry, 46(26), 7706-7712. doi:10.1021/bi700323t 
Bork, P., Hofmann, K., Bucher, P., Neuwald, A. F., Altschul, S. F., & Koonin, E. V. (1997). A superfamily 
of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J, 
11(1), 68-76.  
Botuyan, M. V., Nomine, Y., Yu, X., Juranic, N., Macura, S., Chen, J., & Mer, G. (2004). Structural basis 
of BACH1 phosphopeptide recognition by BRCA1 tandem BRCT domains. Structure, 12(7), 
1137-1146. doi:10.1016/j.str.2004.06.002 
Brodie, S. G., Xu, X., Qiao, W., Li, W. M., Cao, L., & Deng, C. X. (2001). Multiple genetic changes are 
associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene, 20(51), 
7514-7523. doi:10.1038/sj.onc.1204929 
Brose, M. S., Rebbeck, T. R., Calzone, K. A., Stopfer, J. E., Nathanson, K. L., & Weber, B. L. (2002). 
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl 
Cancer Inst, 94(18), 1365-1372.  
	 171	
Bryant, H. E., Petermann, E., Schultz, N., Jemth, A. S., Loseva, O., Issaeva, N., . . . Helleday, T. (2009). 
PARP is activated at stalled forks to mediate Mre11-dependent replication restart and 
recombination. EMBO J, 28(17), 2601-2615. doi:10.1038/emboj.2009.206 
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., . . . Helleday, T. (2005). 
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. 
Nature, 434(7035), 913-917. doi:10.1038/nature03443 
Brzovic, P. S., Rajagopal, P., Hoyt, D. W., King, M. C., & Klevit, R. E. (2001). Structure of a BRCA1-
BARD1 heterodimeric RING-RING complex. Nat Struct Biol, 8(10), 833-837. 
doi:10.1038/nsb1001-833 
Bunting, S. F., Callen, E., Kozak, M. L., Kim, J. M., Wong, N., Lopez-Contreras, A. J., . . . Nussenzweig, 
A. (2012). BRCA1 functions independently of homologous recombination in DNA interstrand 
crosslink repair. Mol Cell, 46(2), 125-135. doi:10.1016/j.molcel.2012.02.015 
Bunting, S. F., Callen, E., Wong, N., Chen, H. T., Polato, F., Gunn, A., . . . Nussenzweig, A. (2010). 
53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA 
breaks. Cell, 141(2), 243-254. doi:10.1016/j.cell.2010.03.012 
Byrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M., . . . Narod, S. (2010). 
Pathologic complete response rates in young women with BRCA1-positive breast cancers after 
neoadjuvant chemotherapy. J Clin Oncol, 28(3), 375-379. doi:10.1200/JCO.2008.20.7019 
Byun, T. S., Pacek, M., Yee, M. C., Walter, J. C., & Cimprich, K. A. (2005). Functional uncoupling of MCM 
helicase and DNA polymerase activities activates the ATR-dependent checkpoint. Genes Dev, 
19(9), 1040-1052. doi:10.1101/gad.1301205 
Caldon, C. E. (2014). Estrogen signaling and the DNA damage response in hormone dependent breast 
cancers. Front Oncol, 4, 106. doi:10.3389/fonc.2014.00106 
Cantor, S. B., Bell, D. W., Ganesan, S., Kass, E. M., Drapkin, R., Grossman, S., . . . Livingston, D. M. 
(2001). BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its 
DNA repair function. Cell, 105(1), 149-160.  
Castillo, A., Paul, A., Sun, B., Huang, T. H., Wang, Y., Yazinski, S. A., . . . Wang, B. (2014). The BRCA1-
interacting protein Abraxas is required for genomic stability and tumor suppression. Cell Rep, 
8(3), 807-817. doi:10.1016/j.celrep.2014.06.050 
Celeste, A., Petersen, S., Romanienko, P. J., Fernandez-Capetillo, O., Chen, H. T., Sedelnikova, O. A., . . 
. Nussenzweig, A. (2002). Genomic instability in mice lacking histone H2AX. Science, 296(5569), 
922-927. doi:10.1126/science.1069398 
Chen, Y., Farmer, A. A., Chen, C. F., Jones, D. C., Chen, P. L., & Lee, W. H. (1996). BRCA1 is a 220-
kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent 
manner. Cancer Res, 56(14), 3168-3172.  
Ciccia, A., Bredemeyer, A. L., Sowa, M. E., Terret, M. E., Jallepalli, P. V., Harper, J. W., & Elledge, S. J. 
(2009). The SIOD disorder protein SMARCAL1 is an RPA-interacting protein involved in 
replication fork restart. Genes Dev, 23(20), 2415-2425. doi:10.1101/gad.1832309 
Ciccia, A., & Elledge, S. J. (2010). The DNA damage response: making it safe to play with knives. Mol 
Cell, 40(2), 179-204. doi:10.1016/j.molcel.2010.09.019 
	 172	
Ciccia, A., Nimonkar, A. V., Hu, Y., Hajdu, I., Achar, Y. J., Izhar, L., . . . Elledge, S. J. (2012). 
Polyubiquitinated PCNA recruits the ZRANB3 translocase to maintain genomic integrity after 
replication stress. Mol Cell, 47(3), 396-409. doi:10.1016/j.molcel.2012.05.024 
Ciccia, A., & Symington, L. S. (2016). Stressing Out About RAD52. Mol Cell, 64(6), 1017-1019. 
doi:10.1016/j.molcel.2016.11.036 
Cimprich, K. A., & Cortez, D. (2008). ATR: an essential regulator of genome integrity. Nature Reviews 
Molecular Cell Biology, 9(8), 616-627. doi:10.1038/nrm2450 
Clapperton, J. A., Manke, I. A., Lowery, D. M., Ho, T., Haire, L. F., Yaffe, M. B., & Smerdon, S. J. (2004). 
Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with 
implications for cancer. Nat Struct Mol Biol, 11(6), 512-518. doi:10.1038/nsmb775 
Clemons, M., & Goss, P. (2001). Estrogen and the risk of breast cancer. N Engl J Med, 344(4), 276-285. 
doi:10.1056/NEJM200101253440407 
Cortez, D. (2015). Preventing replication fork collapse to maintain genome integrity. DNA Repair (Amst), 
32, 149-157. doi:10.1016/j.dnarep.2015.04.026 
Cortez, D., Wang, Y., Qin, J., & Elledge, S. J. (1999). Requirement of ATM-dependent phosphorylation of 
brca1 in the DNA damage response to double-strand breaks. Science, 286(5442), 1162-1166.  
Couch, F. J., Hart, S. N., Sharma, P., Toland, A. E., Wang, X., Miron, P., . . . Fasching, P. A. (2015). 
Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast 
cancer cohort unselected for family history of breast cancer. J Clin Oncol, 33(4), 304-311. 
doi:10.1200/JCO.2014.57.1414 
Couch, F. J., Nathanson, K. L., & Offit, K. (2014). Two decades after BRCA: setting paradigms in 
personalized cancer care and prevention. Science, 343(6178), 1466-1470. 
doi:10.1126/science.1251827 
Cressman, V. L., Backlund, D. C., Avrutskaya, A. V., Leadon, S. A., Godfrey, V., & Koller, B. H. (1999). 
Growth retardation, DNA repair defects, and lack of spermatogenesis in BRCA1-deficient mice. 
Mol Cell Biol, 19(10), 7061-7075.  
Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J., & Shi, B. (2015). Breast cancer intrinsic subtype 
classification, clinical use and future trends. Am J Cancer Res, 5(10), 2929-2943.  
Dantzer, F., Mark, M., Quenet, D., Scherthan, H., Huber, A., Liebe, B., . . . Menissier-de Murcia, J. (2006). 
Poly(ADP-ribose) polymerase-2 contributes to the fidelity of male meiosis I and spermiogenesis. 
Proc Natl Acad Sci U S A, 103(40), 14854-14859. doi:10.1073/pnas.0604252103 
De Brakeleer, S., De Greve, J., Desmedt, C., Joris, S., Sotiriou, C., Piccart, M., . . . Teugels, E. (2016). 
Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast 
cancer patients. Clin Genet, 89(3), 336-340. doi:10.1111/cge.12620 
De Brakeleer, S., De Greve, J., Loris, R., Janin, N., Lissens, W., Sermijn, E., & Teugels, E. (2010). 
Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or 
BRCA2 breast cancer families. Hum Mutat, 31(3), E1175-1185. doi:10.1002/humu.21200 
de Rooij, D. G. (2001). Proliferation and differentiation of spermatogonial stem cells. Reproduction, 
121(3), 347-354.  
	 173	
Densham, R. M., & Morris, J. R. (2017). The BRCA1 Ubiquitin ligase function sets a new trend for 
remodelling in DNA repair. Nucleus, 8(2), 116-125. doi:10.1080/19491034.2016.1267092 
Deshaies, R. J., & Joazeiro, C. A. (2009). RING domain E3 ubiquitin ligases. Annu Rev Biochem, 78, 
399-434. doi:10.1146/annurev.biochem.78.101807.093809 
Dickson, K. A., Cole, A. J., Gill, A. J., Clarkson, A., Gard, G. B., Chou, A., . . . Marsh, D. J. (2016). The 
RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of 
the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary 
high-grade serous ovarian cancer. Hum Mol Genet, 25(24), 5460-5471. doi:10.1093/hmg/ddw362 
Ding, X., Ray Chaudhuri, A., Callen, E., Pang, Y., Biswas, K., Klarmann, K. D., . . . Sharan, S. K. (2016). 
Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies. Nat Commun, 7, 12425. 
doi:10.1038/ncomms12425 
Drost, R., Bouwman, P., Rottenberg, S., Boon, U., Schut, E., Klarenbeek, S., . . . Jonkers, J. (2011). 
BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. 
Cancer Cell, 20(6), 797-809. doi:10.1016/j.ccr.2011.11.014 
Dungrawala, H., Rose, K. L., Bhat, K. P., Mohni, K. N., Glick, G. G., Couch, F. B., & Cortez, D. (2015). 
The Replication Checkpoint Prevents Two Types of Fork Collapse without Regulating Replisome 
Stability. Mol Cell, 59(6), 998-1010. doi:10.1016/j.molcel.2015.07.030 
Dupre, A., Boyer-Chatenet, L., Sattler, R. M., Modi, A. P., Lee, J. H., Nicolette, M. L., . . . Gautier, J. 
(2008). A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 
complex. Nat Chem Biol, 4(2), 119-125. doi:10.1038/nchembio.63 
Early Breast Cancer Trialists' Collaborative, G. (2005). Effects of chemotherapy and hormonal therapy for 
early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. 
Lancet, 365(9472), 1687-1717. doi:10.1016/S0140-6736(05)66544-0 
Easton, D. F. (1999). How many more breast cancer predisposition genes are there? Breast Cancer Res, 
1(1), 14-17.  
Edwards, R. A., Lee, M. S., Tsutakawa, S. E., Williams, R. S., Nazeer, I., Kleiman, F. E., . . . Glover, J. N. 
(2008). The BARD1 C-terminal domain structure and interactions with polyadenylation factor 
CstF-50. Biochemistry, 47(44), 11446-11456. doi:10.1021/bi801115g 
Engel, R. H., & Kaklamani, V. G. (2007). HER2-positive breast cancer: current and future treatment 
strategies. Drugs, 67(9), 1329-1341.  
Errico, A., & Costanzo, V. (2012). Mechanisms of replication fork protection: a safeguard for genome 
stability. Crit Rev Biochem Mol Biol, 47(3), 222-235. doi:10.3109/10409238.2012.655374 
Fabbro, M., Rodriguez, J. A., Baer, R., & Henderson, B. R. (2002). BARD1 induces BRCA1 intranuclear 
foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 
nuclear export. J Biol Chem, 277(24), 21315-21324. doi:10.1074/jbc.M200769200 
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., . . . Ashworth, A. 
(2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 
434(7035), 917-921. doi:10.1038/nature03445 
Fernandez-Capetillo, O., & Nussenzweig, A. (2013). Naked replication forks break apRPArt. Cell, 155(5), 
979-980. doi:10.1016/j.cell.2013.10.049 
	 174	
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., . . . de Bono, J. S. (2009). 
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med, 
361(2), 123-134. doi:10.1056/NEJMoa0900212 
Foulkes, W. D. (2008). Inherited susceptibility to common cancers. N Engl J Med, 359(20), 2143-2153. 
doi:10.1056/NEJMra0802968 
Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010). Triple-negative breast cancer. N Engl J Med, 
363(20), 1938-1948. doi:10.1056/NEJMra1001389 
Foulkes, W. D., Stefansson, I. M., Chappuis, P. O., Begin, L. R., Goffin, J. R., Wong, N., . . . Akslen, L. A. 
(2003). Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl 
Cancer Inst, 95(19), 1482-1485.  
Fox, D., 3rd, Le Trong, I., Rajagopal, P., Brzovic, P. S., Stenkamp, R. E., & Klevit, R. E. (2008). Crystal 
structure of the BARD1 ankyrin repeat domain and its functional consequences. J Biol Chem, 
283(30), 21179-21186. doi:10.1074/jbc.M802333200 
Freemont, P. S., Hanson, I. M., & Trowsdale, J. (1991). A novel cysteine-rich sequence motif. Cell, 64(3), 
483-484.  
Gerloff, D. L., Woods, N. T., Farago, A. A., & Monteiro, A. N. (2012). BRCT domains: A little more than 
kin, and less than kind. FEBS Lett, 586(17), 2711-2716. doi:10.1016/j.febslet.2012.05.005 
Greenberg, R. A. (2008). Recognition of DNA double strand breaks by the BRCA1 tumor suppressor 
network. Chromosoma, 117(4), 305-317. doi:10.1007/s00412-008-0154-8 
Hakem, R., de la Pompa, J. L., Sirard, C., Mo, R., Woo, M., Hakem, A., . . . Mak, T. W. (1996). The tumor 
suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell, 85(7), 
1009-1023.  
Hall, J. M., Lee, M. K., Newman, B., Morrow, J. E., Anderson, L. A., Huey, B., & King, M. C. (1990). 
Linkage of early-onset familial breast cancer to chromosome 17q21. Science, 250(4988), 1684-
1689.  
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646-674. 
doi:10.1016/j.cell.2011.02.013 
Hashizume, R., Fukuda, M., Maeda, I., Nishikawa, H., Oyake, D., Yabuki, Y., . . . Ohta, T. (2001). The 
RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived 
mutation. J Biol Chem, 276(18), 14537-14540. doi:10.1074/jbc.C000881200 
Helleday, T. (2011). The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up 
the misunderstandings. Mol Oncol, 5(4), 387-393. doi:10.1016/j.molonc.2011.07.001 
Hennigs, A., Riedel, F., Gondos, A., Sinn, P., Schirmacher, P., Marme, F., . . . Schneeweiss, A. (2016). 
Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort 
study. BMC Cancer, 16(1), 734. doi:10.1186/s12885-016-2766-3 
Houghtaling, S., Timmers, C., Noll, M., Finegold, M. J., Jones, S. N., Meyn, M. S., & Grompe, M. (2003). 
Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes 
Dev, 17(16), 2021-2035. doi:10.1101/gad.1103403 
Jeng, Y. M., Cai-Ng, S., Li, A., Furuta, S., Chew, H., Chen, P. L., . . . Lee, W. H. (2007). Brca1 
heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with 
	 175	
haploinsufficiency upon ionizing irradiation. Oncogene, 26(42), 6160-6166. 
doi:10.1038/sj.onc.1210451 
Jiang, Q., & Greenberg, R. A. (2015). Deciphering the BRCA1 Tumor Suppressor Network. J Biol Chem, 
290(29), 17724-17732. doi:10.1074/jbc.R115.667931 
Jin, Y., Xu, X. L., Yang, M. C., Wei, F., Ayi, T. C., Bowcock, A. M., & Baer, R. (1997). Cell cycle-
dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains. Proc Natl 
Acad Sci U S A, 94(22), 12075-12080.  
Joukov, V., Groen, A. C., Prokhorova, T., Gerson, R., White, E., Rodriguez, A., . . . Livingston, D. M. 
(2006). The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. 
Cell, 127(3), 539-552. doi:10.1016/j.cell.2006.08.053 
Kim, H., Huang, J., & Chen, J. (2007). CCDC98 is a BRCA1-BRCT domain-binding protein involved in the 
DNA damage response. Nat Struct Mol Biol, 14(8), 710-715. doi:10.1038/nsmb1277 
Kleiman, F. E., & Manley, J. L. (1999). Functional interaction of BRCA1-associated BARD1 with 
polyadenylation factor CstF-50. Science, 285(5433), 1576-1579.  
Kolinjivadi, A. M., Sannino, V., de Antoni, A., Techer, H., Baldi, G., & Costanzo, V. (2017). Moonlighting at 
replication forks - a new life for homologous recombination proteins BRCA1, BRCA2 and RAD51. 
FEBS Lett, 591(8), 1083-1100. doi:10.1002/1873-3468.12556 
Kolinjivadi, A. M., Sannino, V., De Antoni, A., Zadorozhny, K., Kilkenny, M., Techer, H., . . . Costanzo, V. 
(2017). Smarcal1-Mediated Fork Reversal Triggers Mre11-Dependent Degradation of Nascent 
DNA in the Absence of Brca2 and Stable Rad51 Nucleofilaments. Mol Cell, 67(5), 867-881 e867. 
doi:10.1016/j.molcel.2017.07.001 
Konishi, H., Mohseni, M., Tamaki, A., Garay, J. P., Croessmann, S., Karnan, S., . . . Park, B. H. (2011). 
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in 
human breast epithelial cells. Proc Natl Acad Sci U S A, 108(43), 17773-17778. 
doi:10.1073/pnas.1110969108 
Kotaja, N., & Sassone-Corsi, P. (2007). The chromatoid body: a germ-cell-specific RNA-processing 
centre. Nat Rev Mol Cell Biol, 8(1), 85-90. doi:10.1038/nrm2081 
La Vecchia, C., Bosetti, C., Lucchini, F., Bertuccio, P., Negri, E., Boyle, P., & Levi, F. (2010). Cancer 
mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol, 21(6), 1323-
1360. doi:10.1093/annonc/mdp530 
Laufer, M., Nandula, S. V., Modi, A. P., Wang, S., Jasin, M., Murty, V. V., . . . Baer, R. (2007). Structural 
requirements for the BARD1 tumor suppressor in chromosomal stability and homology-directed 
DNA repair. J Biol Chem, 282(47), 34325-34333. doi:10.1074/jbc.M705198200 
Leung, A. K. (2014). Poly(ADP-ribose): an organizer of cellular architecture. J Cell Biol, 205(5), 613-619. 
doi:10.1083/jcb.201402114 
Li, M., Cole, F., Patel, D. S., Misenko, S. M., Her, J., Malhowski, A., . . . Bunting, S. F. (2016). 53BP1 
ablation rescues genomic instability in mice expressing 'RING-less' BRCA1. EMBO Rep, 17(11), 
1532-1541. doi:10.15252/embr.201642497 
Li, M., & Yu, X. (2013). Function of BRCA1 in the DNA damage response is mediated by ADP-
ribosylation. Cancer Cell, 23(5), 693-704. doi:10.1016/j.ccr.2013.03.025 
	 176	
Li, W., Bengtson, M. H., Ulbrich, A., Matsuda, A., Reddy, V. A., Orth, A., . . . Joazeiro, C. A. (2008). 
Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a 
mitochondrial E3 that regulates the organelle's dynamics and signaling. PLoS One, 3(1), e1487. 
doi:10.1371/journal.pone.0001487 
Liedtke, C., Mazouni, C., Hess, K. R., Andre, F., Tordai, A., Mejia, J. A., . . . Pusztai, L. (2008). Response 
to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin 
Oncol, 26(8), 1275-1281. doi:10.1200/JCO.2007.14.4147 
Lim, E., Vaillant, F., Wu, D., Forrest, N. C., Pal, B., Hart, A. H., . . . Lindeman, G. J. (2009). Aberrant 
luminal progenitors as the candidate target population for basal tumor development in BRCA1 
mutation carriers. Nat Med, 15(8), 907-913. doi:10.1038/nm.2000 
Lisby, M., Barlow, J. H., Burgess, R. C., & Rothstein, R. (2004). Choreography of the DNA damage 
response: spatiotemporal relationships among checkpoint and repair proteins. Cell, 118(6), 699-
713. doi:10.1016/j.cell.2004.08.015 
Liu, N., Lamerdin, J. E., Tebbs, R. S., Schild, D., Tucker, J. D., Shen, M. R., . . . Thompson, L. H. (1998). 
XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and 
protect against DNA cross-links and other damages. Mol Cell, 1(6), 783-793.  
Liu, X., Holstege, H., van der Gulden, H., Treur-Mulder, M., Zevenhoven, J., Velds, A., . . . Jonkers, J. 
(2007). Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of 
human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A, 104(29), 12111-
12116. doi:10.1073/pnas.0702969104 
Liu, Z., Wu, J., & Yu, X. (2007). CCDC98 targets BRCA1 to DNA damage sites. Nat Struct Mol Biol, 14(8), 
716-720. doi:10.1038/nsmb1279 
Lomonosov, M., Anand, S., Sangrithi, M., Davies, R., & Venkitaraman, A. R. (2003). Stabilization of 
stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein. Genes Dev, 
17(24), 3017-3022. doi:10.1101/gad.279003 
Long, D. T., Joukov, V., Budzowska, M., & Walter, J. C. (2014). BRCA1 promotes unloading of the CMG 
helicase from a stalled DNA replication fork. Mol Cell, 56(1), 174-185. 
doi:10.1016/j.molcel.2014.08.012 
Lord, C. J., & Ashworth, A. (2013). Mechanisms of resistance to therapies targeting BRCA-mutant 
cancers. Nat Med, 19(11), 1381-1388. doi:10.1038/nm.3369 
Lord, C. J., & Ashworth, A. (2016). BRCAness revisited. Nat Rev Cancer, 16(2), 110-120. 
doi:10.1038/nrc.2015.21 
Ludwig, T., Chapman, D. L., Papaioannou, V. E., & Efstratiadis, A. (1997). Targeted mutations of breast 
cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, 
Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev, 11(10), 1226-1241.  
Ludwig, T., Fisher, P., Ganesan, S., & Efstratiadis, A. (2001). Tumorigenesis in mice carrying a truncating 
Brca1 mutation. Genes Dev, 15(10), 1188-1193. doi:10.1101/gad.879201 
Machwe, A., Xiao, L., Groden, J., & Orren, D. K. (2006). The Werner and Bloom syndrome proteins 
catalyze regression of a model replication fork. Biochemistry, 45(47), 13939-13946. 
doi:10.1021/bi0615487 
	 177	
Manke, I. A., Lowery, D. M., Nguyen, A., & Yaffe, M. B. (2003). BRCT repeats as phosphopeptide-binding 
modules involved in protein targeting. Science, 302(5645), 636-639. 
doi:10.1126/science.1088877 
Martins, F. C., De, S., Almendro, V., Gonen, M., Park, S. Y., Blum, J. L., . . . Polyak, K. (2012). 
Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov, 2(6), 503-511. 
doi:10.1158/2159-8290.CD-11-0325 
Maxwell, K. N., Wubbenhorst, B., Wenz, B. M., De Sloover, D., Pluta, J., Emery, L., . . . Nathanson, K. L. 
(2017). BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat 
Commun, 8(1), 319. doi:10.1038/s41467-017-00388-9 
McCarthy, A., Savage, K., Gabriel, A., Naceur, C., Reis-Filho, J. S., & Ashworth, A. (2007). A mouse 
model of basal-like breast carcinoma with metaplastic elements. J Pathol, 211(4), 389-398. 
doi:10.1002/path.2124 
McCarthy, E. E., Celebi, J. T., Baer, R., & Ludwig, T. (2003). Loss of Bard1, the heterodimeric partner of 
the Brca1 tumor suppressor, results in early embryonic lethality and chromosomal instability. Mol 
Cell Biol, 23(14), 5056-5063.  
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., . . . et al. (1994). A 
strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 
266(5182), 66-71.  
Mimitou, E. P., & Symington, L. S. (2008). Sae2, Exo1 and Sgs1 collaborate in DNA double-strand break 
processing. Nature, 455(7214), 770-774. doi:10.1038/nature07312 
Moynahan, M. E., Chiu, J. W., Koller, B. H., & Jasin, M. (1999). Brca1 controls homology-directed DNA 
repair. Mol Cell, 4(4), 511-518.  
Moynahan, M. E., Cui, T. Y., & Jasin, M. (2001). Homology-directed dna repair, mitomycin-c resistance, 
and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res, 61(12), 
4842-4850.  
Moynahan, M. E., & Jasin, M. (2010). Mitotic homologous recombination maintains genomic stability and 
suppresses tumorigenesis. Nat Rev Mol Cell Biol, 11(3), 196-207. doi:10.1038/nrm2851 
Moynahan, M. E., Pierce, A. J., & Jasin, M. (2001). BRCA2 is required for homology-directed repair of 
chromosomal breaks. Mol Cell, 7(2), 263-272.  
Musgrove, E. A., & Sutherland, R. L. (2009). Biological determinants of endocrine resistance in breast 
cancer. Nat Rev Cancer, 9(9), 631-643. doi:10.1038/nrc2713 
Nagaraju, G., & Scully, R. (2007). Minding the gap: the underground functions of BRCA1 and BRCA2 at 
stalled replication forks. DNA Repair (Amst), 6(7), 1018-1031. doi:10.1016/j.dnarep.2007.02.020 
Neelsen, K. J., & Lopes, M. (2015). Replication fork reversal in eukaryotes: from dead end to dynamic 
response. Nat Rev Mol Cell Biol, 16(4), 207-220. doi:10.1038/nrm3935 
Nolan, E., Vaillant, F., Branstetter, D., Pal, B., Giner, G., Whitehead, L., . . . Lindeman, G. J. (2016). 
RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat 
Med, 22(8), 933-939. doi:10.1038/nm.4118 
	 178	
Pathania, S., Bade, S., Le Guillou, M., Burke, K., Reed, R., Bowman-Colin, C., . . . Livingston, D. M. 
(2014). BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nat 
Commun, 5, 5496. doi:10.1038/ncomms6496 
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., . . . Slamon, D. J. 
(1998). Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-
p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing 
metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol, 16(8), 2659-2671. 
doi:10.1200/JCO.1998.16.8.2659 
Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., . . . Botstein, D. (2000). 
Molecular portraits of human breast tumours. Nature, 406(6797), 747-752. doi:10.1038/35021093 
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., . . . Herceptin 
Adjuvant Trial Study, T. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive 
breast cancer. N Engl J Med, 353(16), 1659-1672. doi:10.1056/NEJMoa052306 
Pierce, A. J., & Jasin, M. (2001). NHEJ deficiency and disease. Mol Cell, 8(6), 1160-1161.  
Pleschke, J. M., Kleczkowska, H. E., Strohm, M., & Althaus, F. R. (2000). Poly(ADP-ribose) binds to 
specific domains in DNA damage checkpoint proteins. J Biol Chem, 275(52), 40974-40980. 
doi:10.1074/jbc.M006520200 
Pommier, Y., O'Connor, M. J., & de Bono, J. (2016). Laying a trap to kill cancer cells: PARP inhibitors and 
their mechanisms of action. Sci Transl Med, 8(362), 362ps317. doi:10.1126/scitranslmed.aaf9246 
Pommier, Y., Redon, C., Rao, V. A., Seiler, J. A., Sordet, O., Takemura, H., . . . Kohn, K. W. (2003). 
Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res, 
532(1-2), 173-203.  
Prat, A., Pineda, E., Adamo, B., Galvan, P., Fernandez, A., Gaba, L., . . . Munoz, M. (2015). Clinical 
implications of the intrinsic molecular subtypes of breast cancer. Breast, 24 Suppl 2, S26-35. 
doi:10.1016/j.breast.2015.07.008 
Raschle, M., Knipscheer, P., Enoiu, M., Angelov, T., Sun, J., Griffith, J. D., . . . Walter, J. C. (2008). 
Mechanism of replication-coupled DNA interstrand crosslink repair. Cell, 134(6), 969-980. 
doi:10.1016/j.cell.2008.08.030 
Ratajska, M., Antoszewska, E., Piskorz, A., Brozek, I., Borg, A., Kusmierek, H., . . . Limon, J. (2012). 
Cancer predisposing BARD1 mutations in breast-ovarian cancer families. Breast Cancer Res 
Treat, 131(1), 89-97. doi:10.1007/s10549-011-1403-8 
Ray Chaudhuri, A., Callen, E., Ding, X., Gogola, E., Duarte, A. A., Lee, J. E., . . . Nussenzweig, A. (2016). 
Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature, 535(7612), 
382-387. doi:10.1038/nature18325 
Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., Van't Veer, L., Garber, J. E., . . . 
Observation of Surgical End Points Study, G. (2002). Prophylactic oophorectomy in carriers of 
BRCA1 or BRCA2 mutations. N Engl J Med, 346(21), 1616-1622. doi:10.1056/NEJMoa012158 
Reid, L. J., Shakya, R., Modi, A. P., Lokshin, M., Cheng, J. T., Jasin, M., . . . Ludwig, T. (2008). E3 ligase 
activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of 
double-strand DNA breaks. Proc Natl Acad Sci U S A, 105(52), 20876-20881. 
doi:10.1073/pnas.0811203106 
	 179	
Rodriguez, M., Yu, X., Chen, J., & Songyang, Z. (2003). Phosphopeptide binding specificities of BRCA1 
COOH-terminal (BRCT) domains. J Biol Chem, 278(52), 52914-52918. 
doi:10.1074/jbc.C300407200 
Rondinelli, B., Gogola, E., Yucel, H., Duarte, A. A., van de Ven, M., van der Sluijs, R., . . . D'Andrea, A. D. 
(2017). EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through 
histone H3 trimethylation. Nat Cell Biol, 19(11), 1371-1378. doi:10.1038/ncb3626 
Rouet, P., Smih, F., & Jasin, M. (1994). Introduction of double-strand breaks into the genome of mouse 
cells by expression of a rare-cutting endonuclease. Mol Cell Biol, 14(12), 8096-8106.  
Roy, R., Chun, J., & Powell, S. N. (2011). BRCA1 and BRCA2: different roles in a common pathway of 
genome protection. Nat Rev Cancer, 12(1), 68-78. doi:10.1038/nrc3181 
Sabatier, R., Adelaide, J., Finetti, P., Ferrari, A., Huiart, L., Sobol, H., . . . Bertucci, F. (2010). BARD1 
homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer. Genes 
Chromosomes Cancer, 49(12), 1143-1151. doi:10.1002/gcc.20822 
Sartori, A. A., Lukas, C., Coates, J., Mistrik, M., Fu, S., Bartek, J., . . . Jackson, S. P. (2007). Human CtIP 
promotes DNA end resection. Nature, 450(7169), 509-514. doi:10.1038/nature06337 
Savage, K. I., Matchett, K. B., Barros, E. M., Cooper, K. M., Irwin, G. W., Gorski, J. J., . . . Harkin, D. P. 
(2014). BRCA1 deficiency exacerbates estrogen-induced DNA damage and genomic instability. 
Cancer Res, 74(10), 2773-2784. doi:10.1158/0008-5472.CAN-13-2611 
Sawyer, S. L., Tian, L., Kahkonen, M., Schwartzentruber, J., Kircher, M., University of Washington Centre 
for Mendelian, G., . . . Greenberg, R. A. (2015). Biallelic mutations in BRCA1 cause a new 
Fanconi anemia subtype. Cancer Discov, 5(2), 135-142. doi:10.1158/2159-8290.CD-14-1156 
Schlacher, K., Christ, N., Siaud, N., Egashira, A., Wu, H., & Jasin, M. (2011). Double-strand break repair-
independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell, 
145(4), 529-542. doi:10.1016/j.cell.2011.03.041 
Schlacher, K., Wu, H., & Jasin, M. (2012). A distinct replication fork protection pathway connects Fanconi 
anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell, 22(1), 106-116. 
doi:10.1016/j.ccr.2012.05.015 
Schreiber, V., Dantzer, F., Ame, J. C., & de Murcia, G. (2006). Poly(ADP-ribose): novel functions for an 
old molecule. Nat Rev Mol Cell Biol, 7(7), 517-528. doi:10.1038/nrm1963 
Scully, R. (2011). Epistatic relationships in the BRCA1-BRCA2 pathway. PLoS Genet, 7(7), e1002183. 
doi:10.1371/journal.pgen.1002183 
Scully, R., Chen, J., Ochs, R. L., Keegan, K., Hoekstra, M., Feunteun, J., & Livingston, D. M. (1997). 
Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA 
damage. Cell, 90(3), 425-435.  
Scully, R., Chen, J., Plug, A., Xiao, Y., Weaver, D., Feunteun, J., . . . Livingston, D. M. (1997). Association 
of BRCA1 with Rad51 in mitotic and meiotic cells. Cell, 88(2), 265-275.  
Seiler, J. A., Conti, C., Syed, A., Aladjem, M. I., & Pommier, Y. (2007). The intra-S-phase checkpoint 
affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses. Mol 
Cell Biol, 27(16), 5806-5818. doi:10.1128/MCB.02278-06 
	 180	
Selbert, S., Bentley, D. J., Melton, D. W., Rannie, D., Lourenco, P., Watson, C. J., & Clarke, A. R. (1998). 
Efficient BLG-Cre mediated gene deletion in the mammary gland. Transgenic Res, 7(5), 387-396.  
Shakya, R., Reid, L. J., Reczek, C. R., Cole, F., Egli, D., Lin, C. S., . . . Ludwig, T. (2011). BRCA1 tumor 
suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science, 
334(6055), 525-528. doi:10.1126/science.1209909 
Shakya, R., Szabolcs, M., McCarthy, E., Ospina, E., Basso, K., Nandula, S., . . . Ludwig, T. (2008). The 
basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the 
BRCA1/BARD1 heterodimer in tumor suppression. Proc Natl Acad Sci U S A, 105(19), 7040-
7045. doi:10.1073/pnas.0711032105 
Sharan, S. K., Morimatsu, M., Albrecht, U., Lim, D. S., Regel, E., Dinh, C., . . . Bradley, A. (1997). 
Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. 
Nature, 386(6627), 804-810. doi:10.1038/386804a0 
Sharan, S. K., Pyle, A., Coppola, V., Babus, J., Swaminathan, S., Benedict, J., . . . Handel, M. A. (2004). 
BRCA2 deficiency in mice leads to meiotic impairment and infertility. Development, 131(1), 131-
142. doi:10.1242/dev.00888 
Shiozaki, E. N., Gu, L., Yan, N., & Shi, Y. (2004). Structure of the BRCT repeats of BRCA1 bound to a 
BACH1 phosphopeptide: implications for signaling. Mol Cell, 14(3), 405-412.  
Siegel, R. L., Miller, K. D., & Jemal, A. (2017). Cancer Statistics, 2017. CA Cancer J Clin, 67(1), 7-30. 
doi:10.3322/caac.21387 
Simhadri, S., Peterson, S., Patel, D. S., Huo, Y., Cai, H., Bowman-Colin, C., . . . Xia, B. (2014). Male 
fertility defect associated with disrupted BRCA1-PALB2 interaction in mice. J Biol Chem, 289(35), 
24617-24629. doi:10.1074/jbc.M114.566141 
Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., . . . Borresen-Dale, A. L. (2001). 
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical 
implications. Proc Natl Acad Sci U S A, 98(19), 10869-10874. doi:10.1073/pnas.191367098 
Sotiriou, C., & Pusztai, L. (2009). Gene-expression signatures in breast cancer. N Engl J Med, 360(8), 
790-800. doi:10.1056/NEJMra0801289 
Stork, C. T., Bocek, M., Crossley, M. P., Sollier, J., Sanz, L. A., Chedin, F., . . . Cimprich, K. A. (2016). 
Co-transcriptional R-loops are the main cause of estrogen-induced DNA damage. Elife, 5. 
doi:10.7554/eLife.17548 
Strumberg, D., Pilon, A. A., Smith, M., Hickey, R., Malkas, L., & Pommier, Y. (2000). Conversion of 
topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-
phosphorylated DNA double-strand breaks by replication runoff. Mol Cell Biol, 20(11), 3977-3987.  
Sugawara, N., Wang, X., & Haber, J. E. (2003). In vivo roles of Rad52, Rad54, and Rad55 proteins in 
Rad51-mediated recombination. Mol Cell, 12(1), 209-219.  
Sy, S. M., Huen, M. S., & Chen, J. (2009). PALB2 is an integral component of the BRCA complex 
required for homologous recombination repair. Proc Natl Acad Sci U S A, 106(17), 7155-7160. 
doi:10.1073/pnas.0811159106 
Symington, L. S., & Gautier, J. (2011). Double-strand break end resection and repair pathway choice. 
Annu Rev Genet, 45, 247-271. doi:10.1146/annurev-genet-110410-132435 
	 181	
Taglialatela, A., Alvarez, S., Leuzzi, G., Sannino, V., Ranjha, L., Huang, J. W., . . . Ciccia, A. (2017). 
Restoration of Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by Inactivation of 
SNF2-Family Fork Remodelers. Mol Cell, 68(2), 414-430 e418. doi:10.1016/j.molcel.2017.09.036 
Trentham-Dietz, A., Sprague, B. L., Hampton, J. M., Miglioretti, D. L., Nelson, H. D., Titus, L. J., . . . 
Newcomb, P. A. (2014). Modification of breast cancer risk according to age and menopausal 
status: a combined analysis of five population-based case-control studies. Breast Cancer Res 
Treat, 145(1), 165-175. doi:10.1007/s10549-014-2905-y 
Turner, J. M. (2007). Meiotic sex chromosome inactivation. Development, 134(10), 1823-1831. 
doi:10.1242/dev.000018 
Turner, J. M., Aprelikova, O., Xu, X., Wang, R., Kim, S., Chandramouli, G. V., . . . Deng, C. X. (2004). 
BRCA1, histone H2AX phosphorylation, and male meiotic sex chromosome inactivation. Curr 
Biol, 14(23), 2135-2142. doi:10.1016/j.cub.2004.11.032 
Turner, N. C., Reis-Filho, J. S., Russell, A. M., Springall, R. J., Ryder, K., Steele, D., . . . Tutt, A. N. 
(2007). BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene, 26(14), 2126-2132. 
doi:10.1038/sj.onc.1210014 
van der Kolk, D. M., de Bock, G. H., Leegte, B. K., Schaapveld, M., Mourits, M. J., de Vries, J., . . . 
Oosterwijk, J. C. (2010). Penetrance of breast cancer, ovarian cancer and contralateral breast 
cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res 
Treat, 124(3), 643-651. doi:10.1007/s10549-010-0805-3 
Varma, A. K., Brown, R. S., Birrane, G., & Ladias, J. A. (2005). Structural basis for cell cycle checkpoint 
control by the BRCA1-CtIP complex. Biochemistry, 44(33), 10941-10946. doi:10.1021/bi0509651 
Venkitaraman, A. R. (2014). Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. 
Science, 343(6178), 1470-1475. doi:10.1126/science.1252230 
Vujanovic, M., Krietsch, J., Raso, M. C., Terraneo, N., Zellweger, R., Schmid, J. A., . . . Lopes, M. (2017). 
Replication Fork Slowing and Reversal upon DNA Damage Require PCNA Polyubiquitination and 
ZRANB3 DNA Translocase Activity. Mol Cell, 67(5), 882-890 e885. 
doi:10.1016/j.molcel.2017.08.010 
Wagner, K. U., Wall, R. J., St-Onge, L., Gruss, P., Wynshaw-Boris, A., Garrett, L., . . . Hennighausen, L. 
(1997). Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res, 25(21), 4323-
4330.  
Wang, B., Matsuoka, S., Ballif, B. A., Zhang, D., Smogorzewska, A., Gygi, S. P., & Elledge, S. J. (2007). 
Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. 
Science, 316(5828), 1194-1198. doi:10.1126/science.1139476 
West, S. C. (2003). Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol, 
4(6), 435-445. doi:10.1038/nrm1127 
Westermark, U. K., Reyngold, M., Olshen, A. B., Baer, R., Jasin, M., & Moynahan, M. E. (2003). BARD1 
participates with BRCA1 in homology-directed repair of chromosome breaks. Mol Cell Biol, 
23(21), 7926-7936.  
Williams, R. S., Green, R., & Glover, J. N. (2001). Crystal structure of the BRCT repeat region from the 
breast cancer-associated protein BRCA1. Nat Struct Biol, 8(10), 838-842. doi:10.1038/nsb1001-
838 
	 182	
Williams, R. S., Lee, M. S., Hau, D. D., & Glover, J. N. (2004). Structural basis of phosphopeptide 
recognition by the BRCT domain of BRCA1. Nat Struct Mol Biol, 11(6), 519-525. 
doi:10.1038/nsmb776 
Wooster, R., & Weber, B. L. (2003). Breast and ovarian cancer. N Engl J Med, 348(23), 2339-2347. 
doi:10.1056/NEJMra012284 
Wu, L. C., Wang, Z. W., Tsan, J. T., Spillman, M. A., Phung, A., Xu, X. L., . . . Baer, R. (1996). 
Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet, 
14(4), 430-440. doi:10.1038/ng1296-430 
Wu, Q., Jubb, H., & Blundell, T. L. (2015). Phosphopeptide interactions with BRCA1 BRCT domains: 
More than just a motif. Prog Biophys Mol Biol, 117(2-3), 143-148. 
doi:10.1016/j.pbiomolbio.2015.02.003 
Wu-Baer, F., Lagrazon, K., Yuan, W., & Baer, R. (2003). The BRCA1/BARD1 heterodimer assembles 
polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin. J 
Biol Chem, 278(37), 34743-34746. doi:10.1074/jbc.C300249200 
Xia, B., Sheng, Q., Nakanishi, K., Ohashi, A., Wu, J., Christ, N., . . . Livingston, D. M. (2006). Control of 
BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell, 22(6), 719-729. 
doi:10.1016/j.molcel.2006.05.022 
Xu, X., Aprelikova, O., Moens, P., Deng, C. X., & Furth, P. A. (2003). Impaired meiotic DNA-damage 
repair and lack of crossing-over during spermatogenesis in BRCA1 full-length isoform deficient 
mice. Development, 130(9), 2001-2012.  
Xu, X., Qiao, W., Linke, S. P., Cao, L., Li, W. M., Furth, P. A., . . . Deng, C. X. (2001). Genetic interactions 
between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet, 
28(3), 266-271. doi:10.1038/90108 
Xu, X., Wagner, K. U., Larson, D., Weaver, Z., Li, C., Ried, T., . . . Deng, C. X. (1999). Conditional 
mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and 
tumour formation. Nat Genet, 22(1), 37-43. doi:10.1038/8743 
Yamane, K., & Tsuruo, T. (1999). Conserved BRCT regions of TopBP1 and of the tumor suppressor 
BRCA1 bind strand breaks and termini of DNA. Oncogene, 18(37), 5194-5203. 
doi:10.1038/sj.onc.1202922 
Yang, Y. G., Cortes, U., Patnaik, S., Jasin, M., & Wang, Z. Q. (2004). Ablation of PARP-1 does not 
interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled 
replication forks. Oncogene, 23(21), 3872-3882. doi:10.1038/sj.onc.1207491 
Ying, S., Hamdy, F. C., & Helleday, T. (2012). Mre11-dependent degradation of stalled DNA replication 
forks is prevented by BRCA2 and PARP1. Cancer Res, 72(11), 2814-2821. doi:10.1158/0008-
5472.CAN-11-3417 
Yu, X., & Baer, R. (2000). Nuclear localization and cell cycle-specific expression of CtIP, a protein that 
associates with the BRCA1 tumor suppressor. J Biol Chem, 275(24), 18541-18549. 
doi:10.1074/jbc.M909494199 
Yu, X., & Chen, J. (2004). DNA damage-induced cell cycle checkpoint control requires CtIP, a 
phosphorylation-dependent binding partner of BRCA1 C-terminal domains. Mol Cell Biol, 24(21), 
9478-9486. doi:10.1128/MCB.24.21.9478-9486.2004 
	 183	
Yu, X., Chini, C. C., He, M., Mer, G., & Chen, J. (2003). The BRCT domain is a phospho-protein binding 
domain. Science, 302(5645), 639-642. doi:10.1126/science.1088753 
Yu, X., Wu, L. C., Bowcock, A. M., Aronheim, A., & Baer, R. (1998). The C-terminal (BRCT) domains of 
BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional 
repression. J Biol Chem, 273(39), 25388-25392.  
Zeman, M. K., & Cimprich, K. A. (2014). Causes and consequences of replication stress. Nat Cell Biol, 
16(1), 2-9. doi:10.1038/ncb2897 
Zhang, F., Ma, J., Wu, J., Ye, L., Cai, H., Xia, B., & Yu, X. (2009). PALB2 links BRCA1 and BRCA2 in the 
DNA-damage response. Curr Biol, 19(6), 524-529. doi:10.1016/j.cub.2009.02.018 
Zhang, H., Liu, H., Chen, Y., Yang, X., Wang, P., Liu, T., . . . Pei, H. (2016). A cell cycle-dependent 
BRCA1-UHRF1 cascade regulates DNA double-strand break repair pathway choice. Nat 
Commun, 7, 10201. doi:10.1038/ncomms10201 
Zhao, W., Steinfeld, J. B., Liang, F., Chen, X., Maranon, D. G., Jian Ma, C., . . . Sung, P. (2017). BRCA1-
BARD1 promotes RAD51-mediated homologous DNA pairing. Nature, 550(7676), 360-365. 
doi:10.1038/nature24060 
Zhou, B. B. S., & Elledge, S. J. (2000). The DNA damage response: putting checkpoints in perspective. 
Nature, 408(6811), 433-439.  
Zhu, Z., Chung, W. H., Shim, E. Y., Lee, S. E., & Ira, G. (2008). Sgs1 helicase and two nucleases Dna2 
and Exo1 resect DNA double-strand break ends. Cell, 134(6), 981-994. 
doi:10.1016/j.cell.2008.08.037 
Zou, L., & Elledge, S. J. (2003). Sensing DNA damage through ATRIP recognition of RPA-ssDNA 
complexes. Science, 300(5625), 1542-1548. doi:10.1126/science.1083430 
 
